



(51) International Patent Classification:

A61P 31/18 (2006.01) C07H 19/173 (2006.01)

A61K 31/7076 (2006.01)

(21) International Application Number:

PCT/IB2020/051878

(22) International Filing Date:

04 March 2020 (04.03.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/814,316 06 March 2019 (06.03.2019) US

(71) Applicants: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED [GB/GB];

980 Great West Road, Brentford Middlesex TW89GS (GB).

VIIV HEALTHCARE COMPANY [US/US]; 251 Little Falls Drive, Wilmington, Delaware 19808 (US).

(72) Inventors: DE LA ROSA, Martha Alicia; Five Moore Drive, Research Triangle Park, North Carolina 27709 (US).

MILLER, John F.; Five Moore Drive, Research Triangle Park, North Carolina 27709 (US). TEMELKOFF, David;

Five Moore Drive, Research Triangle Park, North Carolina 27709 (US). VELTHUISEN, Emile Johann; Five Moore Drive, Research Triangle Park, North Carolina 27709 (US).

NAIDU, B. Narasimhulu; 36 E Industrial Rd, Branford, Connecticut 06405 (US). SAMANO, Vicente; D130F Research Triangle Park, Raleigh, North Carolina 27711 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMPOUNDS USEFUL IN HIV THERAPY



wherein:

R₁ is:

(57) **Abstract:** The invention relates to compounds of Formula (I), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects.



Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

COMPOUNDS USEFUL IN HIV THERAPY

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application claims priority to U.S. Provisional Serial No. 62/814,316 filed March 6, 2019, the disclosure of which is incorporated by reference herein in its entirety.

5

FIELD OF THE INVENTION

The present invention relates to compounds, pharmaceutical compositions, and methods of use thereof in connection with individuals infected with HIV. In particular, such methods of use encompass e.g., methods for treating HIV and methods of preventing HIV.

10

BACKGROUND OF THE INVENTION

Human immunodeficiency virus type 1 (HIV-1) infection leads to the contraction of acquired immune deficiency disease (AIDS). The number of cases of HIV continues to rise, and currently an estimated over thirty-five million individuals worldwide suffer from HIV infection e.g., [http://www.sciencedirect.com/science/article/pii/S235230181630087X?](http://www.sciencedirect.com/science/article/pii/S235230181630087X?via%3Dihub)

15

[via%3Dihub](http://www.sciencedirect.com/science/article/pii/S235230181630087X?via%3Dihub)

Presently, long-term suppression of viral replication with antiretroviral drugs is the only option for treating HIV-1 infection. Indeed, the U.S. Food and Drug Administration has approved twenty-five drugs over six different inhibitor classes, which have been shown to greatly increase patient survival and quality of life. However, additional

20 therapies are still believed to be required due to a number of issues including, but not limited to undesirable drug-drug interactions; drug-food interactions; non-adherence to therapy; drug resistance due to mutation of the enzyme target; and inflammation related to the immunologic damage caused by the HIV infection.

25

Currently, almost all HIV positive patients are treated with therapeutic regimens of antiretroviral drug combinations termed, highly active antiretroviral therapy ("HAART"). However, HAART therapies are often complex because a combination of different drugs must be administered often daily to the patient to avoid the rapid emergence of drug-resistant HIV-1 variants. Despite the positive impact of HAART on patient survival, drug resistance can still occur and the survival and quality of life are not normalized as

30 compared to uninfected persons [Lohse Ann Intern Med 2007 146;87-95]. Indeed, the incidence of several non-AIDS morbidities and mortalities, such as cardiovascular disease, frailty, and neurocognitive impairment, are increased in HAART-suppressed, HIV-infected subjects [Deeks Annu Rev Med 2011;62:141-155]. This increased incidence of

non-AIDS morbidity/mortality occurs in the context of, and is potentially caused by, elevated systemic inflammation related to the immunologic damage caused by HIV infection [Hunt J Infect Dis 2014][Byakagwa J Infect Dis 2014][Tenorio J Infect Dis 2014].

Modern antiretroviral therapy (ART) has the ability to effectively suppress HIV replication and improve health outcomes for HIV-infected persons, but is believed to not be capable of completely eliminating HIV viral reservoirs within the individual. HIV genomes can remain latent within mostly immune cells in the infected individual and may reactivate at any time, such that after interruption of ART, virus replication typically resumes within weeks. In a handful of individuals, the size of this viral reservoir has been significantly reduced and upon cessation of ART, the rebound of viral replication has been delayed [Henrich TJ J Infect Dis 2013][Henrich TJ Ann Intern Med 2014]. In one case, the viral reservoir was eliminated during treatment of leukemia and no viral rebound was observed during several years of follow-up [Hutter G N Engl J Med 2009]. These examples suggest the concept that reduction or elimination of the viral reservoir may be possible and can lead to viral remission or cure. As such, ways have been pursued to eliminate the viral reservoir, by direct molecular means, including excision of viral genomes with CRISPR/Cas9 systems, or to induce reactivation of the latent reservoir during ART so that the latent cells are eliminated. Induction of the latent reservoir typically results in either direct death of the latently infected cell or killing of the induced cell by the immune system after the virus is made visible. As this is performed during ART, viral genomes produced are believed to not result in the infection of new cells and the size of the reservoir may decay.

HAART therapies are often complex because a combination of different drugs must be administered often daily to the patient to avoid the rapid emergence of drug-resistant HIV-1 variants. Despite the positive impact of HAART on patient survival, drug resistance can still occur.


Current guidelines recommend that therapy includes three fully active drugs. See e.g. <https://aidsinfo.nih.gov/guidelines>. Additionally, two drug combinations may be employed as therapeutic regimens. Typically, first-line therapies combine two to three drugs targeting the viral enzymes reverse transcriptase and integrase. It is believed that sustained successful treatment of HIV-1-infected patients with antiretroviral drugs employ the continued development of new and improved drugs that are effective against HIV strains that have formed resistance to approved drugs. For example an individual on a regimen containing 3TC/FTC (lamivudine/emtricitabine) may select for the M184V mutation that reduces susceptibility to these drugs by >100 fold. See e.g., <https://hivdb.stanford.edu/dr-summary/resistance-notes/NRTI>

Another way to potentially address preventing formation of mutations is to increase patient adherence to a drug regimen. One manner that may be employed to accomplish this is by reducing the dosing frequency. For parenteral administration, it is believed to be advantageous to have drug substances with high lipophilicity in order to reduce solubility and limit the release rate within interstitial fluid. However, most nucleoside reverse transcriptase inhibitors are hydrophilic thereby potentially limiting their use as long acting parenteral agents.

There remains a need for compounds which may address the shortcomings set forth above.


SUMMARY OF THE INVENTION

In one aspect, the invention provides a compound of the formula (I):



wherein:

R¹ is:



wherein:


X is selected from the group consisting of NH₂, F and Cl;

R⁵ is selected from the group consisting of H and (C₁-C₁₄) alkyl;

R⁶ is selected from the group consisting of H and -(C=O)-(C₁-C₁₄) alkyl;

R² is selected from the group consisting of (C₁-C₂₄) alkyl; (CH₂)_{n1}-O-(CH₂CH₂O)_{n2}-(C₁-C₁₄ alkyl) where n₁ and n₂ are integers independently selected from 1-4; -R⁷-NH-(C=O)-R⁸ wherein R⁷ may be (C₁-C₁₄) alkyl and R⁸ may be independently selected from H and (C₁-C₁₄) alkyl; -R⁹-(C₆-C₁₄) aryl, wherein R⁹ is a bond or (C₁-C₆) alkyl; -R¹⁰-(C₃-C₁₄)

cycloalkyl, wherein R^{10} is a bond or (C_1-C_6) alkyl; $-(C_1-C_{20})$ alkylene- $(C=O)-O-R^{11}$ wherein R^{11} may be selected from H and (C_1-C_{20}) alkyl;



5 and;

R^3 is selected from the group consisting of H, $-(C=O)-(C_1-C_{24})$ alkyl; $-(C=O)-O-(C_1-C_{24})$ alkyl; and C_3-C_{14} cycloalkyl; or

R^2 and R^3 join together to form a C_3 to C_{28} cyclic structure; and

with the proviso that when R^2 is (C_1-C_{14}) alkyl) at least one of R^3 , R^5 and R^6 is not H.

10 In another aspect, the invention provides pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof and an excipient.

In another aspect, the invention provides a method of treating an HIV infection in a subject at risk for developing an HIV infection, comprising administering to the subject a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

15 In another aspect, the invention provides a method of preventing an HIV infection in a subject at risk for developing an HIV infection, comprising administering to the subject a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

In another aspect, there is provided a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in therapy.

20 In another aspect, there is provided a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in treating an HIV infection.

In another aspect, there is provided a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in preventing an HIV infection.

25 In another aspect, there is provided the use of a compound of Formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating an HIV infection.

In another aspect, there is provided the use of a compound of Formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for preventing an HIV infection.

30 These and other aspects are encompassed by the invention as set forth herein.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1A illustrates an IC_{50} curve shift from $t = 0$ to $t = 48$ h for EFdA.

FIGURE 1B illustrates an IC_{50} curve shift from $t = 0$ to $t = 48$ h for Example 18 of the present invention.

5 **FIGURE 2** illustrates the mean plasma concentration-time profiles of EFdA after subcutaneous dosing at 20 mg/kg in Wistar Han rats ($N = 3$ /time point)

FIGURE 3 illustrates the mean plasma concentration-time profiles of EFdA after intramuscular dosing at 20 mg/kg in Wistar Han rats ($N = 3$ /time point)

10 **FIGURE 4** illustrates the mean plasma concentration-time profiles of Example 11 and EFdA after single IM injection of Example 11 at 20 mg/kg equivalent of EFdA in male Wistar Han rats ($N = 3$ /time point)

FIGURE 5 illustrates the mean plasma concentration-time profiles of Example 17 and EFdA after single IM injection of Example 17 at 20 mg/kg equivalent of EFdA in male Wistar Han rats ($N = 3$ /time point)

15 **FIGURE 6** illustrates the mean plasma concentration-time profiles of Example 18, EFdA and Met1 after single IM injection of Example 18 at 20 mg/kg equivalent of EFdA in male Wistar Han rats ($N = 3$ /time point)

FIGURE 7 illustrates the mean plasma concentration-time profiles of Example 31, EFdA and Met1 after single IM injection of Example 31 at 20 mg/kg equivalent of EFdA in male Wistar Han rats ($N = 3$ /time point)

20 **FIGURE 8** illustrates the mean plasma concentration-time profiles of Example 32, EFdA, Met1 and Met2 after single IM injection of Example 32 at 20 mg/kg equivalent of EFdA in male Wistar Han rats ($N = 3$ /time point)

FIGURE 9 illustrates the mean plasma concentration-time profiles of Example 37, EFdA, Met1 and Met2 after single IM injection of Example 37 at 20 mg/kg equivalent of EFdA in male Wistar Han rats ($N = 3$ /time point)

FIGURE 10 illustrates the mean plasma concentration-time profiles of Example 38, EFdA, Met1 and Met2 after single IM injection of Example 38 at 20 mg/kg equivalent of EFdA in male Wistar Han rats ($N = 3$ /time point)

30 **FIGURE 11** illustrates the mean plasma concentration-time profiles of Example 39, EFdA, Met1 and Met2 after single IM injection of Met2 at 20 mg/kg equivalent of EFdA in male Wistar Han rats ($N = 3$ /time point)

FIGURE 12 illustrates the mean plasma concentration-time profiles of Example 40 and EFdA after single IM injection of Example 40 at 20 mg/kg equivalent of EFdA in male Wistar Han rats (N=3/time point)

5 **FIGURE 13** illustrates the mean plasma concentration-time profiles of Example 42, EFdA, Met1 and Met2 after single IM injection of Example 42 at 20 mg/kg equivalent of EFdA in male Wistar Han rats (N = 3/time point)

FIGURE 14 illustrates the mean plasma concentration-time profiles of Example 45, EFdA, Met1 and Met2 after single IM injection of Example 45 at 20 mg/kg equivalent of EFdA in male Wistar Han rats (N = 3/time point)

10 **FIGURE 15** illustrates the mean plasma concentration-time profiles of Example 48 and EFdA after single IM injection of Example 48 at 20 mg/kg equivalent of EFdA in male Wistar Han rats (N = 3/time point)

FIGURE 16 illustrates the mean plasma concentration-time profiles of Example 50 and EFdA after single IM injection of Example 50 at 20 mg/kg equivalent of EFdA in male Wistar Han rats (N = 3/time point)

FIGURE 17 illustrates the mean plasma concentration-time profiles of Example 58 and EFdA after single IM injection of Example 58 at 20 mg/kg equivalent of EFdA in male Wistar Han rats (N = 3/time point)

20 **FIGURE 18** illustrates the mean plasma concentration-time profiles of Example 59 and EFdA after single IM injection of Example 59 at 20 mg/kg equivalent of EFdA in male Wistar Han rats (N = 3/time point)

FIGURE 19 illustrates the mean plasma concentration-time profiles of Example 61 and EFdA after single IM injection of Example 61 at 20 mg/kg equivalent of EFdA in male Wistar Han rats (N=3/time point)

25 **FIGURE 20** illustrates the mean plasma concentration-time profiles of Example 62 and EFdA after single IM injection of Example 62 at 20 mg/kg in male Wistar Han rats (N = 3/time point)

FIGURE 21 illustrates the mean plasma concentration-time profiles of Example 63 and EFdA after single IM injection of Example 63 at 20 mg/kg equivalent of EFdA in male Wistar Han rats (N = 3/time point)

30 **FIGURE 22** illustrates the mean plasma concentration-time profiles of Example 64 and EFdA after single IM injection of Example 64 at 20 mg/kg equivalent of EFdA in male Wistar Han rats (N = 3/time point)

FIGURE 23 illustrates the mean plasma concentration-time profiles of Example 65 and EFdA after single IM injection of Example 65 at 20 mg/kg equivalent of EFdA in male Wistar Han rats (N = 3/time point)

5 **FIGURE 24** illustrates the mean plasma concentration-time profiles of example 66 and EFdA after single IM injection of Example 66 at 20 mg/kg equivalent of EFdA in male Wistar Han rats (N = 3/time point)

FIGURE 25 illustrates the mean plasma concentration-time profiles of Example 18 and EFdA after subcutaneous dosing Example 18 at 20 mg equivalent of EFdA/kg in Wistar Han rats (N = 3/time point)

10 **FIGURE 26** illustrates the mean plasma concentration-time profiles of Example 18 and EFdA after intramuscular dosing Example 18 at 20 mg equivalent of EFdA/kg in Wistar Han rats (N = 3/time point)

FIGURE 27 illustrates the mean plasma concentration-time profiles of Example 18 and EFdA after subcutaneous dosing Example 18 at 5 mg equivalent of EFdA/kg in Beagle Dogs (N=3/time point)

FIGURE 28 illustrates the mean plasma concentration-time profiles of Example 18 and EFdA after intramuscular dosing Example 18 at 5 mg equivalent of EFdA/kg in Beagle Dogs (N = 3/time point)

20 **FIGURE 29** illustrates the mean plasma concentration-time profiles of Example 18 and EFdA after subcutaneous dosing Example 18 at 5 mg equivalent of EFdA/kg in Cynomolgus Monkey (N = 3/time point)

FIGURE 30 illustrates the mean plasma concentration-time profiles of Example 18 and EFdA after intramuscular dosing Example 18 at 5 mg equivalent of EFdA/kg in Cynomolgus Monkey (N = 3/time point)


25


DETAILED DESCRIPTION OF REPRESENTATIVE EMBODIMENTS


Throughout this application, references are made to various embodiments relating to compounds, compositions, and methods. The various embodiments described are
30 meant to provide a variety of illustrative examples and should not be construed as descriptions of alternative species. Rather it should be noted that the descriptions of various embodiments provided herein may be of overlapping scope. The embodiments discussed herein are merely illustrative and are not meant to limit the scope of the present invention.

It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present invention. In this specification and in the claims that follow, reference will be made to a number of terms that shall be defined to have the following meanings, unless otherwise noted.

As used herein unless otherwise specified and subject to other embodiments set forth herein, "alkyl" e.g., refers to a monovalent saturated aliphatic hydrocarbyl group having e.g., from 1 to 24 carbon atoms, from 1 to 20 carbon atoms, from 1 to 14 carbon atoms or, from 1 to 6 carbon atoms. "(C_x-C_y)alkyl" refers to alkyl groups having from x to y carbon atoms. The term "alkyl" includes, by way of example, linear and branched hydrocarbyl groups such as, e.g., methyl (CH₃-), ethyl (CH₃CH₂-), *n*-propyl (CH₃CH₂CH₂-), isopropyl ((CH₃)₂CH-), *n*-butyl (CH₃CH₂CH₂CH₂-), isobutyl ((CH₃)₂CHCH₂-), *sec*-butyl ((CH₃)(CH₃CH₂)CH-), *t*-butyl ((CH₃)₃C-), *n*-pentyl (CH₃CH₂CH₂CH₂CH₂-), and neopentyl ((CH₃)₃CCH₂-). For the purposes of the invention, alkyl may be interpreted to encompass alkylene groups defined herein.

Subject to various embodiments set forth herein, "Alkylene" or "alkylene" refers to divalent e.g., saturated aliphatic hydrocarbyl groups having from 1 to 6 carbon atoms. The alkylene groups include branched and straight chain hydrocarbyl groups. For example, "(C₁-C₆)alkylene" is meant to include methylene, ethylene, propylene, 2-methylpropylene, dimethylethylene, pentylene, and so forth. As such, the term "propylene" could be exemplified by the following structure: . Likewise, the term "dimethylbutylene"

could be exemplified by any of the following three structures or more: , p, or



. Furthermore, the term "(C₁-C₆)alkylene" is meant to include such branched chain hydrocarbyl groups as

cyclopropylmethylene, which could be exemplified by the following structure:



"Alkenyl" refers to a linear or branched hydrocarbyl group having, e.g., from 2 to 10 carbon atoms and in some embodiments from 2 to 6 carbon atoms or 2 to 4 carbon atoms and having at least 1 site of vinyl unsaturation (>C=C<). For example, (C_x-C_y)alkenyl refers to alkenyl groups having from x to y carbon atoms and is meant to include for example, ethenyl, propenyl, isopropylene, 1,3-butadienyl, and the like.


"Alkynyl" refers to a linear monovalent hydrocarbon radical or a branched monovalent hydrocarbon radical containing at least one triple bond. The term "alkynyl" is also meant to include those hydrocarbyl groups having one triple bond and one double bond. For example, (C₂-C₆)alkynyl is meant to include ethynyl, propynyl, and the like.

5 "Alkoxy" refers to the group -O-alkyl wherein alkyl is defined herein, e.g., C₁ to C₆ alkoxy. Alkoxy includes, by way of example, methoxy, ethoxy, *n*-propoxy, isopropoxy, *n*-butoxy, *t*-butoxy, *sec*-butoxy, and *n*-pentoxy.

"Aryl" refers to an aromatic group of from e.g., 6 to 14 carbon atoms or preferably 5 to 6 carbon atoms and no ring heteroatoms and having a single ring (e.g., phenyl) or
10 multiple condensed (fused) rings (e.g., naphthyl or anthryl). For multiple ring systems, including fused, bridged, and spiro ring systems having aromatic and non-aromatic rings that have no ring heteroatoms, the term "Aryl" or "Ar" applies when the point of attachment is at an aromatic carbon atom (e.g., 5,6,7,8 tetrahydronaphthalene-2-yl is an aryl group as
15 its point of attachment is at the 2-position of the aromatic phenyl ring). As set forth herein, aryl groups may be substituted.

"AUC" refers to the area under the plot of plasma concentration of drug (not logarithm of the concentration) against time after drug administration.

"Cycloalkyl" refers to a saturated or partially saturated cyclic group of from e.g., 3 to 14 carbon atoms and no ring heteroatoms and having a single ring or multiple rings
20 including fused, bridged, and spiro ring systems. For multiple ring systems having aromatic and non-aromatic rings that have no ring heteroatoms, the term "cycloalkyl" applies when the point of attachment is at a non-aromatic carbon atom (e.g., 5,6,7,8,- tetrahydronaphthalene-5-yl). The term "cycloalkyl" includes cycloalkenyl groups, such as cyclohexenyl. Examples of cycloalkyl groups include, for instance, adamantyl,
25 cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, cyclooctyl, cyclopentenyl, and cyclohexenyl. Examples of cycloalkyl groups that include multiple bicycloalkyl ring systems are bicyclohexyl, bicyclopentyl, bicyclooctyl, and the like. Two such bicycloalkyl multiple ring structures are exemplified and named below:



30 "(C_u-C_v)cycloalkyl" refers to cycloalkyl groups having u to v carbon atoms.

"EC₅₀" refers to the concentration of a drug that gives half-maximal response.

"IC₅₀" refers to the half-maximal inhibitory concentration of a drug. Sometimes, it is also converted to the pIC₅₀ scale (-log IC₅₀), in which higher values indicate exponentially greater potency.


“Haloalkyl” refers to substitution of an alkyl group with 1 to 3 halo groups (e.g., bifluoromethyl or trifluoromethyl).

“Heteroaryl” refers to an aromatic group of from 1 to 14 carbon atoms, e.g., 6 heteroatoms selected from oxygen, nitrogen, and sulfur and includes single ring (e.g. imidazolyl) and (e.g. benzimidazol-2-yl and benzimidazol-6-yl). For multiple ring systems, including fused, bridged, and spiro ring systems having aromatic and non-aromatic rings, the term “heteroaryl” applies if there is at least one ring heteroatom and the point of attachment is at an atom of an aromatic ring (e.g. 1,2,3,4-tetrahydroquinolin-6-yl and 5,6,7,8-tetrahydroquinolin-3-yl). In some embodiments, the nitrogen and/or the sulfur ring atom(s) of the heteroaryl group are optionally oxidized to provide for the N-oxide (N→O), sulfinyl, or sulfonyl moieties. More specifically the term heteroaryl includes, but is not limited to, pyridyl, furanyl, thienyl, thiazolyl, isothiazolyl, triazolyl, imidazolyl, imidazolynyl, isoxazolyl, pyrrolyl, pyrazolyl, pyridazinyl, pyrimidinyl, purinyl, phthalazyl, naphthylpyridyl, benzofuranyl, tetrahydrobenzofuranyl, isobenzofuranyl, benzothiazolyl, benzoisothiazolyl, benzotriazolyl, indolyl, isoindolyl, indolizynyl, dihydroindolyl, indazolyl, indolynyl, benzoxazolyl, quinolyl, isoquinolyl, quinolizyl, quianazolyl, quinoxalyl, tetrahydroquinolynyl, isoquinolyl, quinazolinonyl, benzimidazolyl, benzisoxazolyl, benzothienyl, benzopyridazinyl, pteridynyl, carbazolyl, carbolynyl, phenanthridinyl, acridinyl, phenanthrolinyl, phenazinyl, phenoxazinyl, phenothiazinyl, and phthalimidyl.

“Heterocycle” refers “Heterocyclic” or “heterocycle” or “heterocycloalkyl” or “heterocyclyl” refers to a saturated or partially saturated cyclic group having from 1 to 14 carbon atoms and from 1 to 6 heteroatoms selected from nitrogen, sulfur, phosphorus or oxygen and includes single ring and multiple ring systems including fused, bridged, and spiro ring systems. For multiple ring systems having aromatic and/or non-aromatic rings, the terms “heterocyclic”, “heterocycle”, “heterocycloalkyl”, or “heterocyclyl” apply when there is at least one ring heteroatom and the point of attachment is at an atom of a non-aromatic ring (e.g. 1,2,3,4-tetrahydroquinoline-3-yl, 5,6,7,8-tetrahydroquinoline-6-yl, and decahydroquinolin-6-yl). In one embodiment, the nitrogen, phosphorus and/or sulfur atom(s) of the heterocyclic group are optionally oxidized to provide for the N-oxide, phosphinane oxide, sulfinyl, sulfonyl moieties. More specifically the heterocyclyl includes, but is not limited to, tetrahydropyranyl, piperidinyl, piperazinyl, 3-pyrrolidinyl, 2-pyrrolidon-1-yl, morpholynyl, and pyrrolidinyl. A prefix indicating the number of carbon atoms (e.g., C₃-C₁₀) refers to the total number of carbon atoms in the portion of the heterocyclyl group exclusive of the number of heteroatoms.

“Fused heterocyclic” or “fused heterocycle” refer to a 3 to 10 member cyclic substituent formed by the replacement of two hydrogen atoms at different carbon atoms in

a cycloalkyl ring structure, as exemplified by the following structure wherein the cycloalkyl group shown here contains bonds marked with wavy lines which are bonded to carbon atoms that are substituted with a fused heterocyclic group:



5

“Cyclic structure” refers to a series of carbon atoms connected to form a ring. In various embodiments, the cyclic structure may include e.g., cycloalkyl and heterocyclic groups. As noted herein, “C_x to C_y cyclic structure” refers to a cyclic structure wherein x and y are set forth such that the structure may contain x to y carbon atoms. Such a structure may be optionally substituted as set forth herein.

“Compound”, “compounds”, “chemical entity”, and “chemical entities” as used herein refers to a compound encompassed by the generic formulae (I), (Ia), (II) and (IIa) disclosed herein, any subgenus of these generic formulae, and any forms of the compounds within the generic and subgeneric formulae, including the racemates, stereoisomers, and tautomers of the compound or compounds.

The term “heteroatom” means nitrogen, oxygen, or sulfur and includes any oxidized form of phosphorus, nitrogen, such as N(O) {N⁺—O⁻} and sulfur such as S(O) and S(O)₂, and the quaternized form of any basic nitrogen.

“Oxo” refers to a (=O) group.

“Polymorphism” refers to when two or more clearly different phenotypes exist in the same population of a species where the occurrence of more than one form or morph. In order to be classified as such, morphs must occupy the same habitat at the same time and belong to a panmictic population (one with random mating).

“Protein binding” refers to the binding of a drug to proteins in blood plasma, tissue membranes, red blood cells and other components of blood.

“Protein shift” refers to determining a binding shift by comparing the EC₅₀ values determined in the absence and presence of human serum.

“Racemates” refers to a mixture of enantiomers. In an embodiment of the invention, the compounds of Formulas I, Ia, II and IIa or pharmaceutically acceptable salts thereof, are enantiomerically enriched with one enantiomer wherein all of the chiral carbons referred to are in one configuration. In general, reference to an enantiomerically enriched compound or salt, is meant to indicate that the specified enantiomer will

comprise more than 50% by weight of the total weight of all enantiomers of the compound or salt.

“Solvate” or “solvates” of a compound refer to those compounds, as defined above, which are bound to a stoichiometric or non-stoichiometric amount of a solvent. Solvates of a compound includes solvates of all forms of the compound. In certain embodiments, solvents are volatile, non-toxic, and/or acceptable for administration to humans in trace amounts. Suitable solvates include water.

“Stereoisomer” or “stereoisomers” refer to compounds that differ in the chirality of one or more stereocenters. Stereoisomers include enantiomers and diastereomers.

“Tautomer” refer to alternate forms of a compound that differ in the position of a proton, such as enol-keto and imine-enamine tautomers, or the tautomeric forms of heteroaryl groups containing a ring atom attached to both a ring -NH- moiety and a ring =N- moiety such as pyrazoles, imidazoles, benzimidazoles, triazoles, and tetrazoles.

The term ‘atropisomer’ refers to a stereoisomer resulting from an axis of asymmetry. This can result from restricted rotation about a single bond where the rotational barrier is high enough to allow differentiation of the isomeric species up to and including complete isolation of stable non-interconverting diastereomer or enantiomeric species. One skilled in the art will recognize that upon installing a nonsymmetrical R^x to core, the formation of atropisomers is possible. In addition, once a second chiral center is installed in a given molecule containing an atropisomer, the two chiral elements taken together can create diastereomeric and enantiomeric stereochemical species. Depending upon the substitution about the C_x axis, interconversion between the atropisomers may or may not be possible and may depend on temperature. In some instances, the atropisomers may interconvert rapidly at room temperature and not resolve under ambient conditions. Other situations may allow for resolution and isolation but interconversion can occur over a period of seconds to hours or even days or months such that optical purity is degraded measurably over time. Yet other species may be completely restricted from interconversion under ambient and/or elevated temperatures such that resolution and isolation is possible and yields stable species. When known, the resolved atropisomers were named using the helical nomenclature. For this designation, only the two ligands of highest priority in front and behind the axis are considered. When the turn priority from the front ligand 1 to the rear ligand 1 is clockwise, the configuration is *P*, if counterclockwise it is *M*.

“As used herein, the term “pharmaceutically acceptable” refers to those compounds, materials, compositions, and dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and

animals without excessive toxicity, irritation, or other problem or complication.

"Pharmaceutically acceptable salt" refers to pharmaceutically acceptable salts derived from a variety of organic and inorganic counter ions well known in the art and include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, and

- 5 tetraalkylammonium, and when the molecule contains a basic functionality, salts of organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, and oxalate. Suitable salts include those described in P. Heinrich Stahl, Camille G. Wermuth (Eds.), Handbook of Pharmaceutical Salts Properties, Selection, and Use; 2002. Pharmaceutically acceptable salts may be prepared *in situ* during the final
- 10 isolation and purification of the compound, or by separately reacting the purified compound in its free acid or free base form with a suitable base or acid, respectively. Further to the above, illustrative pharmaceutically acceptable acid salts of the compounds of the present invention can be prepared from the following acids, including, without limitation formic, acetic, propionic, benzoic, succinic, glycolic, gluconic, lactic, maleic,
- 15 malic, tartaric, citric, nitic, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, hydrochloric, hydrobromic, hydroiodic, isocitric, trifluoroacetic, pamoic, propionic, anthranilic, mesylic, oxalacetic, oleic, stearic, salicylic, p-hydroxybenzoic, nicotinic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, phosphoric, phosphonic, ethanesulfonic, benzenesulfonic, pantothenic, toluenesulfonic, 2-hydroxyethanesulfonic,
- 20 sulfanilic, sulfuric, salicylic, cyclohexylaminosulfonic, algenic, β -hydroxybutyric, galactaric and galacturonic acids. Preferred pharmaceutically acceptable salts include the salts of hydrochloric acid and trifluoroacetic acid. Illustrative pharmaceutically acceptable inorganic base salts of the compounds of the present invention include metallic ions. More preferred metallic ions include, but are not limited to, appropriate alkali metal salts,
- 25 alkaline earth metal salts and other physiological acceptable metal ions. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like and in their usual valences. Exemplary base salts include aluminum, calcium, lithium, magnesium, potassium, sodium and zinc. Other exemplary base salts include the
- 30 ammonium, calcium, magnesium, potassium, and sodium salts. Still other exemplary base salts include, for example, hydroxides, carbonates, hydrides, and alkoxides including NaOH, KOH, Na_2CO_3 , K_2CO_3 , NaH, and potassium-t-butoxide. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, including in part, trimethylamine, diethylamine, N, N'-
- 35 dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine; substituted amines including naturally

occurring substituted amines; cyclic amines; quaternary ammonium cations; and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, 5 glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like. All of the above salts can be prepared by those skilled in the art by conventional means from the corresponding compound of the present invention. For example, the pharmaceutically 10 acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, 15 ethanol, isopropanol, or acetonitrile are preferred. The salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent. The degree of ionisation in the salt may vary from completely ionised to almost non-ionised. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p.1418, the disclosure of which is hereby 20 incorporated by reference only with regards to the lists of suitable salts.


"Patient" or "subject" refers to mammals and includes humans and non-human mammals. Most preferably, a "patient" is construed to refer to humans.

"Treating" or "treatment" of a disease in a patient refers to 1) preventing the disease from occurring in a patient that is predisposed or does not yet display symptoms of the 25 disease; 2) inhibiting the disease or arresting its development; or 3) ameliorating or causing regression of the disease.

Prevention or "preventing" a disease in a patient refers to the prophylactic administration of a drug to substantially diminish the likelihood or severity of a disorder or biological manifestation thereof, or to delay the onset of such disorder or biological 30 manifestation thereof.


Where specific compounds or generic formulas are drawn that have aromatic rings, such as aryl or heteroaryl rings, then it will be understood by one of skill in the art that the particular aromatic location of any double bonds are a blend of equivalent positions even if they are drawn in different locations from compound to compound or from 35 formula to formula. For example, in the two pyridine rings (A and B) below, the double

bonds are drawn in different locations, however, they are known to be the same structure and compound:



- 5 The present invention includes compounds as well as their pharmaceutically acceptable salts. Accordingly, the word “or” in the context of “a compound or a pharmaceutically acceptable salt thereof” is understood to refer to either: 1) a compound alone or a compound and a pharmaceutically acceptable salt thereof (alternative), or 2) a compound and a pharmaceutically acceptable salt thereof (in combination).
- 10 Unless indicated otherwise, the nomenclature of substituents that are not explicitly defined herein are arrived at by naming the terminal portion of the functionality followed by the adjacent functionality toward the point of attachment. For example, the substituent “arylalkyloxycarbonyl” refers to the group (aryl)-(alkyl)-O-C(O)-. In a term such as “-C(R^x)₂”, it should be understood that the two R^x groups can be the same, or they can be
- 15 different if R^x is defined as having more than one possible identity. In addition, certain substituents are drawn as -R^xR^y, where the “-” indicates a bond adjacent to the parent molecule and R^y being the terminal portion of the functionality. Similarly, it is understood that the above definitions are not intended to include impermissible substitution patterns (e.g., methyl substituted with 5 fluoro groups). Such impermissible substitution patterns
- 20 are well known to the skilled artisan.


In one aspect, there is provided a compound of the formula (I):



25

wherein:

R₁ is:




wherein :

X is selected from the group consisting of NH₂, F and Cl;

R⁵ is selected from the group consisting of H and (C₁-C₁₄) alkyl;

5 R⁶ is selected from the group consisting of H and -(C=O)-(C₁-C₁₄) alkyl;

R² is selected from the group consisting of (C₁-C₂₄) alkyl; (CH₂)_{n1}-O-(CH₂CH₂O)_{n2}-(C₁-C₁₄ alkyl) where n1 and n2 are integers independently selected from 1-4 -R⁷-NH-(C=O)-R⁸ wherein R⁷ may be (C₁-C₁₄) alkyl and R⁸ may be independently selected from H and (C₁-C₁₄) alkyl; -R⁹-(C₆-C₁₄) aryl, wherein R⁹ is a bond or (C₁-C₆) alkyl; -R¹⁰-(C₃-C₁₄) cycloalkyl, wherein R¹⁰ is a bond or (C₁-C₆) alkyl; -(C₁-C₂₀) alkylene-(C=O)-O-R¹¹ wherein R¹¹ may be selected from H and (C₁-C₂₀)alkyl; and




15 and;

R³ is selected from the group consisting of H, -(C=O)-(C₁-C₂₄) alkyl; -(C=O)-O-(C₁-C₂₄) alkyl; and C₃-C₁₄ cycloalkyl, or

R² and R³ join together to form a C₃ to C₂₈ cyclic structure; and


with the proviso that when R² is (C₁-C₁₄ alkyl) at least one of R³, R⁵ and R⁶ is not H.

20 . In another aspect, the invention provides a compound of the formula (Ia):




25 wherein:

R₁ is:




wherein:

- 5 X is selected from the group consisting of NH₂, F and Cl;
 R⁵ is selected from the group consisting of H and (C₁-C₁₄) alkyl;
 R⁶ is selected from the group consisting of H and -(C=O)-(C₁-C₁₄) alkyl;
 R² is selected from the group consisting of (C₁-C₂₄) alkyl; C₃-C₁₄ cycloalkyl; (CH₂)_{n1}-
 O-(CH₂CH₂O)_{n2}-(C₁-C₁₄ alkyl) where n₁ and n₂ are integers independently selected from
 10 1-4, -R⁷-NH-(C=O)-R⁸ wherein R⁷ may be (C₁-C₁₄) alkyl and R⁸ may be independently
 selected from H and (C₁-C₁₄) alkyl; -R⁹-(C₆-C₁₄) aryl, wherein R⁹ is a bond or (C₁-C₆) alkyl;
 -R¹⁰-(C₃-C₁₄) cycloalkyl, wherein R¹⁰ is a bond or (C₁-C₆) alkyl; -(C₁-C₂₀) alkylene-(C=O)-O-
 R¹¹ wherein R¹¹ may be selected from H and (C₁-C₂₀)alkyl; and



and;

- R³ is selected from the group consisting of H, -(C=O)-(C₁-C₂₄) alkyl; -(C=O)-O-(C₁-
 C₂₄) alkyl; and C₃-C₁₄ cycloalkyl; or
 20 R² and R³ join together to form a C₃ to C₂₈ cyclic structure; and
 with the proviso that when R² is (C₁-C₁₈ alkyl) at least one of R³, R⁵ and R⁶ is not H.
 In another aspect, there is provided a compound of the formula (II):



25

wherein:

R₁ is:



5 wherein :


X is selected from the group consisting of NH₂, F and Cl;

R⁵ is selected from the group consisting of H and (C₁-C₁₄) alkyl;

R⁶ is selected from the group consisting of H and -(C=O)-(C₁-C₁₄) alkyl;

10 R² is selected from the group consisting of (C₁-C₂₄) alkyl; (CH₂)_{n1}-O-(CH₂CH₂O)_{n2}-(C₁-C₁₄) alkyl where n₁ and n₂ are integers independently selected from 1-4 -R⁷-NH-(C=O)-R⁸ wherein R⁷ may be (C₁-C₁₄) alkyl and R⁸ may be independently selected from H and (C₁-C₁₄) alkyl; -R⁹-(C₆-C₁₄) aryl, wherein R⁹ is a bond or (C₁-C₆) alkyl; -R¹⁰-(C₃-C₁₄) cycloalkyl, wherein R¹⁰ is a bond or (C₁-C₆) alkyl; -(C₁-C₂₀) alkylene-(C=O)-O-R¹¹ wherein R¹¹ may be selected from H and (C₁-C₂₀) alkyl; and

15




and;

20 R³ is selected from the group consisting of H, -(C=O)-(C₁-C₂₄) alkyl; -(C=O)-O-(C₁-C₂₄) alkyl; and C₃-C₁₄ cycloalkyl; or

R² and R³ join together to form a C₃ to C₂₈ cyclic structure.


. In another aspect, the invention provides a compound of the formula (IIa):



25

wherein:

R₁ is:



5


wherein:

X is selected from the group consisting of NH₂, F and Cl;

R⁵ is selected from the group consisting of H and (C₁-C₁₄) alkyl;

R⁶ is selected from the group consisting of H and -(C=O)-(C₁-C₁₄) alkyl;

- 10 R² is selected from the group consisting of (C₁-C₂₄) alkyl; C₃-C₁₄ cycloalkyl; (CH₂)_{n1}-O-(CH₂CH₂O)_{n2}-(C₁-C₁₄ alkyl) where n1 and n2 are integers independently selected from 1-4, -R⁷-NH-(C=O)-R⁸ wherein R⁷ may be (C₁-C₁₄) alkyl and R⁸ may be independently selected from H and (C₁-C₁₄) alkyl; -R⁹-(C₆-C₁₄) aryl, wherein R⁹ is a bond or (C₁-C₆) alkyl; -R¹⁰-(C₃-C₁₄) cycloalkyl, wherein R¹⁰ is a bond or (C₁-C₆) alkyl; -(C₁-C₂₀) alkylene-(C=O)-O-
- 15 R¹¹ wherein R¹¹ may be selected from H and (C₁-C₂₀) alkyl; and



and;

- 20 R³ is selected from the group consisting of H, -(C=O)-(C₁-C₂₄) alkyl; -(C=O)-O-(C₁-C₂₄) alkyl; and C₃-C₁₄ cycloalkyl; or

R² and R³ join together to form a C₃ to C₂₈ cyclic structure.

In one embodiment of the present invention, there is provided a compound of the formula (I), (Ia), (II) or (IIa), wherein X is F, and R⁵ and R⁶ are each H.

- 25 In one embodiment of the present invention, there is provided a compound of the formula (I), (Ia), (II) or (IIa), wherein X is F, R⁵ is H and R⁶ is -(C=O)-(C₁-C₁₄) alkyl

In one embodiment of the present invention, there is provided a compound of the formula (I), (Ia), (II) or (IIa), wherein R³ is H.

In one embodiment of the present invention, there is provided a compound of the formula (I), (Ia), (II) or (IIa), wherein R^3 is $-(C=O)-(C_1-C_{20})$ alkyl

In one embodiment of the present invention, there is provided a compound of the formula (I), (Ia), (II) or (IIa), wherein R^2 is C_6 aryl.

5 In one embodiment of the present invention, there is provided a compound of the formula (I), (Ia), (II) or (IIa), wherein R^2 is C_6 cycloalkyl.

In one embodiment of the present invention, there is provided a compound of the formula (I), (Ia), (II) or (IIa), wherein R^3 is H, X is F, R^5 is H, R^6 is H, and R^2 is $-R^7-NH-(C=O)-R^8$.

10 In one embodiment of the present invention, there is provided a compound of the formula (I), (Ia), (II) or (IIa), wherein R^3 is H, X is F, R^5 is H, R^6 is H, and R^2 is $-(C_1-C_{20})$ alkylene- $(C=O)-O-R^{11}$

In one embodiment of the present invention, there is provided a compound of the formula (I), (Ia), (II) or (IIa), wherein R^9 is a bond.

15 In one embodiment of the present invention, there is provided a compound of the formula (I), (Ia), (II) or (IIa), wherein R^9 is C_1 alkyl.

In one embodiment of the present invention, there is provided a compound of the formula (I), (Ia), (II) or (IIa), wherein R^2 is $-(CH_2)_{n1}-O-(CH_2CH_2O)_{n2}-(C_1-C_{14})$ alkyl where $n1$ and $n2$ are integers independently selected from 1-4, more preferably $n1$ and $n2$ are

20 independently selected from 1 and 2. In one preferred embodiment, R^2 is of the formula $-(CH_2)-O-(CH_2CH_2O)_{n2}-(C_1-C_2)$ alkyl wherein $n2$ is 1 or 2.


In one embodiment of the present invention, there is provided a compound of the formula (I), (Ia), (II) or (IIa), wherein R^{10} is H.

25 In one embodiment of the present invention, there is provided a compound of the formula (I), (Ia), (II) or (IIa), wherein R^{10} is C_1 alkyl.

In one preferred embodiment of the present invention, R^2 is $-(CH_2)_8-(C=O)-OH$. In one preferred embodiment, R^2 is $-(CH_2)_{12}-(C=O)-OH$. In one preferred embodiment, R^2 is $-(CH_2)_{18}-(C=O)-OH$.


30 In one embodiment of the present invention, there is provided a compound of the formula (I), (Ia), (II) or (IIa), wherein R^2 is $-(CH_2)_3-(C=O)-O-C_{14}$ alkyl.

In one embodiment of the present invention, there is provided a compound of the formula (I), (Ia), (II) or (IIa), wherein R^2 is of the formula:



In one embodiment of the present invention, there is provided a compound of the formula (I), (Ia), (II) or (IIa), wherein R² is of the formula:

5



In one embodiment of the present invention, there is provided a compound of the formula (I), (Ia), (II) or (IIa), wherein R² is (C₁-C₂₄) alkyl and R³ is -(C=O)-(C₁-C₂₀) alkyl

10 In one embodiment of the present invention, there is provided a compound of the formula (I), (Ia), (II) or (IIa), wherein R² is (C₁-C₂₄) alkyl, R⁵ is H and R⁶ is -(C=O)-(C₁-C₁₄) alkyl.

In one embodiment of the present invention, there is provided a compound of the formula (I), (Ia), (II) or (IIa), wherein R³ is H, R⁵ is H, R⁶ is H, and R² is R⁷-NH-(C=O)-R⁸
 15 wherein R⁷ (C₁-C₄) alkyl and R⁸ is (C₁-C₁₄) alkyl.

In one embodiment of the present invention, there is provided a compound of the formula (I), (Ia), (II) or (IIa), wherein R³ is -(C=O)-(C₁-C₂₄) alkyl, R⁵ is H, R⁶ is H, R² is -(C₁-C₂₄) alkyl and X is F.

In one embodiment of the present invention, there is provided a compound of the formula (I), (Ia), (II) or (IIa), wherein R³ is -(C=O)-O-(C₁-C₂₄) alkyl, R⁵ is H, R⁶ is H, R² is -(C₁-C₂₄) alkyl and X is F.
 20





In one embodiment of the present invention, there is provided a compound wherein R² and R³ join together to form a C₃ to C₂₈ cyclic structure. More preferably, in such an embodiment, R³ contains -(C=O)- group attached at one end to the oxygen substituent of formula (I); in preferred embodiments, accordingly, R² and R³ join together wherein R² is -(CH₂)_p- and R³ is -(C=O)-(CH₂)_q- wherein p and q are selected such that a C₃ to C₂₈ cyclic
 25

structure is formed. In a most preferred embodiment, p and q are selected such that a C₈ to C₁₈ structure is formed.

The compounds of the present invention may be optionally substituted by one or more substituents. For example, in one embodiment, each of R², R³, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰ and R¹¹ may be independently and optionally substituted by one or more (C₁-C₁₄) alkyl, Cl, F, oxo, or (C₁-C₆) alkoxy. In another embodiment, each of R², R³, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰ and R¹¹ may be independently and optionally substituted by one or more (C₁-C₆) alkyl, Cl, F, oxo, or (C₁-C₆) alkoxy. Preferably, as an example, each of the (C₆-C₁₄) aryl and (C₃-C₁₄) cycloalkyl groups may be optionally substituted by one or more substituents from (C₁-C₅) alkyl, Cl, F, oxo, or (C₁-C₆) alkoxy. In various preferred embodiments, each of R², R³, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰ and R¹¹, and in particular (C₆-C₁₄) aryl (e.g., (C₆) aryl) may be substituted by one or more -C-O-(C=O)-(C₁-C₆ alkyl).

In another aspect of the present invention, the invention may encompass various individual compounds. As an example, such specific compounds may be selected from the group consisting of Table 1:

Table 1

Example	Structure	Chemical Name
1		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl cyclohexanecarboxylate
2		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl benzoate
3		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl 2-phenylacetate
4		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl trans-4-(tert-butyl)cyclohexane-1-carboxylate

5		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl trans-4-pentylcyclohexane-1-carboxylate
6		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl 2-(2-methoxyethoxy)acetate
7		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl 2-(2-(2-methoxyethoxy)ethoxy)acetate
8		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl 2-(2-butoxyethoxy)acetate
9		10-(((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methoxy)-10-oxodecanoic acid
10		14-(((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methoxy)-14-oxotetradecanoic acid
11		20-(((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methoxy)-20-oxoicosanoic acid
12		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl (1,3-bis(heptanoyloxy)propan-2-yl) glutarate
13		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl (1,3-bis(tetradecanoyloxy)propan-2-yl) glutarate









14		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl tetradecyl glutarate
15		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((ethoxycarbonyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methyl decanoate
16		(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((heptanoyloxy)methyl)tetrahydrofuran-3-yl heptanoate
17		(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((tetradecanoyloxy)methyl)tetrahydrofuran-3-yl tetradecanoate
18		(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-((decanoyloxy)methyl)-2-ethynyltetrahydrofuran-3-yl decanoate
19		(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((pentanoyloxy)methyl)tetrahydrofuran-3-yl tridecanoate
20		(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((pentanoyloxy)methyl)tetrahydrofuran-3-yl heptanoate








21		(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((pentanoyloxy)methyl)tetrahydrofuran-3-yl undecanoate
22		(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((pentanoyloxy)methyl)tetrahydrofuran-3-yl nonanoate
23		(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((pentanoyloxy)methyl)tetrahydrofuran-3-yl pentanoate
24		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-(propionyloxy)tetrahydrofuran-2-yl)methyl pentanoate
25		((2R,3S,5R)-5-(6-butylamido-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl pentanoate
26		((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-octanamido-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl pentanoate
27		((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl pentanoate
28		((2R,3S,5R)-5-(6-dodecanamido-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl pentanoate

29		(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(((2-propylpentanoyl)oxy)methyl)tetrahydrofuran-3-yl dodecanoate
30		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-(butyryloxy)-2-ethynyltetrahydrofuran-2-yl)methyl 2-propylpentanoate
31		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-(butyryloxy)-2-ethynyltetrahydrofuran-2-yl)methyl decanoate
32		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-(heptanoyloxy)tetrahydrofuran-2-yl)methyl benzoate
33		(2R,3aS,20aR)-2-(6-amino-2-fluoro-9H-purin-9-yl)-20a-ethynylhexadecahydro-2H-furo[3,2-b][1,5]dioxacyclononadecine-5,18-dione
34		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl heptanoylglycinate
35		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl tetradecanoylglycinate
36		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl heptanoyl-L-alaninate

37		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-(butyryloxy)-2-ethynyltetrahydrofuran-2-yl)methyl tetradecanoate
38		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-(((hexyloxy)carbonyl)oxy)tetrahydrofuran-2-yl)methyl tetradecanoate
39		(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(((2-propylpentanoyl)oxy)methyl)tetrahydrofuran-3-yl heptanoate
40		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl tetradecanoyl-L-alaninate
41		(2R,3S,5R)-2-(acetoxymethyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-3-yl heptanoate
42		((2R,3S,5R)-5-(6-decanamido-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl heptanoate
43		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-(((hexyloxy)carbonyl)oxy)tetrahydrofuran-2-yl)methyl heptanoate
44		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-(((hexyloxy)carbonyl)oxy)tetrahydrofuran-2-yl)methyl decanoate

45		((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl benzoate
46		((2R,3S,5R)-5-(6-decanamido-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl benzoate
47		((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl heptanoate
48		((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl decanoate
49		((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl 2-propylpentanoate
50		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl 3-(2-acetoxy-4,6-dimethylphenyl)-3-methylbutanoate
51		(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((heptanoyloxy)methyl)tetrahydrofuran-3-yl tetradecanoate
52		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-(((tridecyloxy)carbonyl)oxy)tetrahydrofuran-2-yl)methyl heptanoate
53		(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((propionyloxy)methyl)tetrahydrofuran-3-yl stearate

54		((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-heptanamido-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl 2-propylpentanoate
55		((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl propionate
56		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((ethoxycarbonyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methyl tetradecanoate
57		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl (1,3-bis(isobutyryloxy)propan-2-yl) succinate
58		(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-((dodecanoyloxy)methyl)-2-ethynyltetrahydrofuran-3-yl dodecanoate
59		(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((palmitoyloxy)methyl)tetrahydrofuran-3-yl palmitate
60		(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((icosanoyloxy)methyl)tetrahydrofuran-3-yl icosanoate
61		(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((undecanoyloxy)methyl)tetrahydrofuran-3-yl undecanoate

62		(2R,3aS,26aR)-2-(6-amino-2-fluoro-9H-purin-9-yl)-26a-ethynyldocosahydro-2H-furo[3,2-b][1,5]dioxacyclopentacosine-5,24-dione
63		(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((hexanoyloxy)methyl)tetrahydrofuran-3-yl hexanoate
64		(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((nonanoyloxy)methyl)tetrahydrofuran-3-yl nonanoate
65		(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((octanoyloxy)methyl)tetrahydrofuran-3-yl octanoate
66		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl 3-(2,4-dimethyl-6-(pivaloyloxy)phenyl)-3-methylbutanoate
67		2-(4-(((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methoxy)-2-methyl-4-oxobutan-2-yl)-3,5-dimethylphenyl decanoate
68		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl (1,3-bis(heptanoyloxy)propan-2-yl) succinate

and pharmaceutically acceptable salts thereof.

In one embodiment, the present invention encompasses each individual compound listed in the above Table 1, or a pharmaceutically acceptable salt thereof.

5 In various embodiments, prodrugs of any of the compounds of formula (I), (Ia), (II) or (IIa) set forth herein are also within the scope of the present invention.

In accordance with one embodiment of the present invention, there is provided a pharmaceutical composition comprising a compound of Formulas (I), (Ia), (II) or (IIa) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. In a further embodiment, a compound is present in amorphous form. In a further
5 embodiment, the compound is present in crystalline form. In various preferred embodiments, in particular, the compounds of the structure of Examples 18, 38 and 58 may be each present in crystalline form as well as amorphous form. In a further embodiment, the pharmaceutical composition is in a tablet form. In a further embodiment, the pharmaceutical composition is in parenteral form. In a further embodiment, the
10 compound is present as a spray dried dispersion.

In accordance with one embodiment of the present invention, there is provided a method of treating an HIV infection in a subject comprising administering to the subject a compound of Formulas (I), (Ia), (II) or (IIa) or a pharmaceutically acceptable salt thereof.

In accordance with one embodiment of the present invention, there is provided a
15 method of treating an HIV infection in a subject comprising administering to the subject a pharmaceutical composition as described herein.

In accordance with one embodiment of the present invention, there is provided a method of preventing an HIV infection in a subject at risk for developing an HIV infection, comprising administering to the subject a compound of Formulas (I), (Ia), (II) or (IIa) or a
20 pharmaceutically acceptable salt thereof.

In accordance with one embodiment of the present invention, there is provided the use of a compound of Formula (I), (Ia), (II) or (IIa) in the manufacture of a medicament for treating an HIV infection.

In accordance with one embodiment of the present invention, there is provided the
25 use of a compound of Formula (I), (Ia), (II) or (IIa) in the manufacture of a medicament for preventing an HIV infection.

In accordance with one embodiment of the present invention, there is provided a compound according to Formula (I), (Ia), (II) or (IIa) for use in treating an HIV infection.

In accordance with one embodiment of the present invention, there is provided a
30 compound according to Formula (I), (Ia), (II) or (IIa) for use in preventing an HIV infection.

In accordance with one embodiment of the present invention, there is provided a method of preventing an HIV infection in a subject at risk for developing an HIV infection, comprising administering to the subject a pharmaceutical composition as described
herein.

35 Furthermore, the compounds of the invention can exist in particular geometric or stereoisomeric forms. The invention contemplates all such compounds, including cis- and

trans-isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-
isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, such as
enantiomerically or diastereomerically enriched mixtures, as falling within the scope of the
invention. Additional asymmetric carbon atoms can be present in a substituent such as an
5 alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in
this invention.

Optically active (R)- and (S)-isomers and d and l isomers can be prepared using
chiral synthons or chiral reagents, or resolved using conventional techniques. If, for
instance, a particular enantiomer of a compound of the present invention is desired, it can
10 be prepared by asymmetric synthesis, or by derivatization with a chiral auxiliary, where the
resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide
the pure desired enantiomers. Alternatively, where the molecule contains a basic
functional group, such as an amino group, or an acidic functional group, such as a
carboxyl group, diastereomeric salts can be formed with an appropriate optically active
15 acid or base, followed by resolution of the diastereomers thus formed by fractional
crystallization or chromatographic means known in the art, and subsequent recovery of
the pure enantiomers. In addition, separation of enantiomers and diastereomers is
frequently accomplished using chromatography employing chiral, stationary phases,
optionally in combination with chemical derivatization (e.g., formation of carbamates from
20 amines).

In another embodiment of the invention, there is provided a compound of Formula
(I), (Ia), (II) or (IIa) wherein the compound or salt of the compound is used in the
manufacture of a medicament for use in the treatment of an HIV infection in a human.

In another embodiment of the invention, there is provided a compound of Formula
25 (I), (Ia), (II) or (IIa) wherein the compound or salt of the compound is used in the
manufacture of a medicament for use in the prevention of an HIV infection in a human.

In one embodiment, the pharmaceutical formulation containing a compound of
Formula (I), (Ia), (II) or (IIa) or a salt thereof is a formulation adapted for parenteral
administration. In another embodiment, the formulation is a long-acting parenteral
30 formulation. In a further embodiment, the formulation is a nano-particle formulation.

The compounds of the present invention and their salts, solvates, or other
pharmaceutically acceptable derivatives thereof, may be employed alone or in
combination with other therapeutic agents. Therefore, in other embodiments, the methods
of treating and/or preventing an HIV infection in a subject may in addition to administration
35 of a compound of Formula (I), (Ia), (II) or (IIa) further comprise administration of one or
more additional pharmaceutical agents active against HIV.

In such embodiments, the one or more additional agents active against HIV is selected from the group consisting of zidovudine, didanosine, lamivudine, zalcitabine, abacavir, stavudine, adefovir, adefovir dipivoxil, fozivudine, todoxil, emtricitabine, alovudine, amdoxovir, elvucitabine, nevirapine, delavirdine, efavirenz, loviride, immunocal, oltipraz, capravirine, lersivirine, GSK2248761, TMC-278, TMC-125, etravirine, saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, fosamprenavir, brecanavir, darunavir, atazanavir, tipranavir, palinavir, lasinavir, enfuvirtide, T-20, T-1249, PRO-542, PRO-140, TNX-355, BMS-806, BMS-663068 and BMS-626529, 5-Helix, raltegravir, elvitegravir, dolutegravir, cabotegravir, bictegravir, vicriviroc (Sch-C), Sch-D, TAK779, maraviroc, TAK449, didanosine, tenofovir, lopinavir, and darunavir.

As such, the compounds of the present invention of Formulas (I), (Ia), (II) or (IIa) and any other pharmaceutically active agent(s) may be administered together or separately and, when administered separately, administration may occur simultaneously or sequentially, in any order. The amounts of the compounds of Formula (I), (Ia), (II) or (IIa) of the present invention and the other pharmaceutically active agent(s) and the relative timings of administration will be selected in order to achieve the desired combined therapeutic effect. The administration in combination of a compound of the present invention of Formula (I), (Ia), (II) or (IIa) and salts, solvates, or other pharmaceutically acceptable derivatives thereof with other treatment agents may be in combination by administration concomitantly in: (1) a unitary pharmaceutical composition including both compounds; or (2) separate pharmaceutical compositions each including one of the compounds. Alternatively, the combination may be administered separately in a sequential manner wherein one treatment agent is administered first and the other second or vice versa. Such sequential administration may be close in time or remote in time. The amounts of the compound(s) of Formula (I), (Ia), (II) or (IIa) or salts thereof and the other pharmaceutically active agent(s) and the relative timings of administration will be selected in order to achieve the desired combined therapeutic effect.

In addition, the compounds of the present invention of Formula (I), (Ia), (II) or (IIa) may be used in combination with one or more other agents that may be useful in the prevention or treatment of HIV. Examples of such agents include:

Nucleotide reverse transcriptase inhibitors such as zidovudine, didanosine, lamivudine, zalcitabine, abacavir, stavudine, adefovir, adefovir dipivoxil, fozivudine, todoxil, emtricitabine, alovudine, amdoxovir, elvucitabine, and similar agents;
Non-nucleotide reverse transcriptase inhibitors (including an agent having anti-oxidation activity such as immunocal, oltipraz, etc.) such as nevirapine, delavirdine, efavirenz,

loviride, immunocal, oltipraz, capravirine, lersivirine, doravirine, GSK2248761, TMC-278, TMC-125, etravirine, and similar agents;

Protease inhibitors such as saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, fosamprenavir, brecanavir, darunavir, atazanavir, tipranavir, palinavir, lasinavir, and similar agents;

Entry, attachment and fusion inhibitors such as enfuvirtide (T-20), T-1249, PRO-542, PRO-140, TNX-355, BMS-806, BMS-663068 (Fostemsavir), BMS-626529 (Temsavir), 5-Helix and similar agents;

Integrase inhibitors such as raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir and similar agents;

Maturation inhibitors such as PA-344 and PA-457, and similar agents; and

CXCR4 and/or CCR5 inhibitors such as vicriviroc (Sch-C), Sch-D, TAK779, maraviroc (UK 427,857), TAK449, as well as those disclosed in WO 02/74769, PCT/US03/39644, PCT/US03/39975, PCT/US03/39619, PCT/US03/39618, PCT/US03/39740, and PCT/US03/39732, and similar agents.

CAPSID inhibitors such GS-6207, and similar agents.

Further examples where the compounds of the present invention may be used in combination with one or more agents useful in the prevention or treatment of HIV are found in Table 2.

Table 2:

FDA Approval	Brand Name	Generic Name	Manufacturer
<i>Nucleoside Reverse Transcriptase Inhibitors (NRTIs)</i>			
1987	Retrovir	zidovudine, azidothymidine, AZT, ZDV	GlaxoSmithKline
1991	Videx	didanosine, dideoxyinosine, ddI	Bristol-Myers Squibb
1992	Hivid	zalcitabine, dideoxycytidine, ddC	Roche Pharmaceuticals
1994	Zerit	stavudine, d4T	Bristol-Myers Squibb
1995	Epivir	lamivudine, 3TC	GlaxoSmithKline
1997	Combivir	lamivudine + zidovudine	GlaxoSmithKline
1998	Ziagen	abacavir sulfate, ABC	GlaxoSmithKline
2000	Trizivir	abacavir+ lamivudine+ zidovudine	GlaxoSmithKline
2000	Videx EC	enteric coated didanosine, ddI EC	Bristol-Myers Squibb
2001	Viread	tenofovir disoproxil fumarate, TDF	Gilead Sciences
2003	Emtriva	emtricitabine, FTC	Gilead Sciences
2004	Epzicom	abacavir+ lamivudine	GlaxoSmithKline
2004	Truvada	emtricitabine + tenofovir disoproxil fumarate	Gilead Sciences
<i>Non-Nucleosides Reverse Transcriptase Inhibitors (NNRTIs)</i>			
1996	Viramune	nevirapine, NVP	Boehringer Ingelheim
1997	Rescriptor	delavirdine, DLV	Pfizer
1998	Sustiva	efavirenz, EFV	Bristol-Myers Squibb
2008	Intelence	Etravirine	Tibotec Therapeutics
2011	Edurant	Rilpivirine	Tibotec Therapeutics
2018	Pifeltro	Doravirine	Merck
<i>Protease Inhibitors (PIs)</i>			
1995	Invirase	saquinavir mesylate, SQV	Roche Pharmaceuticals

1996	Norvir	ritonavir, RTV	Abbott Laboratories
1996	Crixivan	indinavir, IDV	Merck
1997	Viracept	nelfinavir mesylate, NFV	Pfizer
1997	Fortovase	saquinavir (no longer marketed)	Roche Pharmaceuticals
1999	Agenerase	amprenavir, APV	GlaxoSmithKline
2000	Kaletra	lopinavir+ ritonavir, LPV/RTV	Abbott Laboratories
2003	Reyataz	atazanavir sulfate, ATV	Bristol-Myers Squibb
2003	Lexiva	fosamprenavir calcium, FOS-APV	GlaxoSmithKline
2005	Aptivus	tripranavir, TPV	Boehringer Ingelheim
2006	Prezista	Darunavir	Tibotec Therapeutics
<i>Fusion Inhibitors</i>			
2003	Fuzeon	Enfuvirtide, T-20	Roche Pharmaceuticals & Trimeris
<i>Entry Inhibitors</i>			
2007	Selzentry	Maraviroc	Pfizer
<i>Integrase Inhibitors</i>			
2007	Isentress	Raltegravir	Merck
2013	Tivicay	Dolutegravir	ViiV Healthcare
2018		Bictegravir	Gilead Sciences
---	---	Cabotegravir	ViiV Healthcare
<i>Capsid Inhibitors</i>			
---		GS-6207	Gilead Sciences

The scope of combinations of compounds of this invention with HIV agents is not limited to those mentioned above, but includes in principle any combination with any pharmaceutical composition useful for the treatment and/or prevention of HIV. As noted, in such combinations the compounds of the present invention and other HIV agents may be administered separately or in conjunction. In addition, one agent may be prior to, concurrent to, or subsequent to the administration of other agent(s).

The present invention may be used in combination with one or more agents useful as pharmacological enhancers as well as with or without additional compounds for the prevention or treatment of HIV. Examples of such pharmacological enhancers (or pharmakinetik boosters) include, but are not limited to, ritonavir, GS-9350, and SPI-452. Ritonavir is 10-hydroxy-2-methyl-5-(1-methylethyl)-1-[2-(1-methylethyl)-4-thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-2,4,7,12-tetraazatridecan-13-oic acid, 5-thiazolylmethyl ester, [5S-(5S*,8R*,10R*,11R*)] and is available from Abbott Laboratories of Abbott park, Illinois, as Norvir. Ritonavir is an HIV protease inhibitor indicated with other antiretroviral

agents for the treatment of HIV infection. Ritonavir also inhibits P450 mediated drug metabolism as well as the P-glycoprotein (Pgp) cell transport system, thereby resulting in increased concentrations of active compound within the organism.

GS-9350 is a compound being developed by Gilead Sciences of Foster City California as
5 a pharmacological enhancer.

SPI-452 is a compound being developed by Sequoia Pharmaceuticals of Gaithersburg, Maryland, as a pharmacological enhancer.

In one embodiment of the present invention, a compound of Formula (I), (Ia), (II) or (IIa) is used in combination with ritonavir. In one embodiment, the combination is an oral
10 fixed dose combination. In another embodiment, the compound of Formula (I), (Ia), (II) or (IIa) is formulated as a long acting parenteral injection and ritonavir is formulated as an oral composition. In one embodiment, a kit containing the compound of Formula (I), (Ia), (II) or (IIa) is formulated as a long acting parenteral injection and ritonavir formulated as an oral composition. In another embodiment, the compound of Formula (I), (Ia), (II) or (IIa) is
15 formulated as a long acting parenteral injection and ritonavir is formulated as an injectable composition. In one embodiment, a kit containing the compound of Formula (I), (Ia), (II) or (IIa) is formulated as a long acting parenteral injection and ritonavir formulated as an injectable composition.

In another embodiment of the present invention, a compound of Formula (I), (Ia),
20 (II) or (IIa) is used in combination with GS-9350. In one embodiment, the combination is an oral fixed dose combination. In another embodiment, the compound of Formula (I), (Ia), (II) or (IIa) is formulated as a long acting parenteral injection and GS-9350 is formulated as an oral composition. In one embodiment, there is provided a kit containing the compound of Formula (I), (Ia), (II) or (IIa) is formulated as a long acting parenteral injection and GS-
25 9350 formulated as an oral composition. In another embodiment, the compound of Formula (I), (Ia), (II) or (IIa) is formulated as a long acting parenteral injection and GS-9350 is formulated as an injectable composition. In one embodiment, is a kit containing the compound of Formula (I), (Ia), (II) or (IIa) is formulated as a long acting parenteral injection and GS-9350 formulated as an injectable composition.

In one embodiment of the present invention, a compound of Formula (I), (Ia), (II) or (IIa) is used in combination with SPI-452. In one embodiment, the combination is an oral
30 fixed dose combination. In another embodiment, the compound of Formula (I), (Ia), (II) or (IIa) is formulated as a long acting parenteral injection and SPI-452 is formulated as an oral composition. In one embodiment, there is provided a kit containing the compound of Formula (I) formulated as a long acting parenteral injection and SPI-452 formulated as an
35 oral composition. In another embodiment, the compound of Formula (I), (Ia), (II) or (IIa) is

formulated as a long acting parenteral injection and SPI-452 is formulated as an injectable composition. In one embodiment, there is provided a kit containing the compound of Formula (I), (Ia), (II) or (IIa) formulated as a long acting parenteral injection and SPI-452 formulated as an injectable composition.

5 In one embodiment of the present invention, a compound of Formula (I), (Ia), (II) or (IIa) is used in combination with compounds which are found in previously filed PCT/CN2011/0013021, which is herein incorporated by reference.

The above other therapeutic agents, when employed in combination with the chemical entities described herein, may be used, for example, in those amounts indicated
10 in the Physicians' Desk Reference (PDR) or as otherwise determined by one of ordinary skill in the art.

In another embodiment of the invention, there is provided a method for treating a viral infection in a mammal mediated at least in part by a virus in the *retrovirus* family of viruses which method comprises administering to a mammal, that has been diagnosed
15 with said viral infection or is at risk of developing said viral infection, a compound of Formula (I), (Ia), (II) or (IIa).

In another embodiment of the invention, there is provided a method for treating a viral infection in a mammal mediated at least in part by a virus in the *retrovirus* family of viruses which method comprises administering to a mammal, that has been diagnosed
20 with said viral infection or is at risk of developing said viral infection, a compound of Formula (I), (Ia), (II) or (IIa), wherein said virus is an HIV virus. In some embodiments, the HIV virus is the HIV-1 virus.

In another embodiment of the invention, there is provided a method for treating a viral infection in a mammal mediated at least in part by a virus in the *retrovirus* family of
25 viruses which method comprises administering to a mammal, that has been diagnosed with said viral infection or is at risk of developing said viral infection, a compound of Formula (I), (Ia), (II) or (IIa) further comprising administration of a therapeutically effective amount of one or more agents active against an HIV virus.

In another embodiment of the invention, there is provided a method for treating a
30 viral infection in a mammal mediated at least in part by a virus in the *retrovirus* family of viruses which method comprises administering to a mammal, that has been diagnosed with said viral infection or is at risk of developing said viral infection, a compound of Formula (I), (Ia), (II) or (IIa), further comprising administration of a therapeutically effective amount of one or more agents active against the HIV virus, wherein said agent active
35 against HIV virus is selected from Nucleotide reverse transcriptase inhibitors; Non-nucleotide reverse transcriptase inhibitors; Protease inhibitors; Entry, attachment and

fusion inhibitors; Integrase inhibitors; Maturation inhibitors; CAPSID inhibitors, CXCR4 inhibitors; and CCR5 inhibitors.

In another embodiment of the invention, there is provided a method for preventing a viral infection in a mammal mediated at least in part by a virus in the *retrovirus* family of viruses which method comprises administering to a mammal, that has been diagnosed
5 with said viral infection or is at risk of developing said viral infection, a compound of Formula (I), (Ia), (II) or (IIa).

In another embodiment of the invention, there is provided a method for preventing a viral infection in a mammal mediated at least in part by a virus in the *retrovirus* family of viruses which method comprises administering to a mammal, that has been diagnosed
10 with said viral infection or is at risk of developing said viral infection, a compound of Formula (I), (Ia), (II) or (IIa), wherein said virus is an HIV virus. In some embodiments, the HIV virus is the HIV-1 virus.

In another embodiment of the invention, there is provided a method for preventing
15 a viral infection in a mammal mediated at least in part by a virus in the *retrovirus* family of viruses which method comprises administering to a mammal, that has been diagnosed with said viral infection or is at risk of developing said viral infection, a compound of Formula (I), (Ia), (II) or (IIa), further comprising administration of a therapeutically effective amount of one or more agents active against an HIV virus.

In another embodiment of the invention, there is provided a method for preventing
20 a viral infection in a mammal mediated at least in part by a virus in the *retrovirus* family of viruses which method comprises administering to a mammal, that has been diagnosed with said viral infection or is at risk of developing said viral infection, a compound of Formula (I), (Ia), (II) or (IIa) further comprising administration of a therapeutically effective
25 amount of one or more agents active against the HIV virus, wherein said agent active against HIV virus is selected from Nucleotide reverse transcriptase inhibitors; Non-nucleotide reverse transcriptase inhibitors; Protease inhibitors; Entry, attachment and fusion inhibitors; Integrase inhibitors; Maturation inhibitors; CAPSID inhibitors, CXCR4 inhibitors; and CCR5 inhibitors.

In further embodiments, the compound of the present invention of Formula (I), (Ia), (II) or (IIa) or a pharmaceutically acceptable salt thereof, is selected from the group of compounds set forth in Table 1 above.

The compounds of Table 1 were synthesized according to the Synthetic Methods, General Schemes, and the Examples described below.

In another embodiment, there is provided a pharmaceutical composition comprising a pharmaceutically acceptable diluent and a therapeutically effective amount of a compound of Formula (I), (Ia), (II) or (IIa) or a pharmaceutically acceptable salt thereof.

In certain embodiments, the compound(s) of the present invention, or a pharmaceutically acceptable salt thereof, is chosen from the compounds set forth in Table 1.

The compounds of the present invention can be supplied in the form of a pharmaceutically acceptable salt. The term "pharmaceutically acceptable salt" may refer to salts prepared from pharmaceutically acceptable inorganic and organic acids and bases. Accordingly, the word "or" in the context of "a compound or a pharmaceutically acceptable salt thereof" is understood to refer to either a compound or a pharmaceutically acceptable salt thereof (alternative), or a compound and a pharmaceutically acceptable salt thereof (in combination).

The compounds of Formula (I), (Ia), (II) or (IIa) of the invention may exist in both unsolvated and solvated forms. The term 'solvate' comprises the compound of the invention and one or more pharmaceutically acceptable solvent molecules, for example, ethanol. The term 'hydrate' is employed when said solvent is water. Pharmaceutically acceptable solvates include hydrates and other solvates wherein the solvent of crystallization may be isotopically substituted, e.g. D₂O, d₆-acetone, d₆-DMSO.

Compounds of Formula (I), (Ia), (II) or (IIa) containing one or more asymmetric carbon atoms can exist as two or more stereoisomers. Where a compound of Formula (I), (Ia), (II) or (IIa) contains an alkenyl or alkenylene group or a cycloalkyl group, geometric *cis/trans* (or *Z/E*) isomers are possible. Where the compound contains, for example, a keto or oxime group or an aromatic moiety, tautomeric isomerism ('tautomerism') can occur. It follows that a single compound may exhibit more than one type of isomerism.

Included within the scope of the claimed compounds present invention are all stereoisomers, geometric isomers and tautomeric forms of the compounds of Formula (I), (Ia), (II) or (IIa), including compounds exhibiting more than one type of isomerism, and mixtures of one or more thereof. Also included are acid addition or base salts wherein the counterion is optically active, for example, D-lactate or L-lysine, or racemic, for example, DL-tartrate or DL-arginine.

Cis/trans isomers may be separated by conventional techniques well known to those skilled in the art, for example, chromatography and fractional crystallisation.

Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the

racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC), Supercritical fluid chromatography (SFC).

Alternatively, the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound of
5 Formula (I) contains an acidic or basic moiety, an acid or base such as tartaric acid or 1-phenylethylamine. The resulting diastereomeric mixture may be separated by chromatography and/or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to a skilled person.

10 Chiral compounds of the invention (and chiral precursors thereof) may be obtained in enantiomerically-enriched form using chromatography, typically HPLC or SFC, on a resin with an asymmetric stationary phase and with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50% isopropanol, typically from 2 to 20%, and from 0 to 5% of an alkylamine, typically 0.1% diethylamine.

15 Concentration of the eluate affords the enriched mixture.

Mixtures of stereoisomers may be separated by conventional techniques known to those skilled in the art. [see, for example, "Stereochemistry of Organic Compounds" by E L Eliel (Wiley, New York, 1994).]


The present invention includes all pharmaceutically acceptable isotopically-labelled
20 compounds of Formula (I), (Ia), (II) or (IIa) wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature.

Examples of isotopes suitable for inclusion in the compounds of the invention include isotopes of hydrogen, such as ^2H and ^3H , carbon, such as ^{11}C , ^{13}C and ^{14}C ,
25 chlorine, such as ^{36}Cl , fluorine, such as ^{18}F , iodine, such as ^{123}I and ^{125}I , nitrogen, such as ^{13}N and ^{15}N , oxygen, such as ^{15}O , ^{17}O and ^{18}O , phosphorus, such as ^{32}P , and sulphur, such as ^{35}S .

Certain isotopically-labelled compounds of Formula (I), (Ia), (II) or (IIa), for example, those incorporating a radioactive isotope, are useful in drug and/or substrate
30 tissue distribution studies. The radioactive isotopes tritium, *i.e.* ^3H , and carbon-14, *i.e.* ^{14}C , are particularly useful for this purpose in view of their ease of incorporation and ready means of detection. Substitution with heavier isotopes such as deuterium, *i.e.* ^2H , may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased *in vivo* half-life or reduced dosage requirements, and hence may be
35 preferred in some circumstances.

Isotopically-labelled compounds of Formula (I), (Ia), (II) or (IIa) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein using an appropriate isotopically-labelled reagents in place of the non-labelled reagent previously employed.

5 The compounds of the present invention may be administered as prodrugs. Thus, certain derivatives of compounds of Formula (I), (Ia), (II) or (IIa), which may have little or no pharmacological activity themselves can, when administered into or onto the body, be converted into compounds of Formula (I), (Ia), (II) or (IIa) as 'prodrugs'. One example of a compound that such prodrugs may encompass is 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) disclosed e.g., in U.S. Patent No. 7,339,053. The compounds of the present
10 invention may be administered as prodrugs. In one embodiment, the compounds of the invention are prodrugs of 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) disclosed e.g., in U.S. Patent No. 7,339,053, which is a nucleoside reverse transcriptase inhibitor of the formula:



4'-Ethynyl-2-fluoro-2'-deoxyadenosine

15 (EFdA)

The prodrugs are useful in that they are capable of modulating physicochemical properties, facilitating multiple dosing paradigms and improving pharmacokinetic and/or pharmacodynamic profiles of the active parent (EFdA). For example, the prodrugs may facilitate long-acting parenteral dosing modalities, and/or improvements in antiviral
20 persistence profiles as compared to EFdA.

Administration of the chemical entities and combinations of entities described herein can be *via* any of the accepted modes of administration for agents that serve similar utilities including, but not limited to, orally, sublingually, subcutaneously, intravenously, intranasally, topically, transdermally, intraperitoneally, intramuscularly,
25 intrapulmonarily, vaginally, rectally, or intraocularly. In some embodiments, oral or parenteral administration is used. Examples of dosing include, without limitation, once every seven days for oral, once every eight weeks for intramuscular, or once every six months for subcutaneous.

Pharmaceutical compositions or formulations include solid, semi-solid, liquid and
30 aerosol dosage forms, such as, e.g., tablets, capsules, powders, liquids, suspensions,

suppositories, aerosols or the like. The chemical entities can also be administered in sustained or controlled release dosage forms, including depot injections, osmotic pumps, pills, transdermal (including electrotransport) patches, and the like, for prolonged and/or timed, pulsed administration at a predetermined rate. In certain embodiments, the compositions are provided in unit dosage forms suitable for single administration of a precise dose.

The chemical entities described herein can be administered either alone or more typically in combination with a conventional pharmaceutical carrier, excipient or the like (e.g., mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, sodium crosscarmellose, glucose, gelatin, sucrose, magnesium carbonate, and the like). If desired, the pharmaceutical composition can also contain minor amounts of nontoxic auxiliary substances such as wetting agents, emulsifying agents, solubilizing agents, pH buffering agents and the like (e.g., sodium acetate, sodium citrate, cyclodextrine derivatives, sorbitan monolaurate, triethanolamine acetate, triethanolamine oleate, and the like). Generally, depending on the intended mode of administration, the pharmaceutical composition will contain about 0.005% to 95%; in certain embodiments, about 0.5% to 50% by weight of a chemical entity. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see *Remington's Pharmaceutical Sciences*, Mack Publishing Company, Easton, Pennsylvania.

In certain embodiments, the compositions will take the form of a pill or tablet and thus the composition will contain, along with the active ingredient, a diluent such as lactose, sucrose, dicalcium phosphate, or the like; a lubricant such as magnesium stearate or the like; and a binder such as starch, gum acacia, polyvinylpyrrolidone, gelatin, cellulose, cellulose derivatives or the like. In another solid dosage form, a powder, marume, solution or suspension (e.g., in propylene carbonate, vegetable oils or triglycerides) is encapsulated in a gelatin capsule.

Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc. at least one chemical entity and optional pharmaceutical adjuvants in a carrier (e.g., water, saline, aqueous dextrose, glycerol, glycols, ethanol or the like) to form a solution or suspension. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, as emulsions, or in solid forms suitable for dissolution or suspension in liquid prior to injection. The percentage of chemical entities contained in such parenteral compositions is highly dependent on the specific nature thereof, as well as the activity of the chemical entities and the needs of the subject. However, percentages of active ingredient of 0.01% to 10% in solution are employable, and will be higher if the composition is a solid which will be subsequently diluted to the

above percentages. In certain embodiments, the composition may comprise from about 0.2 to 2% of the active agent in solution.

Pharmaceutical compositions of the chemical entities described herein may also be administered to the respiratory tract as an aerosol or solution for a nebulizer, or as a microfine powder for insufflation, alone or in combination with an inert carrier such as lactose. In such a case, the particles of the pharmaceutical composition have diameters of less than 50 microns, in certain embodiments, less than 10 microns.

In general, the chemical entities provided will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities. The actual amount of the chemical entity, i.e., the active ingredient, will depend upon numerous factors such as the severity of the disease to be treated, the age and relative health of the subject, the potency of the chemical entity used the route and form of administration, and other factors. The drug can be administered more than once a day, such as once or twice a day.

In general, the chemical entities will be administered as pharmaceutical compositions by any one of the following routes: oral, systemic (e.g., transdermal, intranasal or by suppository), or parenteral (e.g., intramuscular, intravenous or subcutaneous) administration. In certain embodiments, oral administration with a convenient daily dosage regimen that can be adjusted according to the degree of affliction may be used. Compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols, or any other appropriate compositions. Another manner for administering the provided chemical entities is inhalation.

The choice of formulation depends on various factors such as the mode of drug administration and bioavailability of the drug substance. For delivery *via* inhalation the chemical entity can be formulated as liquid solution, suspensions, aerosol propellants or dry powder and loaded into a suitable dispenser for administration. There are several types of pharmaceutical inhalation devices-nebulizer inhalers, metered dose inhalers (MDI) and dry powder inhalers (DPI). Nebulizer devices produce a stream of high velocity air that causes the therapeutic agents (which are formulated in a liquid form) to spray as a mist that is carried into the patient's respiratory tract. MDIs typically are formulation packaged with a compressed gas. Upon actuation, the device discharges a measured amount of therapeutic agent by compressed gas, thus affording a reliable method of administering a set amount of agent. DPI dispenses therapeutic agents in the form of a free flowing powder that can be dispersed in the patient's inspiratory air-stream during breathing by the device. In order to achieve a free flowing powder, the therapeutic agent is

formulated with an excipient such as lactose. A measured amount of the therapeutic agent is stored in a capsule form and is dispensed with each actuation.

Recently, pharmaceutical compositions have been developed for drugs that show poor bioavailability based upon the principle that bioavailability can be increased by increasing the surface area i.e., decreasing particle size. For example, U.S. Patent No. 4,107,288 describes a pharmaceutical formulation having particles in the size range from 10 to 1,000 nm in which the active material is supported on a cross-linked matrix of macromolecules. U.S. Patent No. 5,145,684 describes the production of a pharmaceutical formulation in which the drug substance is pulverized to nanoparticles (average particle size of 400 nm) in the presence of a surface modifier and then dispersed in a liquid medium to give a pharmaceutical formulation that exhibits remarkably high bioavailability.

The compositions are comprised of, in general, at least one chemical entity described herein in combination with at least one pharmaceutically acceptable excipient. Acceptable excipients are non-toxic, aid administration, and do not adversely affect the therapeutic benefit of the at least one chemical entity described herein. Such excipient may be any solid, liquid, semi-solid or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art.

Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like. Liquid and semisolid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc. Liquid carriers, for injectable solutions, include water, saline, aqueous dextrose, and glycols.

Compressed gases may be used to disperse a chemical entity described herein in aerosol form. Inert gases suitable for this purpose are nitrogen, carbon dioxide, etc. Other suitable pharmaceutical excipients and their formulations are described in Remington's Pharmaceutical Sciences, edited by E. W. Martin (Mack Publishing Company, 18th ed., 1990).

The amount of the chemical entity in a composition can vary within the full range employed by those skilled in the art. Typically, the composition will contain, on a weight percent (wt%) basis, from about 0.01-99.99 wt% of at least one chemical entity described herein based on the total composition, with the balance being one or more suitable pharmaceutical excipients. In certain embodiments, the at least one chemical entity described herein is present at a level of about 1-80 wt%.

In various embodiments, pharmaceutical compositions of the present invention encompass compounds of Formula (I), (Ia), (II) or (IIa), salts thereof, and combinations of the above.

5 Synthetic Methods

The methods of synthesis may employ readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (*i.e.*, reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given; other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.

15 Additionally, the methods of this invention may employ protecting groups which prevent certain functional groups from undergoing undesired reactions. Suitable protecting groups for various functional groups as well as suitable conditions for protecting and deprotecting particular functional groups are well known in the art. For example, numerous protecting groups are described in T. W. Greene and G. M. Wuts, *Protecting Groups in Organic Synthesis*, Third Edition, Wiley, New York, 1999, and references cited therein.

Furthermore, the provided chemical entities may contain one or more chiral centers and such compounds can be prepared or isolated as pure stereoisomers, *i.e.*, as individual enantiomers or diastereomers, or as stereoisomer-enriched mixtures. All such stereoisomers (and enriched mixtures) are included within the scope of this specification, unless otherwise indicated. Pure stereoisomers (or enriched mixtures) may be prepared using, for example, optically active starting materials or stereoselective reagents well-known in the art. Alternatively, racemic mixtures of such compounds can be separated using, for example, chiral column chromatography, chiral resolving agents and the like.

The starting materials for the following reactions are generally known compounds or can be prepared by known procedures or obvious modifications thereof. For example, many of the starting materials are available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA), Bachem (Torrance, California, USA), Emka-Chemce or Sigma (St. Louis, Missouri, USA). Others may be prepared by procedures, or obvious modifications thereof, described in standard reference texts such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-15 (John Wiley and Sons, 1991), Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplementals (Elsevier Science Publishers, 1989), Organic Reactions, Volumes 1-40 (John Wiley and Sons,

1991), March's Advanced Organic Chemistry, (John Wiley and Sons, 4th Edition), and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989).

Unless specified to the contrary, the reactions described herein may take place at atmospheric pressure, generally within a temperature range from -78 °C to 200 °C.

5 Further, except as employed in the Example or as otherwise specified, reaction times and conditions are intended to be approximate, *e.g.*, taking place at about atmospheric pressure within a temperature range of about -78 °C to about 110 °C over a period of about 1 to about 24 hours; reactions left to run overnight average a period of about 16 hours.

10 The terms "solvent," "organic solvent," and "inert solvent" each mean a solvent inert under the conditions of the reaction being described in conjunction therewith, including, for example, benzene, toluene, acetonitrile, tetrahydrofuran ("THF"), dimethylformamide ("DMF"), chloroform, methylene chloride (or dichloromethane), diethyl ether, methanol, N-methylpyrrolidone ("NMP"), pyridine and the like.

15 Isolation and purification of the chemical entities and intermediates described herein can be affected, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography or thick-layer chromatography, or a combination of these procedures. Specific illustrations of suitable separation and isolation
20 procedures can be had by reference to the examples herein below. However, other equivalent separation or isolation procedures can also be used.

When desired, the (R)- and (S)-isomers may be resolved by methods known to those skilled in the art, for example by formation of diastereoisomeric salts or complexes which may be separated, for example, by crystallization; *via* formation of diastereoisomeric
25 derivatives which may be separated, for example, by crystallization, gas-liquid or liquid chromatography; selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic oxidation or reduction, followed by separation of the modified and unmodified enantiomers; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support, such as silica with a bound chiral ligand or
30 in the presence of a chiral solvent. Alternatively, a specific enantiomer may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer to the other by asymmetric transformation.

EXAMPLE AND GENERAL SYNTHESIS

The following example and prophetic synthesis method serve to more fully describe the manner of making and using the above-described invention. It is understood that this in no way serve to limit the true scope of the invention, but rather is presented for illustrative purposes. Unless otherwise specified, the following abbreviations have the following meanings. If an abbreviation is not defined, it has its generally accepted meaning.

aq.	= aqueous
μL	= microliters
μM	= micromolar
NMR	= nuclear magnetic resonance
Boc	= tert-butoxycarbonyl
br	= broad
Cbz	= benzyloxycarbonyl
d	= doublet
°C	= degrees Celsius
DCM	= dichloromethane
dd	= doublet of doublets
DMAP	= N,N-dimethylaminopyridine
DMEM	= Dulbecco's Modified Eagle's Medium
DMF	= N,N-dimethylformamide
DMSO	= dimethylsulfoxide
EDC	= <i>N</i> -(3-Dimethylaminopropyl)- <i>N'</i> -ethylcarbodiimide hydrochloride
EtOAc	= ethyl acetate
g	= gram
h or hr	= hour(s)
HPLC	= high performance liquid chromatography
Hz	= Hertz
IU	= International Units
IC ₅₀	= 50% inhibitory concentration
J	= coupling constant in Hz
LCMS	= liquid chromatography mass spectrometry
m	= multiplet
M	= molar concentration


M+H ⁺	= parent mass spectrum peak plus H ⁺
mg	= milligram
min	= minute(s)
mL	= milliliter
mM	= millimolar
mmol	= millimole
MMTr	= monomethoxytrityl
MS	= mass spectrum
MTBE	= methyl tert-butyl ether
nM	= nanomolar
PE	= petroleum ether
ppm	= parts per million
q.s.	= sufficient amount
s	= singlet
RT	= room temperature
sat.	= saturated
t	= triplet
TBDMS	= tert-butyldimethylsilyl
TBDPS	= tert-butyldiphenylsilyl
TEA	= triethylamine
THF	= tetrahydrofuran
TMS	= trimethylsilyl

Additionally, various compounds of the invention may be made, in one embodiment, by way of the general synthesis routes set forth in Schemes 1-4 below:

5

10

Scheme 1




5

10

15

5

Scheme 2




10

15

5


Scheme 3



10

5

Scheme 4



wherein n is from 0 to 20, and each of R, R₁, R₂, R₃, R₄ and R₅ are alkyl.

10

Equipment Description

¹H NMR spectra were recorded on Varian or Bruker spectrometers. Chemical shifts are expressed in parts per million (ppm, δ units). Coupling constants are in units of hertz (Hz). Splitting patterns describe apparent multiplicities and are designated as s (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), m (multiplet), br (broad).

Representative equipment and conditions for acquiring analytical low resolution LCMS are described below.

Instrumentation:

Waters Acquity UPLC-MS system with SQ detectors

MS Conditions:

Scan Mode: Alternating positive/negative electrospray

Scan Range: 125-1200 amu

Scan Time: 150 msec

Interscan Delay: 50 msec

LC Conditions:

The UPLC analysis was conducted on a Phenomenex Kinetex 1.7 μ m 2.1 x 50mm XB-C18 column at 40°C.

0.2 μ L of sample was injected using PLNO (partial loop with needle overfill) injection mode.

The gradient employed was:


Mobile Phase A: Water + 0.2% v/v Formic Acid


Mobile Phase B: Acetonitrile + 0.15% v/v Formic Acid

Time	%A	%B	Flow Rate
0.00 min	95	5	1 ml/min
1.1 min	1	99	1 ml/min
1.5 min	1	99	1 ml/min

UV detection provided by summed absorbance signal from 210 to 350nm scanning at 40Hz.

Example 1: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl cyclohexanecarboxylate





Step A: *(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-(((tert-*

butyldiphenylsilyl)oxy)methyl)-2-ethynyltetrahydrofuran-3-yl acetate. A suspension of 2-

fluoro-9H-purin-6-amine (0.545 g, 3.56 mmol) in anhydrous MeCN (10 mL) in a screw-
capped glass pressure vessel under a nitrogen atmosphere was treated with trimethylsilyl
2,2,2-trifluoro-N-(trimethylsilyl)acetimidate (1.89 mL, 7.12 mmol) and heated to 80 °C with
stirring in an oil bath. After 45 minutes most of the solid had dissolved. The solution was
treated with (4S,5R)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-5-ethynyltetrahydrofuran-2,4-
diyl diacetate (1.14 g, 2.37 mmol, prepared according to *Org. Lett.*, Vol. 13, No. 19, 2011)

dissolved in MeCN (9 mL) followed by freshly prepared 0.2M trifluoromethanesulfonic
acid/MeCN (2.37 mL, 0.474 mmol) (prepared by dissolving 44 μ L of triflic acid in 2.5 mL of
MeCN). The temperature was maintained at 80 °C. After 1.5 hour at 80 °C LCMS indicated
complete reaction. The solution was cooled to RT, quenched by addition of 1M aqueous
HCl (3 mL). After stirring the mixture briefly, it was partitioned between saturated aqueous
NaHCO₃ and EtOAc and the phases separated. The aqueous phase was extracted with
EtOAc (2x). The combined EtOAc solutions were dried over Na₂SO₄ and concentrated at
reduced pressure to give a tan solid. This material was subjected to flash chromatography
(silica gel, 0-100% EtOAc/DCM) and the higher R_f component isolated to afford the title
compound (0.63 g, 46%) as a white solid. LCMS (ESI) m/z calcd for C₃₀H₃₂FN₅O₄Si:

573.2. Found: 574.4 (M+1)⁺. ¹H NMR (400 MHz, Methanol-*d*₄) δ 8.10 (s, 1H), 7.59 - 7.67 (m, 4H), 7.26 - 7.45 (m, 6H), 6.39 (t, *J* = 6.6 Hz, 1H), 5.91 (dd, *J* = 7.0, 5.5 Hz, 1H), 3.97 (d, *J* = 10.9 Hz, 1H), 3.86 (d, *J* = 10.9 Hz, 1H), 3.05 - 3.18 (m, 2H), 2.64 - 2.74 (m, 1H), 2.14 (s, 3H), 0.97 - 1.04 (m, 9H).

5

Step B: (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-(((tert-

butyldiphenylsilyl)oxy)methyl)-2-ethynyltetrahydrofuran-3-ol. To a stirred solution of

(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-(((tert-butylidiphenylsilyl)oxy)methyl)-2-ethynyltetrahydrofuran-3-yl acetate (0.62 g, 1.08 mmol) in 1:1 THF/MeOH (4 mL) was

10 added 25% NaOMe/MeOH (3 drops). The resulting solution was stirred at RT. After 30 minutes LCMS indicated complete reaction. The solution was treated with glacial AcOH (5 drops) and concentrated to dryness at reduced pressure. The residue was partitioned between 8:2 chloroform/iPrOH and half-saturated aqueous NaHCO₃ and the phases separated. The aqueous phase was extracted with two additional portions of 8:2

15 chloroform/iPrOH. The combined organic solutions were dried over Na₂SO₄ and concentrated to dryness at reduced pressure to afford the title compound (0.52 g, 91%) as a white solid. LCMS (ESI) *m/z* calcd for C₂₈H₃₀FN₅O₃Si: 531.2. Found: 532.3 (M+1)⁺. ¹H NMR (400 MHz, Methanol-*d*₄) δ 8.17 (s, 1H), 7.53 - 7.66 (m, 4H), 7.22 - 7.45 (m, 6H), 6.32 (dd, *J* = 7.8, 3.1 Hz, 1H), 5.01 (t, *J* = 7.8 Hz, 1H), 3.87 (q, *J* = 11.3 Hz, 2H), 3.05 (s, 1H),
20 2.90 - 2.99 (m, 1 H), 2.63 - 2.72 (m, 1H), 0.94 (s, 9H).

Step C: 9-((2R,4S,5R)-5-(((tert-butylidiphenylsilyl)oxy)methyl)-5-ethynyl-4-((4-

methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)-2-fluoro-N-((4-

methoxyphenyl)diphenylmethyl)-9H-purin-6-amine. To a stirred suspension of (2R,3S,5R)-

25 5-(6-amino-2-fluoro-9H-purin-9-yl)-2-(((tert-butylidiphenylsilyl)oxy)methyl)-2-ethynyltetrahydrofuran-3-ol (0.510 g, 0.959 mmol) in DCM (8 mL) was added silver nitrate (0.489 g, 2.88 mmol), 2,4,6-trimethylpyridine (0.766 mL, 5.76 mmol), and (chloro(4-methoxyphenyl)methylene)dibenzene (0.889 g, 2.88 mmol). The resulting orange suspension was stirred at RT. After 2 hours LCMS indicated complete reaction. The
30 mixture was diluted with EtOAc and filtered through celite to remove solids. The filtrate was washed with 10% aqueous citric acid (2x), saturated aqueous NaHCO₃ (2x), dried over Na₂SO₄ and concentrated at reduced pressure to give a pale yellow foam. This material was subjected to flash chromatography (silica gel, 0-100% EtOAc/hexanes) to afford the title compound (1.00 g, 97%) as a white foam. LCMS (ESI) *m/z* calcd for
35 C₆₈H₆₂FN₅O₅Si: 1075.5. Found: 1076.7 (M+1)⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.12 - 7.62 (m, 35H), 6.98 (s, 1H), 6.74 - 6.82 (m, 4H), 6.22 (t, *J* = 6.6 Hz, 1H), 4.75 (t, *J* = 5.9 Hz,

1H), 3.93 (d, $J = 11.3$ Hz, 1H), 3.86 (d, $J = 11.3$ Hz, 1H), 3.77 (s, 3H), 3.75 (s, 3H), 2.77 (s, 1H), 1.71 (t, $J = 6.3$ Hz, 2H), 0.87 (s, 9H).


Step D: ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methanol. To a stirred solution of 9-((2R,4S,5R)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-5-ethynyl-4-((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)-2-fluoro-N-((4-methoxyphenyl)diphenylmethyl)-9H-purin-6-amine (0.99 g, 0.92 mmol) in THF (8 mL) was added 1M TBAF/THF (1.38 mL, 1.38 mmol) by dropwise addition. The resulting solution was stirred at RT. After 1 hour LCMS indicated complete reaction. The solution was treated with glacial AcOH (0.10 mL) and concentrated at reduced pressure. The residue was dissolved in MeOH/DCM and again concentrated to dryness. The residue was subjected to flash chromatography (silica gel, 0-100% EtOAc/hexanes) to afford the title compound (0.623 g, 81%) as a white solid. LCMS (ESI) m/z calcd for $C_{52}H_{44}FN_5O_5$: 837.3. Found: 838.6 ($M+1$)⁺. ¹H NMR (400 MHz, DMSO- d_6) δ 8.04 (s, 1H), 8.00 (s, 1H), 7.47 - 7.54 m, 4H), 7.12 - 7.38 (m, 20H), 6.79 - 6.88 (m, 4H), 6.04 (t, $J = 6.3$ Hz, 1H), 5.15 (t, $J = 6.1$ Hz, 1H), 4.47 (t, $J = 6.1$ Hz, 1H), 3.84 (s, 1H), 3.69 (s, 3H), 3.67 (s, 3H), 3.49 - 3.57 (m, 1H), 3.38 - 3.47 (m, 1H), 1.63 - 1.72 (m, 1H), 1.49 - 1.58 (m, 1H).

Step E: ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methyl cyclohexanecarboxylate. To a stirred solution of ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methanol (51 mg, 0.061 mmol), cyclohexanecarboxylic acid (15.60 mg, 0.122 mmol) and DMAP (7.44 mg, 0.061 mmol) in DCM (0.8 mL) was added EDC (35.0 mg, 0.183 mmol), followed by DIPEA (0.053 mL, 0.304 mmol) at ambient temperature. The mixture was allowed to stir overnight. The mixture was concentrated and then purified on silica gel (0-50% hexanes/EtOAc) to afford the title compound (53 mg, 90%) as a colorless residue. LCMS (ESI) m/z calcd for $C_{66}H_{68}FN_5O_8Si$: 1078. Found: 1079 ($M+1$)⁺. LCMS (ESI) m/z calcd for $C_{59}H_{54}FN_5O_6$: 947.4. Found: 948.8 ($M+1$)⁺.

Step F: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl cyclohexanecarboxylate. To a stirred solution of ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methyl


cyclohexanecarboxylate (53 mg, 0.055 mmol) in DCM (0.8 mL) was added formic acid (0.2 mL), followed by triethylsilane (0.018 mL, 0.11 mmol). The resulting orange solution was stirred for 60 minutes and was then concentrated. The residue was purified on silica gel (0-10% DCM/MeOH) to afford the title compound (17 mg, 78%) as a white solid. LCMS (ESI) m/z calcd for $C_{19}H_{22}FN_5O_4$: 403.2. Found: 404.3 ($M+1$)⁺. ¹H NMR (400 MHz, DMSO- d_6) δ = 8.25 (s, 1H), 7.81 (br s, 2H), 6.24 (dd, J = 3.8, 8.1 Hz, 1H), 5.76 (d, J = 5.5 Hz, 1H), 4.75 - 4.69 (m, 1H), 4.41 (d, J = 11.7 Hz, 1H), 4.06 (d, J = 11.9 Hz, 1H), 3.61 (s, 1H), 2.88 - 2.80 (m, 1H), 2.54 - 2.42 (m, 1H, overlapping DMSO peak), 2.20 - 2.10 (m, 1H), 1.80 - 1.69 (m, 1H), 1.66 - 1.45 (m, 4H), 1.32 - 1.01 (m, 5H).

Example 2: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl benzoate




The title compound was prepared according to example 1, substituting benzoic acid for cyclohexanecarboxylic acid in Step E. LCMS (ESI) m/z calcd for $C_{19}H_{16}FN_5O_4$: 397.1. Found: 398.2 ($M+1$)⁺. ¹H NMR (400 MHz, DMSO- d_6) δ = 8.27 (s, 1H), 7.91 - 7.86 (m, 2H), 7.81 (br s, 2H), 7.68 - 7.62 (m, 1H), 7.52 - 7.44 (m, 2H), 6.29 (dd, J = 3.9, 8.2 Hz, 1H), 5.84 (d, J = 5.5 Hz, 1H), 4.92 - 4.84 (m, 1H), 4.61 (d, J = 11.9 Hz, 1H), 4.40 (d, J = 11.7 Hz, 1H), 3.67 (s, 1H), 2.91 - 2.83 (m, 1H), 2.57 - 2.47 (m, 1H, overlapping DMSO peak).

Example 3: [(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxyoxolan-2-yl]methyl 2-phenylacetate




The title compound was prepared according to example 1, substituting 2-phenylacetic acid for cyclohexanecarboxylic acid in Step E. LCMS (ESI) m/z calcd for $C_{20}H_{18}FN_5O_4$: 411.1. Found: 412.6 ($M+1$)⁺. ¹H NMR (400 MHz, DMSO- d_6) δ = 8.27 (s, 1H), 7.83 (br s, 2H), 7.29 - 7.20 (m, 3H), 7.19 - 7.13 (m, 2H), 6.26 (dd, J = 4.1, 8.1 Hz, 1H), 5.77 (d, J = 5.5 Hz, 1H), 4.76 - 4.68 (m, 1H), 4.44 (d, J = 11.7 Hz, 1H), 4.15 (d, J = 11.7 Hz, 1H), 3.71 - 3.48 (m, 3H), 2.83 - 2.74 (m, 1H), 2.56 - 2.43 (m, 1H, overlapping DMSO peak).

Example 4: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl 2-phenylacetate




5 The title compound was prepared according to example 1, substituting *trans*-4-(tert-butyl)cyclohexanecarboxylic acid for cyclohexanecarboxylic acid in Step E. LCMS (ESI) m/z calcd for $C_{23}H_{30}FN_5O_4$: 459.2. Found: 460.3 ($M+1$)⁺. ^1H NMR (400 MHz, DMSO- d_6) δ = 8.25 (s, 1H), 7.80 (br s, 2H), 6.23 (dd, J = 3.9, 8.0 Hz, 1H), 5.75 (d, J = 5.5, 1H), 4.76 - 4.69 (m, 1H), 4.42 (d, J = 11.7 Hz, 1H), 4.05 (d, J = 11.7 Hz, 1H), 3.61 (s, 1H), 2.88 - 2.80
10 (m, 1H), 2.54 - 2.42 (m, 1H, overlapping DMSO peak), 2.10 - 1.96 (m, 1H), 1.91 - 1.80 (m, 1H), 1.75 - 1.59 (m, 3H), 1.26 - 1.03 (m, 2H), 0.98 - 0.84 (m, 3H), 0.81 (s, 9H).

Example 5: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl *trans*-4-pentylcyclohexane-1-carboxylate



15 The title compound was prepared according to example 1, substituting *trans*-4-pentylcyclohexanecarboxylic acid for cyclohexanecarboxylic acid in Step E. LCMS (ESI) m/z calcd for $C_{24}H_{33}FN_5O_4$: 473.2. Found: 474.4 ($M+1$)⁺. ^1H NMR (400 MHz, DMSO- d_6) δ = 8.25 (s, 1H), 7.81 (br s, 2H), 6.23 (dd, J = 3.9, 8.0 Hz, 1H), 5.75 (d, J = 5.5 Hz, 1H), 4.76 - 4.68 (m, 1H), 4.42 (d, J = 11.9 Hz, 1H), 4.05 (d, J = 11.7 Hz, 1H), 3.61 (s, 1H), 2.87 - 2.79 (m, 1H), 2.54 - 2.42 (m, 1H, overlapping DMSO peak), 2.11 - 2.02 (m, 1H), 1.85 - 1.75 (m, 1H), 1.73 - 1.57 (m, 3H), 1.35 - 1.04 (m, 11H), 0.92 - 0.74 (m, 5H).

Example 6: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl 2-(2-methoxyethoxy)acetate




25 The title compound was prepared according to example 1, substituting 2-(2-methoxyethoxy)acetic acid for cyclohexanecarboxylic acid in Step E. LCMS (ESI) m/z calcd for $C_{17}H_{20}FN_5O_6$: 409.1. Found: 410.3 ($M+1$)⁺. ^1H NMR (400 MHz, DMSO- d_6) δ =

8.27 (s, 1H), 7.83 (br s, 2H), 6.25 (dd, $J = 4.3, 7.9$ Hz, 1H), 5.78 (d, $J = 5.5$ Hz, 1H), 4.72 - 4.65 (m, 1H), 4.48 (d, $J = 11.7$ Hz, 1H), 4.18 (d, $J = 11.7$ Hz, 1H), 4.12 (d, $J = 16.7$ Hz, 1H), 3.99 (d, $J = 16.7$ Hz, 1H), 3.64 (s, 1H), 3.54 - 3.48 (m, 2H), 3.44 - 3.38 (m, 2H), 3.21 (s, 3H), 2.82 - 2.74 (m, 1H), 2.54 - 2.43 (m, 1H, overlapping DMSO peak).

5


Example 7: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl 2-(2-(2-methoxyethoxy)ethoxy)acetate



The title compound was prepared according to example 1, substituting 2-(2-methoxyethoxy)ethoxy)acetic acid for cyclohexanecarboxylic acid in Step E. LCMS (ESI) m/z calcd for $C_{19}H_{24}FN_5O_7$: 453.2. Found: 454.7 ($M+1$)⁺. ^1H NMR (400 MHz, DMSO- d_6) δ = 8.27 (s, 1H), 7.82 (br s, 2H), 6.25 (dd, $J = 4.1, 7.9$ Hz, 1H), 5.78 (d, $J = 5.5$ Hz, 1H), 4.71 - 4.64 (m, 1H), 4.48 (d, $J = 11.7$ Hz, 1H), 4.18 (d, $J = 11.7$ Hz, 1H), 4.12 (d, $J = 16.9$ Hz, 1H), 4.00 (d, $J = 16.7$ Hz, 1H), 3.63 (s, 1H), 3.54 - 3.45 (m, 6H), 3.43 - 3.36 (m, 2H), 3.21 (s, 3H), 2.81 - 2.73 (m, 1H), 2.53 - 2.43 (m, 1H, overlapping DMSO peak).

15

Example 8: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl 2-(2-butoxyethoxy)acetate




The title compound was prepared according to example 1, substituting 2-(2-butoxyethoxy)acetic acid for cyclohexanecarboxylic acid in Step E. LCMS (ESI) m/z calcd for $C_{20}H_{26}FN_5O_6$: 451.2. Found: 452.3 ($M+1$)⁺. ^1H NMR (400 MHz, DMSO- d_6) δ = 8.28 (s, 1H), 7.84 (br s, 2H), 6.26 (dd, $J = 4.2, 7.7$ Hz, 1H), 5.79 (d, $J = 5.5$ Hz, 1H), 4.72 - 4.65 (m, 1H), 4.49 (d, $J = 11.7$ Hz, 1H), 4.19 (d, $J = 11.7$ Hz, 1H), 4.14 (d, $J = 16.7$ Hz, 1H), 4.02 (d, $J = 16.7$ Hz, 1H), 3.64 (s, 1H), 3.55 - 3.49 (m, 2H), 3.48 - 3.43 (m, 2H), 3.37 - 3.32 (m, 2H), 2.82 - 2.74 (m, 1H), 2.54 - 2.44 (m, 1H, overlapping DMSO peak), 1.49 - 1.37 (m, 2H), 1.35 - 1.20 (m, 2H), 0.90 - 0.80 (m, 3H).

25

30

Example 9: 10-(((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methoxy)-10-oxodecanoic acid



5

Step A: 1-(((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-

hydroxytetrahydrofuran-2-yl)methyl) 10-(tert-butyl) decanedioate. 10-(tert-butoxy)-10-

oxodecanoic acid (96 mg, 0.37 mmol) was dissolved in DMF (1 mL), EDC (286 mg, 1.50 mmol) and DMAP (182 mg, 1.489 mmol) were added, the resulting mixture was stirred for

10

2h at RT. Then, ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-((4-

methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methanol (260 mg, 0.310 mmol)

was added, and the resulting mixture was stirred for 1 h at RT. The reaction mixture was added mixed water (10 mL) and extracted with EtOAc (3x5 mL). The combined organic

15

phases were washed with brine (10 mL), dried over Na₂SO₄, and concentrated under

vacuum. The residue was purified by preparative TLC (MeOH:DCM = 1:20) to afford the title compound (89 mg, 26%) as a white solid. LCMS (ESI) m/z calcd for C₂₆H₃₆FN₅O₆:

533. Found: 534 (M+1)⁺.

20

Step B: 10-(((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-

hydroxytetrahydrofuran-2-yl)methoxy)-10-oxodecanoic acid. 1-(tert-butyl) 10-(((2R,3S,5R)-

2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methyl decanedioate (115 mg,


0.107 mmol) was dissolved in DCM (3 mL). TFA (0.158 mL, 2.13 mmol) was added, and

25

the resulting mixture was stirred at RT. After 1 h the solution was concentrated to dryness at reduced pressure and the residue purified by RP-HPLC (C18, MeCN/water with 0.1%


formic acid) to afford the title compound (15.6 mg, 31%) as a white solid. LCMS (ESI) m/z calcd for $C_{22}H_{28}FN_5O_6$: 477. Found: 478 ($M+1$)⁺. ¹H NMR (400 MHz, DMSO- d_6) δ 10.90 (s, 1 H), 8.27 (s, 1 H), 7.86 (d, J = 6.0 Hz, 2 H), 6.23 (dd, J = 8.0, 4.4 Hz, 1 H), 4.71 (t, J = 5.2 Hz, 1 H), 4.42 (d, J = 11.6 Hz, 1 H), 4.08 (d, J = 11.6 Hz, 1 H), 3.63 (s, 1 H), 2.80 - 2.77 (m, 1 H), 2.47 (dd, J = 8.4, 3.0 Hz, 1 H), 2.20 - 2.14 (m, 4 H), 1.48 - 1.39 (m, 4 H), 1.18 (d, J = 9.4 Hz, 8 H).

Example 10: 14-(((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methoxy)-14-oxotetradecanoic acid



The title compound was prepared according to example 9, substituting 14-(tert-butoxy)-14-oxotetradecanoic acid for 10-(tert-butoxy)-10-oxodecanoic acid in step A. LCMS (ESI) m/z calcd for $C_{26}H_{36}FN_5O_6$: 533. Found: 534 ($M+1$)⁺. ¹H NMR (400 MHz, Methanol- d_4) δ 8.15 (s, 1H), 6.30 (dd, J = 3.6, 8.0 Hz, 1H), 4.87 (s, 1H), 4.47 (d, J = 12.0 Hz, 1H), 4.25 (d, J = 12.0 Hz, 1H), 3.17 (s, 1H), 2.91 - 2.88 (m, 1H), 2.70 - 2.64 (m, 1H), 2.29 - 2.18 (m, 4H), 1.63 - 1.55 (m, 2H), 1.51 - 1.43 (m, 2H), 1.26 (m, 16H).


Example 11: 20-(((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methoxy)-20-oxoicosanoic acid



The title compound was prepared according to example 9, substituting 20-(tert-butoxy)-20-oxoicosanoic acid for 10-(tert-butoxy)-10-oxodecanoic acid in step A. LCMS (ESI) m/z calcd for $C_{32}H_{48}FN_5O_6$: 617. Found: 618 ($M+1$)⁺. ¹H NMR (400 MHz, Methanol- d_4) δ 8.15 (s, 1H), 6.30 (dd, J = 3.6, 8.0 Hz, 1H), 4.87 (s, 1H), 4.47 (d, J = 12.0 Hz, 1H), 4.25 (d, J = 12.0 Hz, 1H), 3.17 (s, 1H), 2.93 - 2.88 (m, 1H), 2.70 - 2.62 (m, 1H), 2.29 - 2.15 (m, 4H), 1.63 - 1.55 (m, 2H), 1.52 - 1.44 (m, 2H), 1.28 (m, 28H).

5

Example 12: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl (1,3-bis(heptanoyloxy)propan-2-yl) glutarate



- Step A: 2-oxopropane-1,3-diyl diheptanoate.** To a suspension of 1,3-dihydroxypropan-2-one (500 mg, 5.55 mmol) in DCM (20 mL) was added pyridine (0.940 mL, 11.6 mmol) and heptanoyl chloride (1.76 mL, 11.4 mmol) and the mixture was stirred at ambient temperature for 18 h. The mixture was diluted with DCM and washed with water. The organic phase was washed with brine, dried (Na₂SO₄), concentrated and purified on silica gel (EtOAc/hexanes 0-20%) to provide 2-oxopropane-1,3-diyl diheptanoate (1.17 g, 66%) as an off-white solid. LCMS (ESI) m/z calcd for C₁₇H₃₂O₅: 316. Found: 315 (M-1)⁺. ¹H NMR (400 MHz, Chloroform-d): δ 4.77 (s, 4 H), 2.45 (t, J = 7.5 Hz, 4H), 1.61 - 1.77 (m, 4H), 1.23 - 1.43 (m, 12H), 0.85 - 0.99 (m, 6H).

Step B: 2-hydroxypropane-1,3-diyl diheptanoate. To a solution of 2-oxopropane-1,3-diyl diheptanoate (500 mg, 1.59 mmol) in THF (10 mL) was added water (0.5 mL) and the mixture was cooled to 0 °C then NaBH₄ (36.1 mg, 0.954 mmol) was added and stirring under nitrogen atmosphere continued for 1 h and then 1 h at ambient temperature.

- 5 Saturated NH₄Cl/water was added and the mixture was extracted with EtOAc. The organic phase was dried (Na₂SO₄), concentrated and purified on silica gel (EtOAc/hexanes 0-100%) to provide 2-hydroxypropane-1,3-diyl diheptanoate (487 mg, 64%) as a clear oil. ¹H NMR (400 MHz, Chloroform-*d*): δ 4.03 - 4.29 (m, 5H), 2.42 - 2.51 (m, 1H), 2.37 (t, *J* = 7.5 Hz, 4H), 1.61 - 1.74 (m, 4H), 1.24 - 1.44 (m, 12H), 0.86 - 0.98 (m, 6H).

10

Step C: 5-((1,3-bis(heptanoyloxy)propan-2-yl)oxy)-5-oxopentanoic acid. To a solution of 2-hydroxypropane-1,3-diyl diheptanoate (160 mg, 0.506 mmol) in DCM (1 mL) /tetrahydrofuran (1 mL)/pyridine (1 mL) was added DMAP (6.18 mg, 0.051 mmol) followed by dihydro-2H-pyran-2,6(3H)-dione (115 mg, 1.01 mmol) and the mixture was heated to 15 60 °C for 6.5 h. The mixture was diluted with EtOAc and washed with 1 M HCl/water. The organic phase was dried (Na₂SO₄), concentrated and purified on silica gel (MeOH/dichloromethane 0-5%) to provide 5-((1,3-bis(heptanoyloxy)propan-2-yl)oxy)-5-oxopentanoic acid (190 mg, 87%) as a clear oil. LCMS (ESI) *m/z* calcd for C₂₂H₃₈O₈: 430. Found: 431 (M-1)⁺. ¹H NMR (400 MHz, Chloroform-*d*): δ 5.21 - 5.35 (m, 1H), 4.28 - 4.42 (m, 2H), 4.09 - 4.25 (m, 2H), 2.40 - 2.53 (m, 4H), 2.27 - 2.38 (m, 4H), 1.99 (t, *J* = 7.3 Hz, 2H), 1.51 - 1.73 (m, 4H), 1.25 - 1.43 (m, 12H), 0.85 - 0.98 (m, 6H).

20

Step D: 9-((2R,4S,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(((tert-butyldimethylsilyl)oxy)methyl)-5-ethynyltetrahydrofuran-2-yl)-2-fluoro-9H-purin-6-amine. To 25 a suspension of (2R,3S)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-ol (268 mg, 0.914 mmol) (*Org. Lett.*, Vol. 13, No. 19, **2011**, 5264-5299), in DMF (2 mL) was added imidazole (311 mg, 4.57 mmol) and TBDMS-Cl (344 mg, 2.285 mmol) and the mixture was stirred at ambient temperature for 1 h and then at 50 °C for 1 h. LCMS showed mono-silyl product only so more imidazole (311 mg, 4.57 mmol) and 30 TBDMS-Cl (344 mg, 2.285 mmol) was added and the mixture was stirred at 50 °C under nitrogen atmosphere for 1 h. Water was added and the mixture was stirred at ambient temperature for 18 h. The mixture was filtered and the sticky solid residue was dissolved in DCM, dried (Na₂SO₄), concentrated and purified on silica gel (EtOAc/hexanes 20-100%) to provide 9-((4S,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(((tert-butyldimethylsilyl)oxy)methyl)-5-ethynyltetrahydrofuran-2-yl)-2-fluoro-9H-purin-6-amine (430 mg, 90%) as an off- 35 white solid. LCMS (ESI) *m/z* calcd for C₂₄H₄₀FN₅O₃Si₂: 521. Found: 522 (M+1)⁺. ¹H NMR

(400 MHz, Chloroform-*d*): δ 8.01 - 8.10 (m, 1H), 6.38 (dd, J = 7.2, 4.3 Hz, 1H), 5.80 (br s, 2H), 4.84 (t, J = 7.0 Hz, 1H), 3.98 (d, J = 11.2 Hz, 1H), 3.82 (d, J = 11.2 Hz, 1H), 2.59 - 2.79 (m, 2H), 2.56 (s, 1H), 0.96 (s, 9H), 0.91 (s, 9H), 0.16 (s, 3H), 0.15 (s, 3H), 0.10 (s, 3H), 0.06 (s, 3H).

5

Step E: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methanol. To a solution of 9-((4S,5R)-4-((tert-

butyldimethylsilyl)oxy)-5-(((tert-butyldimethylsilyl)oxy)methyl)-5-ethynyltetrahydrofuran-2-yl)-2-fluoro-9H-purin-6-amine (32 mg, 0.061 mmol) in MeOH (0.7 mL) was added phosphomolybdic acid hydrate (56.0 mg, 6.13 μ mol) and the mixture was stored at -5 °C for 18 h. The mixture was filtered and the yellowish solid washed with MeOH and DCM.

The filtrate was concentrated and purified on silica gel (EtOAc/hexanes 20-100%) to provide ((2R,3S)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methanol (16.4 mg, 65%) as an off-white solid. LCMS (ESI) m/z calcd for $C_{18}H_{26}FN_5O_3Si$: 407. Found: 408 ($M+1$)⁺. ¹H NMR (400 MHz, DMSO-*d*₆): δ 7.74 - 8.04 (m, 2H), 6.26 (dd, J = 6.9, 5.7 Hz, 1H), 5.30 (dd, J = 6.7, 5.5 Hz, 1H), 4.77 (t, J = 6.2 Hz, 1H), 3.62 - 3.73 (m, 1H), 3.47 - 3.57 (m, 2H), 2.84 (dt, J = 12.5, 6.4 Hz, 1H), 2.50 - 2.52 (m, 1H), 2.35 - 2.45 (m, 1H), 0.89 - 0.97 (m, 9H), 0.14 (d, J = 3.3 Hz, 6H).

Step F: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methyl (1,3-bis(heptanoyloxy)propan-2-yl) glutarate. To a

suspension of ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methanol (11.7 mg, 0.029 mmol) in DCM (1.5 mL) was added 5-((1,3-bis(heptanoyloxy)propan-2-yl)oxy)-5-oxopentanoic acid (25 mg, 0.057


mmol) followed by DMAP (3.5 mg, 0.029 mmol), EDC (16.5 mg, 0.0860 mmol) and DIEA (0.025 mL, 0.144 mmol) and the cloudy mixture was stirred at ambient temperature for 3.5 h. The mixture was diluted with DCM and washed with water. The organic phase was dried (Na₂SO₄), concentrated and purified on silica gel (EtOAc/hexanes 0-40-100%) to

provide ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methyl (1,3-bis(heptanoyloxy)propan-2-yl) glutarate (17.8 mg, 76%). LCMS (ESI) m/z calcd for $C_{40}H_{62}FN_5O_{10}Si$: 819. Found: 820 ($M+1$)⁺. ¹H NMR (400 MHz, Chloroform-*d*): δ 7.86 (s, 1H), 6.23 - 6.30 (m, 1H), 5.87 - 6.03 (m, 2H), 5.28 (ddd, J = 5.7, 4.4, 1.3 Hz, 1H), 4.97 (t, J = 7.51 Hz, 1H), 4.50 (d, J = 12.2 Hz, 1H), 4.33 (dt, J = 11.9, 4.4 Hz, 2H), 4.26 (d, J = 11.9 Hz, 1H), 4.18 (ddd, J = 11.9, 5.90, 1.6 Hz, 2H), 2.85 - 2.97 (m, 1H), 2.63 (s, 2H), 2.28 - 2.44 (m, 8H), 1.84 - 1.98 (m, 2H), 1.57 - 1.68 (m, 4H), 1.25 - 1.39 (m, 12H), 0.94 - 0.99 (m, 9H), 0.86 - 0.93 (m, 6H), 0.17 (s, 3H), 0.16 (s, 3H).

Step G: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-**hydroxytetrahydrofuran-2-yl)methyl (1,3-bis(heptanoyloxy)propan-2-yl) glutarate.**

To a solution of ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methyl (1,3-bis(heptanoyloxy)propan-2-yl) glutarate (17 mg, 0.021 mmol) in tetrahydrofuran (0.7 mL) at 0 °C was added ~ 50 uL of a solution prepared by adding acetic acid (58 uL, 1 mmol) to 1M TBAF/THF (1 mL, 1 mmol). The mixture was stored at 0 °C for 18 h then stirred 2 h at ambient temperature. The mixture was concentrated and purified on silica gel (EtOAc/hexanes 0-100%) to provide ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl (1,3-bis(heptanoyloxy)propan-2-yl) glutarate (10.3 mg, 70% yield) as a sticky solid. LCMS (ESI) m/z calcd for C₃₄H₄₈FN₅O₁₀: 705. Found: 706 (M+1)⁺. ¹H NMR (400 MHz, Chloroform-*d*): δ 7.84 - 7.94 (m, 1H), 6.32 (dd, *J* = 7.5, 4.4 Hz, 1H), 5.85 (br s, 2H), 5.21 - 5.36 (m, 1H), 4.85 (q, *J* = 7.07 Hz, 1H), 4.47 (s, 2H), 4.35 (ddd, *J* = 11.9, 4.4, 2.0 Hz, 2H), 4.18 (ddd, *J* = 11.9, 5.7, 3.3 Hz, 2H), 2.94 - 3.12 (m, 1H), 2.81 (s, 1H), 2.68 (dd, *J* = 7.4, 6.2 Hz, 2H), 2.39 - 2.54 (m, 4H), 2.34 (t, *J* = 7.51 Hz, 4H), 1.87 - 2.08 (m, 2H), 1.50-1.67 (m, 4H), 1.23 - 1.42 (m, 12H), 0.83 - 0.96 (m, 6H).

Example 13: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl (1,3-bis(tetradecanoyloxy)propan-2-yl) glutarate




The title compound was prepared according to example 12, substituting tetradecanoyl

chloride for heptanoyl chloride in step A. LCMS (ESI) m/z calcd for C₄₈H₇₆FN₅O₁₀: 902.

Found: 903 (M+1)⁺. ¹H NMR (400 MHz, Chloroform-*d*): δ 7.89 (s, 1H), 6.32 (dd, *J* = 7.5,


4.4 Hz, 1H), 5.95 (d, *J* = 1.0 Hz, 2H), 5.19 - 5.38 (m, 1H), 4.84 (br s, 1H), 4.47 (s, 2H), 4.34 (ddd, *J* = 11.9, 4.5, 2.3 Hz, 2H), 4.18 (ddd, *J* = 11.9, 5.7, 3.3 Hz, 2H), 2.92 - 3.10 (m, 1H), 2.81 (s, 1H), 2.68 (d, *J* = 13.6 Hz, 2H), 2.38 - 2.56 (m, 4H), 2.34 (t, *J* = 7.5 Hz, 4H), 1.88 - 2.08 (m, 2H), 1.59 - 1.64 (m, 4H), 1.19 - 1.40 (m, 40H), 0.83 - 0.97 (m, 6H).

Example 14: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl tetradecyl glutarate



The title compound was obtained as a by-product from example 13, step G. LCMS (ESI) m/z calcd for $C_{31}H_{46}FN_5O_6$: 603. Found: 604 ($M+1$)⁺. ^1H NMR (400 MHz, Methanol- d_4): δ 8.16 (s, 1H), 6.33 (dd, $J = 7.9, 3.8$ Hz, 1H), 4.87 (t, $J = 7.9$ Hz, 1H), 4.50 (d, $J = 11.9$ Hz, 1H), 4.31 (d, $J = 11.7$ Hz, 1H), 4.06 (t, $J = 6.7$ Hz, 2H), 3.17 (s, 1H), 2.92 (ddd, $J = 13.6, 7.3, 3.7$ Hz, 1H), 2.68 (dt, $J = 13.7, 8.2$ Hz, 1H), 2.23 - 2.47 (m, 4H), 1.84 (td, $J = 7.3, 1.3$ Hz, 2H), 1.52 - 1.67 (m, 2H), 1.30 (s, 22H), 0.82 - 1.00 (m, 3H).

Example 15: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((ethoxycarbonyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methyl decanoate



Step A: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-(((tert-


butyldiphenylsilyl)oxy)methyl)-2-ethynyltetrahydrofuran-3-yl ethyl carbonate. To a stirred solution of ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-(((tert-butyldiphenylsilyl)oxy)methyl)-2-ethynyltetrahydrofuran-3-ol (51 mg, 0.096 mmol), triethylamine (0.067 mL, 0.480 mmol) and DMAP (11.72 mg, 0.096 mmol) in DCM (0.8

mL) at 0 °C was added ethyl carbonochloridate (0.018 mL, 0.192 mmol) in DCM (82 uL). The mixture was stirred at 0 °C for 5 minutes, then stirred at ambient temperature for 2 hours. LCMS of the reaction mixture indicated a mixture of tri-, di- and monosubstituted compounds. The mixture was diluted with EtOAc, washed with sat'd NaHCO₃ mixed with
5 brine, followed by brine only and finally dried (Na₂SO₄), filtered and concentrated. The residue was purified on silica gel (0-50% DCM/EtOAc) to afford the title compound (15 mg, 26%) as a colorless residue. LCMS (ESI) m/z calcd for C₃₁H₃₄FN₅O₅Si: 603.2. Found: 604.4 (M+1)⁺.

10 Step B: (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl ethyl carbonate. To a stirred solution of (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-(((tert-butyldiphenylsilyl)oxy)methyl)-2-ethynyltetrahydrofuran-3-yl ethyl carbonate (15 mg, 0.025 mmol) in THF (0.5 mL) at ambient temperature was added TBAF, 1M solution in THF (0.033 mL, 0.033 mmol) and
15 the mixture was allowed to stir for 15 minutes. AcOH (5 drops) was added, stirred for several minutes and the mixture was then concentrated. The residue was diluted with EtOAc, washed with sat'd NaHCO₃, then brine, dried over Na₂SO₄, filtered and concentrated to a colorless residue which was used crude in the next step. LCMS (ESI) m/z calcd for C₁₅H₁₆FN₅O₅: 365.1. Found: 366.2 (M+1)⁺.


20 Step C: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((ethoxycarbonyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methyl decanoate. To a solution of the crude product from the previous step, decanoic acid (8.61 mg, 0.050 mmol) and DMAP (3.05 mg, 0.025 mmol) in DCM (0.5 mL) at ambient temperature was added EDC (14.38 mg, 0.075 mmol), followed
25 by DIPEA (0.022 mL, 0.125 mmol) and the mixture was allowed to stir overnight. The mixture was concentrated and then purified by RP-HPLC purification (C18, 10-100% MeCN/water with 0.1% FA) to afford the title compound (4.5 mg, 34% over 2 steps) as a white solid. LCMS (ESI) m/z calcd for C₂₅H₃₄FN₅O₆: 519.3. Found: 520.3 (M+1)⁺. ¹H NMR (400MHz, DMSO-*d*₆) δ 8.32 (s, 1H), 8.07 - 7.76 (m, 2H), 6.37 - 6.31 (m, 1H), 5.57 (dd, J =
30 5.3, 6.8 Hz, 1H), 4.42 (d, J = 11.7 Hz, 1H), 4.28 - 4.13 (m, 3H), 3.83 (s, 1H), 3.24 - 3.15 (m, 1H), 2.73 - 2.61 (m, 1H), 2.35 - 2.14 (m, 2H), 1.50 - 1.38 (m, 2H), 1.31 - 1.11 (m, 15H), 0.84 (t, J = 6.8 Hz, 3H).

35 **Example 16: (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((heptanoyloxy)methyl)tetrahydrofuran-3-yl heptanoate**



To a stirred solution of (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-ol (54 mg, 0.184 mmol) (*Org. Lett.*, Vol. 13, No. 19, **2011**, 5264-5299), heptanoic acid (0.104 mL, 0.737 mmol) and DMAP (45.0 mg, 0.368 mmol) in DMF (1.6 mL) at ambient temperature was added EDC (176 mg, 0.921 mmol) followed by DIPEA (0.322 mL, 1.841 mmol) and the mixture was allowed to stir overnight. Water was added and the mixture was extracted with EtOAc. The combined extracts were washed with water, then brine, dried over Na₂SO₄, filtered and concentrated. The residue was purified on silica gel (0-10% DCM/MeOH) to afford the title compound (80 mg, 84%) as a white solid. LCMS (ESI) m/z calcd for C₂₆H₃₆FN₅O₅: 517.3. Found: 518.4 (M+1)⁺. ¹H NMR (400MHz, DMSO-d₆) δ 8.33 (s, 1H), 8.05 - 7.75 (m, 2H), 6.37 - 6.31 (m, 1H), 5.73 - 5.67 (m, 1H), 4.40 (d, J = 11.7 Hz, 1H), 4.22 (d, J = 11.7 Hz, 1H), 3.79 (s, 1H), 3.19 - 3.10 (m, 1H), 2.66 - 2.56 (m, 1H), 2.43 - 2.15 (m, 4H), 1.63 - 1.53 (m, 2H), 1.49 - 1.38 (m, 2H), 1.36 - 1.10 (m, 12H), 0.91 - 0.79 (m, 6H).


Example 17: (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((tetradecanoyloxy)methyl)tetrahydrofuran-3-yl tetradecanoate



The title compound was prepared according to example 16, substituting tetradecanoic acid for heptanoic acid. LCMS (ESI) m/z calcd for C₄₀H₆₄FN₅O₅: 713.5. Found: 714.5 (M+1)⁺. ¹H NMR (400 MHz, Chloroform-d) δ 7.96 (s, 1H), 6.39 (t, J = 6.4 Hz, 1H), 6.16 (br s, 2H), 5.61 - 5.66 (m, 1H), 4.48 (d, J = 12.1 Hz, 1H), 4.38 (J = 12.1 Hz, 1H), 2.98 (dt, J = 13.8,

6.6 Hz, 1H), 2.64 - 2.74 (m, 2H), 2.27 - 2.46 (m, 4H), 1.55 - 1.69 (m, 4H), 1.20 - 1.32 (m, 40H), 0.86 (t, $J = 6.64$ Hz, 6H).

Example 18: (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-((decanoyloxy)methyl)-2-ethynyltetrahydrofuran-3-yl decanoate



Synthesis A


The title compound was prepared according to example 16, substituting decanoic acid for heptanoic acid. LCMS (ESI) m/z calcd for $C_{32}H_{48}FN_5O_5$: 601.4. Found: 602.7 ($M+1$)⁺. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.96 (s, 1H), 6.39 (t, $J = 6.4$ Hz, 1H), 6.14 - 6.33 (m, 2H), 5.64 (dd, $J = 7.4, 5.5$ Hz, 1H), 4.48 (d, $J = 12.1$ Hz, 1H), 4.38 (d, $J = 12.1$ Hz, 1H), 2.98 (dt, $J = 13.5, 6.9$ Hz, 1H), 2.62 - 2.74 (m, 2H), 2.27 - 2.42 (m, 4H), 1.55 - 1.69 (m, 4H), 1.17 - 1.35 (m, 24H), 0.80 - 0.90 (m, 6H).

Synthesis B: Large scale preparation: To a solution of (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-ol (4.75 g, 16.2 mmol), TEA (9.03 mL, 64.8 mmol) and DMAP (0.396 g, 3.24 mmol) in DCM (100 mL) was added decanoyl chloride (6.80 g, 35.6 mmol) dropwise. The resulting mixture was stirred for 2 hours at room temperature. LCMS indicated completion of reaction. The reaction was quenched with water (100 mL) and extracted with DCM (100 mL X 2). The combined organic phases were dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. The reaction was repeated for four times and the combined residues were purified by flash chromatography (silica gel, 660 g, pet. ether – 0-80% EtOAc) to give the desired product (purity: 95%) as a white solid. The solid was triturated with EtOAc (300 mL), stirred for 0.5 h, filtered through a Buchner funnel, rinsed with EtOAc, and dried under sun lamp for 6 h ($T = 50$ °C). This solid was stored in a cool dry place overnight to give crystalline (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-((decanoyloxy)methyl)-2-ethynyltetrahydrofuran-3-yl decanoate (34 g, 99.43%, yield: 87%) as a white solid. LCMS (ESI) m/z calcd for $C_{32}H_{48}FN_5O_5$: 601. Found: 602 ($M+1$)⁺. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.93 (s, 1H), 6.40 (t, $J = 6.4$ Hz, 1H), 6.13 (br s, 2H), 5.65 (dd, $J = 6.8, 5.6$ Hz, 1H),

4.49 (d, $J = 12.0$ Hz, 1H), 4.39 (d, $J = 12.0$ Hz, 1H), 3.02 - 3.00 (m, 1H), 2.78 - 2.67 (m, 1H), 2.66 (s, 1H), 2.43 - 2.30 (m, 4H), 1.67 - 1.58 (m, 4H), 1.40 - 1.17 (m, 24H), 0.89 - 0.86 (m, 6H).

5

Example 19: (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((pentanoyloxy)methyl)tetrahydrofuran-3-yl tridecanoate



10

Step A: ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-(((4-methoxyphenyl)diphenylmethoxy)methyl)tetrahydrofuran-2-yl)methyl pentanoate. To a stirred solution of ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-(((4-methoxyphenyl)diphenylmethoxy)methyl)tetrahydrofuran-2-yl)methanol (1.50 g, 1.79 mmol) and DMAP (0.109 g, 0.895 mmol) in DCM (15 mL) at 0 °C was added TEA (0.749 mL, 5.37 mmol) followed by a solution of pentanoyl chloride (0.234 mL, 1.97 mmol) in DCM (1 mL). The resulting solution was stirred at 0 °C for 10 minutes and at RT for 30 minutes. LCMS indicated complete reaction. The reaction mixture was quenched with water, extracted with EtOAc (3x20 mL), the organic phase was combined, washed with brine, dried over Na₂SO₄ and concentrated under vacuum. The residue was subjected to preparative - TLC (MeOH:DCM = 1:20) to give the desired product (1.5 g, 88%) as a white solid. LCMS (ESI) m/z calcd for C₅₇H₅₂FN₅O₆: 921. Found: 922 (M+1)⁺. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.12 - 7.91 (m, 2H), 7.51 (d, $J = 7.6$ Hz, 4H), 7.42 - 7.11 (m, 20H), 6.84 (d, $J = 8$ Hz, 4H), 6.13 (s, 1H),

15

the organic phase was combined, washed with brine, dried over Na₂SO₄ and concentrated under vacuum. The residue was subjected to preparative - TLC (MeOH:DCM = 1:20) to give the desired product (1.5 g, 88%) as a white solid. LCMS (ESI) m/z calcd for C₅₇H₅₂FN₅O₆: 921. Found: 922 (M+1)⁺. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.12 - 7.91 (m, 2H), 7.51 (d, $J = 7.6$ Hz, 4H), 7.42 - 7.11 (m, 20H), 6.84 (d, $J = 8$ Hz, 4H), 6.13 (s, 1H),

20

4.68 (s, 1H), 4.06 - 3.95 (m, 2H), 3.85 - 3.77 (m, 1H), 3.74 - 3.54 (m, 6H), 2.10 - 1.99 (m, 2H), 1.95 - 1.87 (m, 2H), 1.24 - 1.18 (m, 2H), 1.10 - 1.01 (m, 2H), 0.78 - 0.67 (m, 3H).

Step B: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-


- 5 hydroxytetrahydrofuran-2-yl)methyl pentanoate. ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methyl pentanoate (1.46 g, 1.58 mmol) was dissolved in DCM (14 mL) and TFA (3 mL), the resulting mixture was stirred for 1 h at RT. LCMS indicated complete reaction. The reaction mixture was diluted with
- 10 MeOH (14 mL) and concentrated under vacuum. The residue was subjected to reverse phase HPLC purification (C18, 20-60% ACN/water with 0.1% FA) to give the desired product as a white solid (525 mg, 87%). LCMS (ESI) m/z calcd for C₁₇H₂₀FN₅O₄: 377. Found: 378 (M+1)⁺. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.28 (s, 1H), 7.87 (br, 2H), 6.24 (dd, *J* = 8.0, 3.9 Hz, 1H), 5.80 (d, *J* = 5.4 Hz, 1H), 4.74 - 4.69 (m, 1H), 4.43 (d, *J* = 11.6 Hz,
- 15 1H), 4.09 (d, *J* = 12.0 Hz, 1H), 3.64 (s, 1H), 2.83 - 2.78 (m, 1H), 2.49 - 2.44 (m, 1H), 2.27 - 2.08 (m, 2H), 1.45 - 1.33 (m, 2H), 1.24 - 1.14 (m, 2H), 0.80 (t, *J* = 7.3 Hz, 3H).

Step C: (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-

- ((pentanoyloxy)methyl)tetrahydrofuran-3-yl tridecanoate. Tridecanoic acid (68.2 mg, 0.318 mmol) was dissolved in DMF (1 mL), DMAP (155 mg, 1.27 mmol) and EDC (244 mg, 1.27 mmol) were added. The resulting mixture was stirred for 2 h at RT. Then, ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl
- 20 pentanoate (100 mg, 0.265 mmol) was added. The resulting mixture was stirred for overnight at RT. LCMS indicated complete reaction. The reaction mixture was quenched
- 25 with water and extracted with EtOAc (3x). The organic phases were combined, washed with brine, dried over Na₂SO₄ and concentrated under vacuum. The residue was subjected to preparative TLC (MeOH: DCM = 1: 20) to give the desired product as a white solid (34 mg, 22%). LCMS (ESI) m/z calcd for C₃₀H₄₄FN₅O₅: 573. Found: 574(M+1)⁺. ¹H
- 30 NMR (400 MHz, DMSO-*d*₆) δ 8.33 (s, 1H), 7.89 (br, 2H), 6.34 (t, *J* = 6.7 Hz, 1H), 5.70 (t, *J* = 12.4 Hz, 1H), 4.40 (d, *J* = 11.6 Hz, 1H), 4.21 (d, *J* = 11.6 Hz, 1H), 3.79 (s, 1H), 3.18 - 3.11 (m, 1H), 2.64 - 2.57 (m, 1H), 2.43 - 2.34 (m, 2H), 2.32 - 2.18 (m, 2H), 1.59 - 1.54 (m, 2H), 1.47 - 1.39 (m, 2H), 1.37 - 1.17 (m, 20H), 0.87 - 0.79 (m, 6H).

**Example 20: (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-
((pentanoyloxy)methyl)tetrahydrofuran-3-yl heptanoate**

35




The title compound was prepared according to example 19, substituting heptanoic acid for tridecanoic acid in step C. LCMS (ESI) m/z calcd for $C_{24}H_{32}FN_5O_5$: 489. Found: 490

($M+1$)⁺. ^1H NMR (400 MHz, Methanol- d_4) δ 8.18 (s, 1H), 6.38 (dd, J = 7.2, 5.5 Hz, 1H),

5 5.82 (dd, J = 7.3, 6.1 Hz, 1H), 4.45 (d, J = 11.8 Hz, 1H), 4.33 (d, J = 11.7 Hz, 1H), 3.26 (s, 1H), 3.22 - 3.15 (m, 1H), 2.75 - 2.69 (m, 1H), 2.43 (t, J = 7.4 Hz, 2H), 2.32 - 2.24 (m, 2H), 1.71 - 1.63 (m, 2H), 1.52 - 1.43 (m, 2H), 1.36 - 1.26 (m, 8H), 0.92 - 0.86 (m, 6H).

Example 21: (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((pentanoyloxy)methyl)tetrahydrofuran-3-yl undecanoate




The title compound was prepared according to example 19, substituting undecanoic acid for tridecanoic acid in step C. LCMS (ESI) m/z calcd for $C_{28}H_{40}FN_5O_5$: 545. Found: 546

($M+1$)⁺. ^1H NMR (400 MHz, Methanol- d_4) δ 8.18 (s, 1H), 6.38 (dd, J = 7.2, 5.5 Hz, 1H),

15 5.82 (dd, J = 7.4, 6.1 Hz, 1H), 4.45 (d, J = 11.6 Hz, 1H), 4.33 (d, J = 11.6 Hz, 1H), 3.25 (s, 1H), 3.22 - 3.15 (m, 1H), 2.75 - 2.68 (m, 1H), 2.43 (t, J = 7.4 Hz, 2H), 2.32 - 2.24 (m, 2H), 1.71 - 1.64 (m, 2H), 1.53 - 1.49 (m, 2H), 1.39 - 1.24 (m, 16H), 0.91 - 0.86 (m, 6H).

Example 22: (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((pentanoyloxy)methyl)tetrahydrofuran-3-yl nonanoate




The title compound was prepared according to example 19, substituting nonanoic acid for tridecanoic acid in step C. LCMS (ESI) m/z calcd for $C_{26}H_{36}FN_5O_5$: 517. Found: 518

($M+1$)⁺. ^1H NMR (400 MHz, Methanol- d_4) δ 8.18 (s, 1H), 6.38 (dd, J = 7.2, 5.5 Hz, 1H),

5.82 (dd, $J = 7.4, 6.1$ Hz, 1H), 4.45 (d, $J = 11.8$ Hz, 1H), 4.33 (d, $J = 11.8$ Hz, 1H), 3.25 (s, 1H), 3.22 - 3.15 (m, 1H), 2.75 - 2.68 (m, 1H), 2.43 (t, $J = 7.4$ Hz, 2H), 2.33 - 2.22 (m, 2H), 1.71 - 1.64 (m, 2H), 1.55 - 1.47 (m, 2H), 1.39 - 1.26 (m, 12H), 0.92 - 0.85 (m, 6H).

5

10 **Example 23: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((pentanoyloxy)methyl)tetrahydrofuran-3-yl) pentanoate**




The title compound was prepared according to example 19, substituting pentanoic acid for tridecanoic acid in step C. LCMS (ESI) m/z calcd for $C_{22}H_{28}FN_5O_5$: 461. Found: 462

15 (M+1)⁺. ¹H NMR (400 MHz, Methanol- d_4) δ 8.18 (s, 1H), 6.38 (dd, $J = 7.2, 5.6$ Hz, 1H), 5.82 (dd, $J = 7.3, 6.0$ Hz, 1H), 4.45 (d, $J = 11.7$ Hz, 1H), 4.33 (d, $J = 11.7$ Hz, 1H), 3.26 (s, 1H), 3.22 - 3.16 (m, 1H), 2.75 - 2.68 (m, 1H), 2.44 (t, $J = 7.4$ Hz, 2H), 2.33 - 2.21 (m, 2H), 1.69 - 1.62 (m, 2H), 1.56 - 1.47 (m, 2H), 1.45 - 1.36 (m, 2H), 1.33 - 1.24 (m, 2H), 0.95 (t, $J = 7.3$ Hz, 3H), 0.87 (t, $J = 7.3$ Hz, 3H).

20

Example 24: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-(propionyloxy)tetrahydrofuran-2-yl)methyl pentanoate




The title compound was prepared according to example 19, substituting propanoic acid for tridecanoic acid in step C. LCMS (ESI) m/z calcd for $C_{20}H_{24}FN_5O_5$: 433. Found: 456

25 (M+23)⁺. ¹H NMR (400 MHz, Methanol- d_4) δ 8.18 (s, 1H), 6.39 (dd, $J = 7.1, 5.8$ Hz, 1H), 5.81 (dd, $J = 7.3, 5.8$ Hz, 1H), 4.45 (d, $J = 11.7$ Hz, 1H), 4.33 (d, $J = 11.8$ Hz, 1H), 3.26 (s, 1H), 3.23 - 3.16 (m, 1H), 2.75 - 2.68 (m, 1H), 2.46 (dd, $J = 15.2, 7.6$ Hz, 2H), 2.36 - 2.20 (m, 2H), 1.56 - 1.45 (m, 2H), 1.34 - 1.24 (m, 2H), 1.18 (t, $J = 7.6$ Hz, 3H), 0.87 (t, $J = 7.3$ Hz, 3H).

30

Example 25: ((2R,3S,5R)-5-(6-butylamido-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl pentanoate



5 Step A: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methyl pentanoate. ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl pentanoate (1.00 g, 2.65 mmol) was dissolved in DMF (20 mL), imidazole (0.541 g, 7.95 mmol) and tert-

10 butylchlorodimethylsilane (1.20 g, 7.95 mmol) was added at 0 °C. The resulting mixture was stirred for 16 h at RT. LCMS indicated complete reaction. The reaction was diluted with water and extracted with EA (3x). The organic phases were combined, washed with saturated brine, dried over Na₂SO₄ and concentrated under vacuum. The residue was subjected to flash chromatography (silica gel, 40 g, EtOAc/PE = 1:3) to give the desired

15 product (1.0 g, 69%) as a white solid. LCMS (ESI) m/z calcd for C₂₃H₃₄FN₅O₄Si: 491. Found: 492 (M+1)⁺. ¹H NMR (300 MHz, DMSO-d₆) δ 8.28 (s, 1H), 7.91 (br, 2H), 6.30 - 6.26 (m, 1H), 4.99 (t, J = 7.1 Hz, 1H), 4.35 (d, J = 11.8 Hz, 1H), 4.10 (d, J = 11.8 Hz, 1H), 3.66 (s, 1H), 3.01 - 2.91 (m, 1H), 2.49 - 2.40 (m, 1H), 2.22 - 2.09 (m, 2H), 1.40-1.38 (m, 2H), 1.24 - 1.16 (m, 2H), 0.92 (s, 9H), 0.80 (t, J = 7.3 Hz, 3H), 0.15 (s, 6H).

20


Step B: ((2R,3S,5R)-3-((tert-butyldimethylsilyl)oxy)-5-(6-butylamido-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-2-yl)methyl pentanoate. ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methyl pentanoate (200 mg, 0.407 mmol) and DMAP (25.0 mg, 0.203 mmol) were dissolved in DCM (5 mL).

25 TEA (0.227 mL, 1.63 mmol) was added at 0 °C. Then a solution of butanoyl chloride (97.0

mg, 0.814 mmol) in DCM (2 mL) was added dropwise. Then the resulting mixture was stirred for 16 h at RT. LCMS indicated complete reaction. The reaction was quenched with water, and extracted with EA (3x). The organic phases were combined, washed with saturated brine, dried over Na₂SO₄ and concentrated under vacuum. The residue was subjected to preparative TLC (100% EtOAc) to give the desired product (110 mg, 48%) as yellow oil. LCMS (ESI) m/z calcd for C₂₇H₄₀FN₅O₅Si: 561. Found: 562 (M+1)⁺. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.65 (s, 1H), 8.10 (s, 1H), 6.39 - 6.28 (m, 1H), 4.95 - 4.85 (m, 1H), 4.46 (d, *J* = 11.8 Hz, 1H), 4.28 (d, *J* = 12.0 Hz, 1H), 3.51 (s, 1H), 2.99 - 2.81 (m, 3H), 2.77 - 2.69 (m, 1H), 2.33 - 2.25 (m, 2H), 1.86 - 1.80 (m, 2H), 1.61 - 1.56 (m, 2H), 1.37-1.30 (m, 2H), 1.07 (t, *J* = 7.2 Hz, 3H), 0.96 (s, 9H), 0.90 (t, *J* = 7.3 Hz, 3H), 0.16 (d, *J* = 4.4 Hz, 6H).

Step C: ((2R,3S,5R)-5-(6-butyramido-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl pentanoate. ((2R,3S,5R)-3-((tert-butyldimethylsilyl)oxy)-5-(6-butyramido-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-2-yl)methyl pentanoate (110 mg, 0.19 mmol) was dissolved in THF (10 mL), TBAF (0.38 mL, 1M in THF, 0.38 mmol) was added, the resulting mixture was stirred for 1 h at RT. LCMS indicated complete reaction. The reaction mixture was concentrated under vacuum. Water was added, the mixture was extracted with EtOAc (3x). The organic phases were combined, washed with brine, dried over Na₂SO₄ and concentrated under vacuum. The residue was subjected to preparative TLC (MeOH:DCM = 1: 10) followed by reverse phase HPLC purification (C18, MeCN/water with 0.1% formic acid) to give the desired product (25mg, 41%). LCMS (ESI) m/z calcd for C₂₁H₂₆FN₅O₅: 447. Found: 448 (M+1)⁺. ¹H NMR (300 MHz, DMSO-*d*₆) δ 11.04 (s, 1H), 8.61 (s, 1H), 6.35 (q, *J* = 3.9 Hz, 1H), 5.85 (d, *J* = 5.4 Hz, 1H), 4.75 - 4.71 (m, 1H), 4.43 (d, *J* = 11.7 Hz, 1H), 4.11 (d, *J* = 11.7 Hz, 1H), 3.68 (s, 1H), 2.91 - 2.83 (m, 1H), 2.58 - 2.51 (m, 3H), 2.28 - 2.07 (m, 2H), 1.62 (h, *J* = 7.2 Hz, 2H), 1.48 - 1.26 (m, 2H), 1.17 (h, *J* = 7.2 Hz, 2H), 0.93 (t, *J* = 7.2 Hz, 3H), 0.78 (t, *J* = 7.2 Hz, 3H).


Example 26: ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-octanamido-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl pentanoate



The title compound was prepared according to example 25, substituting octanoyl chloride


for butanoyl chloride in step B. LCMS (ESI) m/z calcd for $C_{25}H_{34}FN_5O_5$: 503. Found: 504 ($M+1$)⁺. ¹H NMR (400 MHz, DMSO- d_6) δ 11.04 (s, 1H), 8.60 (s, 1H), 6.36 - 6.33 (m, 1H), 5.85 (d, J = 5.2 Hz, 1H), 4.75 - 4.71 (m, 1H), 4.42 (d, J = 11.6 Hz, 1H), 4.10 (d, J = 11.6 Hz, 1H), 3.68 (s, 1H), 2.89 - 2.83 (m, 1H), 2.55 - 2.49 (m, 3H), 2.21 - 2.18 (m, 1H), 2.15 - 2.11 (m, 1H), 1.62 - 1.52 (m, 2H), 1.40 - 1.20 (m, 10H), 1.20 - 1.15 (m, 2H), 0.90 - 0.81 (m, 3H), 0.77 (t, J = 7.2 Hz, 3H).

Example 27: ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl pentanoate




The title compound was prepared according to example 25, substituting tetradecanoyl chloride for butanoyl chloride in step B. LCMS (ESI) m/z calcd for $C_{31}H_{46}FN_5O_5$: 587. Found: 588 ($M+1$)⁺. ¹H NMR (400 MHz, Methanol- d_4) δ 8.39 (s, 1H), 6.39 (dd, J = 8.4, 3.6 Hz, 1H), 4.91 - 4.88 (m, 1H), 4.46 (d, J = 11.6 Hz, 1H), 4.24 (d, J = 12.0 Hz, 1H), 3.19 (s, 1H), 2.99 - 2.92 (m, 1H), 2.72 - 2.64 (m, 3H), 2.25 - 2.16 (m, 2H), 1.79 - 1.69 (m, 2H), 1.52 - 1.19 (m, 24H), 0.89 - 0.82 (m, 6H).

Example 28: ((2R,3S,5R)-5-(6-dodecanamido-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl pentanoate




The title compound was prepared according to example 25, substituting dodecanoyl chloride for butanoyl chloride in step B. LCMS (ESI) m/z calcd for $C_{29}H_{42}FN_5O_5$: 559. Found: 560 ($M+1$)⁺. ¹H NMR (400 MHz, DMSO- d_6) δ 11.04 (s, 1H), 8.60 (s, 1H), 6.35 (dd, J = 8.0, 3.6 Hz, 1H), 5.85 (d, J = 5.6 Hz, 1H), 4.75 - 4.71 (m, 1H), 4.43 (d, J = 11.6 Hz, 1H), 4.11 (d, J = 12.0 Hz, 1H), 3.68 (s, 1H), 2.86 - 2.82 (m, 1H), 2.57 - 2.49 (m, 3H), 2.21 - 2.11 (m, 2H), 1.58 - 1.57 (m, 2H), 1.37 - 1.13 (m, 20H), 0.85 (t, J = 6.8 Hz, 3H), 0.78 (t, J = 7.2 Hz, 3H).

Example 29: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(((2-propylpentanoyl)oxy)methyl)tetrahydrofuran-3-yl) dodecanoate




The title compound was prepared according to example 19, substituting 2-propylpentanoyl chloride for pentanoyl chloride in step A and dodecanoic acid for tridecanoic acid in step C. LCMS (ESI) m/z calcd for $C_{32}H_{48}FN_5O_5$: 601. Found: 602 ($M+1$)⁺. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.05 (s, 1H), 6.42 (t, J = 6.4 Hz, 1H), 5.99 (br, 2H), 5.63 - 5.60 (dd, J = 7.1, 5.3 Hz, 1H), 4.47 - 4.39 (m, 2H), 3.00 - 2.95 (m, 1H), 2.77 - 2.72 (m, 1H), 2.66 (s, 1H), 2.43 - 2.39 (m, 3H), 1.67 - 1.65 (m, 2H), 1.57 - 1.54 (m, 2H), 1.42 - 1.41 (m, 2H), 1.26 (s, 20H), 0.88 (m, 9H).

Example 30: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-(butyryloxy)-2-ethynyltetrahydrofuran-2-yl)methyl 2-propylpentanoate



The title compound was prepared according to example 19, substituting 2-propylpentanoyl chloride for pentanoyl chloride in step A and butanoic acid for tridecanoic acid in step C. LCMS (ESI) m/z calcd for $C_{24}H_{32}FN_5O_5$: 489. Found: 490 ($M+1$)⁺. ¹H NMR (300 MHz, Methanol-*d*₄) δ 8.18 (s, 1H), 6.42 - 6.38 (m, 1H), 5.86 - 5.81 (m, 1H), 4.37 - 4.32 (m, 2H), 3.28 - 3.22 (m, 2H), 2.76 - 2.72 (m, 1H), 2.44 - 2.42 (m, 2H), 2.31 - 2.29 (m, 1H), 1.75 - 1.67 (m, 2H), 1.51 - 1.45 (m, 2H), 1.39 - 1.14 (m, 6H), 1.00 (t, J = 7.4 Hz, 3H), 0.83 (m, 6H).

Example 31: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-(butyryloxy)-2-ethynyltetrahydrofuran-2-yl)methyl decanoate



Step A: (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-((tert-

- 5 butyldiphenylsilyl)oxy)methyl)-2-ethynyltetrahydrofuran-3-yl butyrate. A suspension of (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-((tert-butyl)oxy)methyl-2-ethynyltetrahydrofuran-3-ol (800 mg, 1.505 mmol) in DCM (15 mL) was treated with butyric acid (0.275 mL, 3.01 mmol), DMAP (184 mg, 1.51 mmol), EDC (865 mg, 4.51 mmol), DIEA (1.314 mL, 7.52 mmol), and stirred at RT for 1.5 h. The reaction was
- 10 concentrated and purified by flash chromatography (silica gel, 0-100% EtOAc/DCM) to give the title compound (466 mg, 52%) as white solid. LCMS (ESI) m/z calcd for $C_{32}H_{36}FN_5O_4Si$: 601.3. Found: 602.3 ($M+1$)⁺. ¹H NMR (400MHz, Chloroform-*d*) δ 7.96 (s, 1H), 7.71 - 7.63 (m, 4H), 7.48 - 7.33 (m, 6H), 6.49 (dd, J = 6.4, 7.2 Hz, 1H), 5.83 (dd, J = 4.2, 6.8 Hz, 1H), 5.74 (br s, 2H), 4.09 - 4.01 (m, 1H), 4.00 - 3.92 (m, 1H), 2.87 (td, J = 7.1,
- 15 13.9 Hz, 1H), 2.67 (ddd, J = 4.1, 6.2, 13.8 Hz, 1H), 2.56 (s, 1H), 2.44 - 2.36 (m, 2H), 1.79 - 1.68 (m, 2H), 1.10 (s, 9H), 1.00 (t, J = 7.4 Hz, 3H).

Step B: (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-

- 20 (hydroxymethyl)tetrahydrofuran-3-yl butyrate. An ice cold solution of (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-((tert-butyl)oxy)methyl-2-ethynyltetrahydrofuran-3-yl butyrate (665 mg, 1.105 mmol) in THF (22 mL) was treated

with TBAF (1M in THF) (1.66 mL, 1.66 mmol) and stirred at 0 °C for 2 h. The reaction was quenched with AcOH (~1 mL), diluted with water, and extracted with EtOAc. The combined organics were washed with brine 4x, dried over Na₂SO₄, filtered, and concentrated. Purification by flash chromatography [silica gel, 0-100% (3:1


5 EtOAc:EtOH)/hexanes] afforded the title compound (297 mg, 70%) as white solid. LCMS (ESI) m/z calcd for C₁₆H₁₈FN₅O₄: 363.1. Found: 364.1 (M+1)⁺. ¹H NMR (400MHz, DMSO-*d*₆) δ 8.33 (s, 1H), 7.87 (br s, 2H), 6.32 (dd, *J* = 6.2, 7.9 Hz, 1H), 5.60 (dd, *J* = 3.2, 6.6 Hz, 1H), 5.54 (dd, *J* = 5.5, 6.9 Hz, 1H), 3.75 - 3.56 (m, 3H), 3.00 (ddd, *J* = 6.8, 7.7, 14.1 Hz, 1H), 2.57 - 2.52 (m, 1H), 2.43 - 2.33 (m, 2H), 1.62 (sxt, *J* = 7.3 Hz, 2H), 0.94 (t, *J* = 7.4 Hz, 3H).

Step C((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-(butyryloxy)-2-

ethynyltetrahydrofuran-2-yl)methyl decanoate. A suspension of (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl butyrate (248 mg, 0.683 mmol) in DCM (6.8 mL) was treated with decanoic acid (141 mg, 0.819 mmol), DMAP (83 mg, 0.683 mmol), EDC (236 mg, 1.229 mmol), DIEA (0.596 mL, 3.41 mmol), and stirred at RT for 3.5 h. The reaction was diluted with water and extracted with DCM. The DCM solution was washed with sat. NaHCO₃, brine, dried over Na₂SO₄, filtered, and concentrated. Purification by flash chromatography (silica gel, 0-100% EtOAc/DCM)

20 afforded the title compound (261 mg, 70%) as white solid. LCMS (ESI) m/z calcd for C₂₆H₃₆FN₅O₅: 517.3. Found: 518.8 (M+1)⁺. ¹H NMR (400MHz, DMSO-*d*₆) δ 8.31 (s, 1H), 7.84 (br s, 2H), 6.34 (t, *J* = 6.8 Hz, 1H), 5.69 (dd, *J* = 5.2, 6.9 Hz, 1H), 4.40 (d, *J* = 11.7 Hz, 1H), 4.23 (d, *J* = 11.7 Hz, 1H), 3.76 (s, 1H), 3.15 (td, *J* = 6.9, 13.8 Hz, 1H), 2.61 (ddd, *J* = 5.2, 6.9, 14.1 Hz, 1H), 2.38 (dt, *J* = 2.9, 7.3 Hz, 2H), 2.34 - 2.15 (m, 2H), 1.62 (sxt, *J* = 7.3 Hz, 2H), 1.53 - 1.38 (m, 2H), 1.31 - 1.12 (m, 12H), 0.93 (t, *J* = 7.4 Hz, 3H), 0.89 - 0.80 (m, 3H).


Example 32: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-(heptanoyloxy)tetrahydrofuran-2-yl)methyl benzoate



The title compound was prepared according to example 31, substituting benzoic acid for butyric acid in step A and heptanoic acid for decanoic acid in step C. LCMS (ESI) m/z

calcd for $C_{26}H_{28}FN_5O_5$: 509.2. Found: 510.5 ($M+1$)⁺. ^1H NMR (400MHz, Chloroform- d) δ 8.06 - 7.99 (m, 2H), 7.85 (s, 1H), 7.61 - 7.54 (m, 1H), 7.49 - 7.41 (m, 2H), 6.42 (t, J = 6.6 Hz, 1H), 5.84 (dd, J = 5.5, 7.2 Hz, 1H), 5.77 (br s, 2H), 4.80 (d, J = 11.9 Hz, 1H), 4.62 (d, J = 11.9 Hz, 1H), 3.11 (ddd, J = 6.4, 7.4, 13.8 Hz, 1H), 2.81 - 2.67 (m, 2H), 2.44 (t, J = 7.5 Hz, 2H), 1.76 - 1.64 (m, 2H), 1.44 - 1.28 (m, 6H), 0.96 - 0.87 (m, 3H).

Example 33: (2R,3aS,20aR)-2-(6-amino-2-fluoro-9H-purin-9-yl)-20a-ethynylhexadecahydro-2H-furo[3,2-b][1,5]dioxacyclononadecine-5,18-dione



Step A: 1-((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-(((tert-butyl)diphenylsilyl)oxy)methyl)-2-ethynyltetrahydrofuran-3-yl) 14-tert-butyl tetradecanedioate. To a stirred solution of (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-(((tert-butyl)diphenylsilyl)oxy)methyl)-2-ethynyltetrahydrofuran-3-ol (146 mg, 0.275 mmol), 14-(tert-butoxy)-14-oxotetradecanoic acid (130 mg, 0.412 mmol) and DMAP (33.5 mg, 0.275 mmol) in DCM (1.5 mL) at ambient temperature was added EDC (158 mg,


0.824 mmol), followed by DIPEA (0.240 mL, 1.373 mmol) and the mixture was allowed to stir overnight. The mixture was concentrated and then purified on silica gel (0-50% DCM/EtOAc) to afford the title compound (187 mg, 82%) as a colorless residue. LCMS (ESI) m/z calcd for $C_{46}H_{62}FN_5O_6Si$: 827.5. Found: 828.7 ($M+1$)⁺. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.96 (s, 1H), 7.70 - 7.63 (m, 4H), 7.47 - 7.35 (m, 6H), 6.49 (dd, J = 6.2, 7.2 Hz, 1H), 5.90 - 5.74 (m, 3H), 4.05 (d, J = 11.2 Hz, 1H), 3.96 (d, J = 11.2 Hz, 1H), 2.90 - 2.81 (m, 1H), 2.70 - 2.63 (m, 1H), 2.56 (s, 1H), 2.41 (t, J = 7.5 Hz, 2H), 2.21 (t, J = 7.5 Hz, 2H), 1.75 - 1.52 (m, 4H), 1.45 (s, 9H), 1.40 - 1.22 (m, 16H), 1.10 (s, 9H).

- 10 Step B: 1-(((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl) 14-tert-butyl tetradecanedioate. To a solution of 1-(((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-(((tert-butyl)diphenylsilyl)oxy)methyl)-2-ethynyltetrahydrofuran-3-yl) 14-(tert-butyl) tetradecanedioate (185 mg, 0.223 mmol) in THF (2.0 mL) was added TBAF, 1M solution in THF (0.335 mL, 0.335 mmol) and the mixture was allowed to stir at ambient temperature for 60 minutes. AcOH (335 μ L) was added and the mixture was concentrated. The residue was purified on silica gel (0-10% DCM/MeOH) to afford the title compound (101 mg, 77%) as a white solid. LCMS (ESI) m/z calcd for $C_{30}H_{44}FN_5O_6$: 589.3. Found: 590.6 ($M+1$)⁺. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.84 (s, 1H), 6.34 (dd, J = 5.5, 9.3 Hz, 1H), 5.97 - 5.72 (m, 3H), 5.41 (dd, J = 3.3, 11.4 Hz, 1H), 4.07 - 4.01 (m, 1H), 3.98 - 3.90 (m, 1H), 3.21 (ddd, J = 6.3, 9.3, 13.7 Hz, 1H), 2.62 (s, 1H), 2.50 - 2.38 (m, 3H), 2.21 (t, J = 7.5 Hz, 2H), 1.74 - 1.65 (m, 2H), 1.63 - 1.52 (m, 2H), 1.45 (s, 9H), 1.41 - 1.23 (m, 16H).

- 25 Step C: 14-(((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl)oxy)-14-oxotetradecanoic acid. To a solution of 1-(((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl) 14-(tert-butyl) tetradecanedioate (101 mg, 0.171 mmol) in DCM (3.0 mL) at ambient temperature was added TFA (50 μ L, 0.649 mmol) and the mixture was stirred for 25 minutes. LCMS indicated mostly starting material remained. Additional TFA (50 μ L) was added and the mixture was stirred for six hours. The mixture was concentrated and then purified on silica gel (0-10% DCM/MeOH) to afford the title compound (56 mg, 61%) as a white solid. LCMS (ESI) m/z calcd for $C_{26}H_{36}FN_5O_6$: 533.3. Found: 534.5 ($M+1$)⁺. ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.03 - 11.75 (m, 1H), 8.33 (s, 1H), 7.97 - 7.74 (m, 2H), 6.31 (dd, J = 6.4, 7.9 Hz, 1H), 5.67 - 5.41 (m, 2H), 3.79 - 3.55 (m, 3H), 3.04 - 2.94 (m, 1H), 2.57 - 2.46 (m, 1H, overlapping DMSO peak), 2.41 - 2.34 (m, 2H), 2.17 (t, J = 7.4 Hz, 2H), 1.65 - 1.40 (m, 4H), 1.37 - 1.10 (m, 16H).

Step D: ((2R,3aS,20aR)-2-(6-amino-2-fluoro-9H-purin-9-yl)-20a-ethynylhexadecahydro-2H-furo[3,2-b][1,5]dioxacyclononadecine-5,18-dione. To a solution of 14-(((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl)oxy)-14-oxotetradecanoic acid (56 mg, 0.105 mmol) in DCM (6.5 mL) at ambient temperature was sequentially added DMAP (12.82 mg, 0.105 mmol), DIPEA (0.092 mL, 0.525 mmol) and EDC (60.4 mg, 0.315 mmol) and the mixture was allowed to stir for 3 days. The mixture was concentrated in the presence of Celite. Silica gel chromatography (0-50% DCM/EtOAc) afforded the title compound (4.6 mg, 8.5%) as a colorless residue. LCMS (ESI) m/z calcd for C₂₆H₃₄FN₅O₅: 515.3. Found: 516.8 (M+1)⁺. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.92 (s, 1H), 6.39 (dd, *J* = 5.5, 6.9 Hz, 1H), 5.87 (br s, 2H), 5.76 - 5.71 (m, 1H), 4.48 (d, *J* = 11.9 Hz, 1H), 4.40 (d, *J* = 11.7 Hz, 1H), 3.15 - 3.06 (m, 1H), 2.79 - 2.70 (m, 1H), 2.66 (s, 1H), 2.48 - 2.35 (m, 4H), 1.79 - 1.61 (m, 4H), 1.48 - 1.18 (m, 16H).

Example 34: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl heptanoylglycinate



Step A: ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-(((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methyl 2-((tert-butoxycarbonyl)amino)acetate. To a stirred solution of ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-(((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methanol (31 mg, 0.037 mmol),

(tert-butoxycarbonyl)glycine (12.96 mg, 0.074 mmol) and DMAP (4.52 mg, 0.037 mmol) in DCM (0.6 mL) at ambient temperature was added EDC (21.28 mg, 0.111 mmol), followed by DIPEA (0.032 mL, 0.185 mmol). The mixture was allowed to stir for 24 hours.


Additional (tert-butoxycarbonyl)glycine (12.96 mg, 0.074 mmol), DMAP (4.52 mg, 0.037 mmol), EDC (21.28 mg, 0.111 mmol) and DIPEA (0.032 mL, 0.185 mmol) were added and the mixture was stirred overnight. The mixture was concentrated and then purified on silica gel (0-50% DCM/EtOAc) to afford the title compound (16 mg, 44%) as a colorless residue. LCMS (ESI) m/z calcd for $C_{59}H_{55}FN_6O_8$: 995.1. Found: 996.3 ($M+1$)⁺.


- 10 Step B: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl 2-aminoacetate. To a solution of ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methyl 2-((tert-butoxycarbonyl)amino)acetate (16 mg, 0.016 mmol) in DCM (0.8 mL) was added TFA (0.2 ml). The resulting orange solution was stirred overnight, then concentrated and used in the next step without further purification. LCMS (ESI) m/z calcd for $C_{14}H_{15}FN_6O_4$: 350.1. Found: 351.7 ($M+1$)⁺.

- 20 Step C: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl heptanoylglycinate. To a solution of the crude amine product from the previous step in DMF (0.6 mL) was added heptanoic acid (6.81 μ L, 0.048 mmol), DIPEA (0.014 mL, 0.080 mmol) and finally HATU (12.17 mg, 0.032 mmol). The mixture was stirred for 20 minutes then purified directly by RP-HPLC (C18, 10-100% MeCN/water with 0.1% FA) to afford the title compound (4.6 mg, 27% over two steps) as a white residue. LCMS (ESI) m/z calcd for $C_{21}H_{27}FN_6O_5$: 462.2. Found: 463.8 ($M+1$)⁺. ¹H NMR (400 MHz, Methanol- d_4) δ 8.18 (s, 1H), 6.32 (dd, J = 3.9, 7.7 Hz, 1H), 4.85 - 4.77 (m, 1H, overlapping water signal), 4.50 (d, J = 11.7 Hz, 1H), 4.37 (d, J = 11.9 Hz, 1H), 3.96 (d, J = 17.6 Hz, 1H), 3.84 (d, J = 17.6 Hz, 1H), 3.16 (s, 1H), 2.90 - 2.83 (m, 1H), 2.69 - 2.61 (m, 1H), 2.26 - 2.16 (m, 2H), 1.66 - 1.51 (m, 2H), 1.39 - 1.20 (m, 6H), 0.94 - 0.84 (m, 3H).

30

Example 35: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl tetradecanoylglycinate






Step A: *tert*-butyl 2-tetradecanamidoacetate. To a solution of tetradecanoic acid (200 mg, 0.876 mmol), *tert*-butyl glycinate, hydrochloride (176 mg, 1.051 mmol) and DIPEA (0.459 mL, 2.63 mmol) in DMF (5 mL) was added HATU (533 mg, 1.401 mmol) and the mixture was allowed to stir at ambient temperature for 3 hours. Water was added and the mixture was extracted with EtOAc. The extracts were washed with 1N HCl, then sat'd NaHCO₃ at which point an emulsion formed. Brine was added and the mixture was filtered over Celite and the layers were separated. The organic phase was further washed with water, then brine, dried over Na₂SO₄, filtered and concentrated to afford the title compound (98 mg, 33%) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ = 8.10 - 8.03 (m, 1H), 3.66 (d, *J* = 6.0 Hz, 2H), 2.08 (t, *J* = 7.4 Hz, 2H), 1.53 - 1.43 (m, 2H), 1.39 (s, 9H), 1.23 (s, 20H), 0.89 - 0.81 (m, 3H).

Step B: 2-tetradecanamidoacetic acid. A solution of *tert*-butyl tetradecanoylglycinate (98 mg, 0.287 mmol) in DCM (0.8 mL) was treated with TFA (0.2 mL, 2.60 mmol) and the mixture was stirred at ambient temperature for 2 hours. Additional TFA (0.2 mL, 2.60 mmol) was added and stirring at ambient temperature was continued overnight. The mixture was concentrated to give a sticky brown solid which was used without further purification. ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.40 (br. s, 1H), 8.08 - 8.02 (m, 1H), 3.72 (d, *J* = 6.0 Hz, 2H), 2.10 (t, *J* = 7.4 Hz, 2H), 1.56 - 1.42 (m, 2H), 1.34 - 1.15 (m, 20H), 0.91 - 0.80 (m, 3H).

Steps C and D: ((2*R*,3*S*,5*R*)-5-(6-amino-2-fluoro-9*H*-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl tetradecanoylglycinate. The title compound was prepared from ((2*R*,3*S*,5*R*)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9*H*-purin-9-yl)-3-(((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methanol and 2-tetradecanamidoacetic acid according to example 1, steps E and F. LCMS (ESI) *m/z* calcd for C₂₈H₄₁FN₆O₅: 560.3. Found: 561.5 (*M*+1)⁺. ¹H NMR (400 MHz, Methanol-*d*₄) δ 8.18 (s, 1H), 6.33 (dd, *J* = 3.9, 7.7 Hz, 1H), 4.87 - 4.74 (m, 1H, overlapping H₂O peak), 4.50 (d, *J* = 11.9 Hz, 1H), 4.38 (d, *J* = 11.7 Hz, 1H), 3.97 (d, *J* = 17.6 Hz, 1H), 3.84 (d, *J* = 17.6 Hz, 1H), 3.16 (s, 1H), 2.91 - 2.83 (m, 1H), 2.70 - 2.61 (m, 1H), 2.27 - 2.15 (m, 2H), 1.65 - 1.52 (m, 2H), 1.28 (s, 20H), 0.93 - 0.85 (m, 3H).

Example 36: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl heptanoyl-L-alaninate



5

Step A: (S)-((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)-amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methyl 2-((tert-butoxycarbonyl)amino)propanoate. To a stirred solution of ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methanol (39 mg, 0.047 mmol), (tert-butoxycarbonyl)-L-alanine (17.61 mg, 0.093 mmol) and DMAP (5.69 mg, 0.047 mmol) in DCM (0.5 mL) at ambient temperature was added EDC (26.8 mg, 0.140 mmol), followed by DIPEA (0.041 mL, 0.233 mmol). The mixture was allowed to stir at ambient temperature overnight. The mixture was concentrated and then purified on silica gel (0-50% hexanes/EtOAc) to afford the title compound (41 mg, 87%) as a colorless residue (41 mg). LCMS (ESI) m/z calcd for C₆₀H₅₇FN₆O₈: 1008.4. Found: 1009.6 (M+1)⁺.

10

15


Step B: (S)-((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl 2-aminopropanoate. To a solution of (S)-((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methyl 2-((tert-butoxycarbonyl)amino)propanoate (41 mg, 0.041 mmol) in DCM (0.8 mL) was added TFA (0.2 mL). The

20

resulting orange solution was stirred for two hours, then concentrated and used in the next step without further purification. LCMS (ESI) m/z calcd for $C_{15}H_{17}FN_6O_4$: 364.1. Found: 365.1 ($M+1$)⁺.

- 5 Step C: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetra-
hydrofuran-2-yl)methyl heptanoyl-L-alaninate. To a mixture of the crude product from the
 previous step in DMF (0.500 mL) was added heptanoic acid (6.06 mg, 0.047 mmol),
 DIPEA (0.024 mL, 0.140 mmol) and finally HATU (28.3 mg, 0.074 mmol) at ambient
 temperature and the mixture was allowed to stir for 30 minutes. Sat'd $NaHCO_3$ was added
 10 and the mixture was extracted with EtOAc. The combined extracts were washed with
 water, then brine, dried over Na_2SO_4 , filtered and concentrated to a pale brown. The
 residue was dissolved in DCM (0.8 mL), treated with formic acid (0.2 mL), followed by
 triethylsilane (0.015 mL, 0.093 mmol) and the mixture was stirred at ambient temperature
 for 30 minutes. The mixture was concentrated and then purified on silica gel (0-10%
 15 DCM/MeOH) to afford the title compound (10.2 mg, 51% over two steps) as a colorless
 residue. LCMS (ESI) m/z calcd for $C_{22}H_{29}FN_6O_6$: 476.2. Found: 477.2 ($M+1$)⁺. ¹H NMR
 (400 MHz, $DMSO-d_6$) δ 8.26 (s, 1H), 8.14 - 8.09 (m, 1H), 7.80 (br s, 2H), 6.25 (dd, J = 5.0,
 7.6 Hz, 1H), 5.77 - 5.74 (m, 1H), 4.68 - 4.52 (m, 1H), 4.32 (d, J = 11.4 Hz, 1H), 4.24 - 4.15
 (m, 2H), 3.59 (s, 1H), 2.84 - 2.75 (m, 1H), 2.53 - 2.40 (m, 1H, overlapping DMSO peak),
 20 2.09 - 2.02 (m, 2H), 1.52 - 1.35 (m, 2H), 1.31 - 1.09 (m, 9H), 0.89 - 0.74 (m, 3H).


Example 37: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-(butyryloxy)-2-ethynyltetrahydrofuran-2-yl)methyl tetradecanoate



25

The title compound was prepared according to example 31, substituting tetradecanoic acid for decanoic acid in step C. LCMS (ESI) m/z calcd for $C_{30}H_{44}FN_5O_5$: 573. Found: 574 ($M+1$)⁺. ¹H NMR (400 MHz, Chloroform- d) δ 7.95 (s, 1H), 6.42 (t, J = 6.4 Hz, 1H), 5.80 (br s, 2H), 5.68 (dd, J = 6.9, 5.5 Hz, 1H), 4.51 (d, J = 11.9 Hz, 1H), 4.41 (d, J = 11.9 Hz, 1H),
 30 3.03 (ddd, J = 13.8, 7.5, 6.2 Hz, 1H), 2.67 - 2.76 (m, 2H), 2.32 - 2.47 (m, 4H), 1.57 - 1.81 (m, 4H), 1.24 - 1.34 (m, 20H), 1.02 (t, J = 7.39 Hz, 3H), 0.87 - 0.94 (m, 3H).

Example 38: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-(((hexyloxy)carbonyl)oxy)tetrahydrofuran-2-yl)methyl tetradecanoate



Step A: hexyl (4-nitrophenyl) carbonate. A mixture of 4-nitrophenyl carbonochloridate (2.00 g, 9.92 mmol) and hexan-1-ol (1.24 ml, 9.92 mmol) in DCM (20 mL) was treated with TEA (2.08 ml, 14.9 mmol) and the mixture was stirred at RT for 1h. The reaction was concentrated and used in the next step without further purification.


Step B: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-(((tert-butyldiphenylsilyloxy)methyl)-2-ethynyltetrahydrofuran-3-yl) hexyl carbonate. A mixture of ((2R,3S,5R)-5-(6-amino-2-fluoro-4,5-dihydro-9H-purin-9-yl)-2-(((tert-butyldiphenylsilyloxy)methyl)-2-ethynyltetrahydrofuran-3-ol (300 mg, 0.562 mmol) and DMAP (68.7 mg, 0.562 mmol) in DCM (6.0 mL) was treated with TEA (0.235 mL, 1.69 mmol) followed by hexyl (4-nitrophenyl) carbonate (300 mg, 1.12 mmol) and the mixture was stirred at RT for 2 days. Concentrated and purified by flash chromatography (silica gel, 0-10% MeOH/DCM) to give the desired product as a white foam. (332 mg, 90%). LCMS (ESI) m/z calcd for C₃₅H₄₂FN₅O₅Si: 659. Found: 660 (M+1)⁺. ¹H NMR (400 MHz, Chloroform-d) δ 8.00 (s, 1H), 7.64 - 7.73 (m, 4H), 7.35 - 7.47 (m, 6H), 6.62 (s, 2H), 6.51 (t, J = 6.7 Hz, 1H), 5.75 (dd, J = 6.8, 4.4 Hz, 1H), 4.18 - 4.29 (m, 2H), 4.12 (d, J = 11.2 Hz,

1H), 4.02 (d, $J = 11.0$ Hz, 1H), 2.98 (dt, $J = 13.9, 7.0$ Hz, 1H), 2.81 (ddd, $J = 13.8, 6.4, 4.4$ Hz, 1H), 2.64 (s, 1H), 1.68 - 1.79 (m, 2H), 1.26 - 1.46 (m, 6H), 1.06 - 1.16 (m, 9H), 0.87 - 0.99 (m, 3H).

- 5 Step C: (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl hexyl carbonate. To a solution of (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-(((tert-butylidiphenylsilyl)oxy)methyl)-2-ethynyltetrahydrofuran-3-yl hexyl carbonate (332 mg, 0.503 mmol) in THF (8.0 mL) was added TBAF (1M, THF) (0.843 mL, 0.843 mmol) and the mixture was stirred at RT for 1 h. The mixture was concentrated and
- 10 the residue purified by flash chromatography (silica gel, 0-10% MeOH/DCM) to give the desired product as a white solid. (203 mg, 96%). LCMS (ESI) m/z calcd for $C_{19}H_{24}FN_5O_5$: 421. Found: 422 ($M+1$)⁺. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.82 (s, 1 H), 6.37 (dd, $J = 9.4, 5.4$ Hz, 1H), 6.02 (br s, 2H), 5.66 (dd, $J = 6.2, 1.2$ Hz, 1H), 4.18 - 4.29 (m, 2H), 4.07 (d, $J = 12.4$ Hz, 1H), 3.97 (br d, $J = 12.6$ Hz, 1H), 3.25 (ddd, $J = 13.9, 9.5, 6.2$ Hz, 1H),
- 15 2.66 (s, 1H), 2.57 (ddd, $J = 14.0, 5.6, 1.4$ Hz, 1H), 1.66 - 1.85 (m, 3H), 1.27 - 1.47 (m, 6H), 0.88 - 0.97 (m, 3H).

- Step D: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-(((hexyloxy)carbonyl)oxy)tetrahydrofuran-2-yl)methyl tetradecanoate. To a stirred solution of (2R,3S)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl hexyl carbonate (50.0 mg, 0.119 mmol), EDC (45.5 mg, 0.237 mmol) and DMAP (14.5 mg, 0.119 mmol) in DCM (3.0 mL) was added tetradecanoic acid (32.5 mg, 0.142 mmol) followed by DIEA (0.083 mL, 0.48 mmol) and the mixture was stirred at RT for 16 h. The reaction mixture was concentrated and purified by flash chromatography (silica gel, 0-10%
- 20 MeOH/DCM) to afford the product as a white solid. (58 mg, 77% yield). LCMS (ESI) m/z calcd for $C_{33}H_{50}FN_5O_6$: 631. Found: 632 ($M+1$)⁺. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.91 (s, 1H), 6.50 (s, 2H), 6.39 (t, $J = 6.4$ Hz, 1H), 5.60 (dd, $J = 7.0, 5.6$ Hz, 1H), 4.55 (d, $J = 11.9$ Hz, 1H), 4.41 (d, $J = 11.9$ Hz, 1H), 4.21 (m, 2 H), 3.14 (dt, $J = 13.4, 7.0$ Hz, 1H), 2.80 (ddd, $J = 13.9, 6.7, 5.6$ Hz, 1H), 2.71 (s, 1H), 2.28 - 2.42 (m, 2H), 1.55 - 1.76 (m, 4H), 1.28
- 30 - 1.44 (m, 10H), 1.25 (br s, 16H), 0.83 - 0.96 (m, 6H).

Example 39: (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(((2-propylpentanoyl)oxy)methyl)tetrahydrofuran-3-yl heptanoate




The title compound was prepared according to example 19, substituting 2-propylpentanoyl chloride for pentanoyl chloride in step A and heptanoic acid for tridecanoic acid in step C.

LCMS (ESI) m/z calcd for $C_{27}H_{38}FN_5O_5$: 531. Found: 532 ($M+1$)⁺. ¹H NMR (400 MHz,

- 5 Chloroform-*d*) δ 7.96 (s, 1H), 6.43 (t, J = 6.4 Hz, 1H), 5.84 (br s, 2H), 5.65 (dd, J = 7.0, 5.4 Hz, 1H), 4.41 - 4.49 (m, 2H), 3.01 (ddd, J = 13.7, 7.2, 6.3 Hz, 1H), 2.66 - 2.77 (m, 2H), 2.39 - 2.48 (m, 3H), 1.55 - 1.78 (m, 4H), 1.26 - 1.50 (m, 12H), 0.86 - 0.94 (m, 9H).

Example 40: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl tetradecanoyl-L-alaninate

10



Step 1: tetradecanoyl-L-alanine. To a solution of L-alanine (1.6 g, 17.96 mmol), sodium

- 15 bicarbonate (3.02 g, 35.9 mmol) in THF (40.0 mL)/ Water (40mL) at 20 °C was added tetradecanoyl chloride (2.216 g, 8.98 mmol) dropwise over 15 min. The reaction mixture was stirred at r.t. for 5 h. LCMS indicated completion of reaction. The reaction mixture was diluted with water (30 ml), and extracted with EtOAc (50 ml *2).The aqueous phase was

acidified with 1 M hydrochloric acid. The resulting solid was filtered through a Buchner funnel, rinsed with water (40 mL), and collected to give the crude tetradecanoyl-L-alanine as a white solid (800 mg, 27%). LCMS (ESI) m/z calcd for $C_{17}H_{33}NO_3$: 299. Found: 300 (M+H)⁺. ¹HNMR (400 MHz, DMSO- d_6) δ 8.02-7.91 (m, 1H), 4.16-4.05 (m, 1H), 2.05 (t, J = 7.2 Hz, 2H), 1.48-1.41 (m, 2H), 1.26-1.17 (m, 23H), 0.83 (t, J = 6.8 Hz, 3H).

Step 2: ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methyl-tetradecanoyl-L-alaninate. Tetradecanoyl-L-alanine (1 g, 3.34 mmol) was dissolved in

DCM (30 mL) and added EDC (3.20 g, 16.70 mmol) and DMAP (2.040 g, 16.70 mmol). The resulting mixture was stirred for 40 min at room temperature. Then, ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methanol (1.399 g, 1.670 mmol) was added and the resulting mixture was stirred overnight at room temperature. LCMS indicated completion of reaction. The reaction mixture was concentrated to dryness under vacuum to afford the crude product. The crude product was pre-absorbed on silica and purified on a silica column (120 g) using a 0%-60% pet. ether-EtOAc solvent gradient over 60 mins, Flow rate: 70 mL/min. The appropriate fractions were identified by UV absorbance (254 nm), combined and evaporated under vacuum to give the title product as a white solid (800 mg, 19%). LCMS (ESI) m/z calcd for $C_{69}H_{75}FN_6O_7$: 1119, Found: 1120 (M+H)⁺. ¹HNMR (400 MHz, $CDCl_3$) δ 7.55-7.49 (m, 4H), 7.42-7.37 (m, 2H), 7.33-7.18 (m, 18H), 6.80 (t, J = 12 Hz, 4H), 5.90 (dd, J = 24.4, 7.6 Hz, 1H), 4.47-4.28 (m, 2H), 4.15-4.06 (m, 4H), 3.78 (s, 3H), 3.74 (d, J = 8.0 Hz, 1H), 2.82 (d, J = 8.0 Hz, 1H), 2.05 (s, 4H), 1.29-1.24 (m, 22H), 1.19-1.13 (m, 2H), 1.11-1.05 (m, 2H), 0.85 (t, J = 6.4 Hz, 3H).


Step 3: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl tetradecanoyl-L-alaninate. To a stirred solution of ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl) amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methyl tetradecanoyl-L-alaninate (800 mg, 0.715 mmol) in DCM (3 mL) at 15 °C was added TFA (300 μ L, 3.89 mmol) dropwise. The reaction mixture was stirred at 15 °C for 1 h. LCMS indicated completion of reaction. The reaction mixture was diluted with $NaHCO_3$ (30 mL), and extracted with DCM (15 mL * 2). The combined organic phases were washed with brine (15 mL). The organic layers were dried over anhydrous sodium sulphate and concentrated under reduced pressure to afford crude product as a white solid. The sample was pre-absorbed on silica and purified on a silica column (80 g) using a 0%-10% DCM-MeOH solvent gradient over

30 mins, Flow rate: 45 mL/min. The appropriate fractions were identified by UV absorbance (254 nm), combined and evaporated in vacuo to give ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydro-furan-2-yl)methyl tetradecanoyl-L-alaninate (189 mg, 46%) as a white solid. LCMS (ESI) m/z calcd for $C_{29}H_{43}FN_6O_5$: 574.

- 5 Found: 575 (M+H)⁺. ¹HNMR (400MHz, CDCl₃) δ 7.95 (s, 1H), 6.32 (dd, J = 7.2, 4.8 Hz, 1H), 6.05 - 6.07 (m, 3H), 4.75 (t, J = 6.4 Hz, 1H), 4.61 (d, J = 11.6 Hz, 1H), 4.52 (t, J = 6.8 Hz, 1H), 4.42 (d, J = 11.6, 1H), 3.31 (s, 1H), 2.98-3.02 (m, 1H), 2.79 (s, 1H), 2.63-2.70 (m, 1H), 2.21 (t, J = 7.6 Hz, 2H), 1.58 - 1.63 (m, 2H), 1.40 (d, J = 7.2 Hz, 3H) 1.24-1.31 (m, 20H), 0.83 - 0.89 (m, 3H).

10

Example 41: ((2R,3S,5R)-2-(acetoxymethyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-3-yl) heptanoate




15


The title compound was isolated as a by product from example 32 preparation. This product was formed due to the presence of acetic acid in the starting material. ¹HNMR (400MHz, CHLOROFORM-d) δ ppm 7.92 (s, 1H), 6.39 (t, J = 6.4 Hz, 1H), 5.77 (br s, 2H), 5.69 (dd, J = 5.5, 7.2 Hz, 1H), 4.52 (d, J = 12.2 Hz, 1H), 4.38 (d, J = 12.2 Hz, 1H), 3.04 (ddd, J = 6.1, 7.4, 13.7 Hz, 1H), 2.76 - 2.63 (m, 2H), 2.42 (t, J = 7.5 Hz, 2H), 2.12 (s, 3H), 1.75 - 1.63 (m, 2H), 1.41 - 1.28 (m, 6H), 0.95 - 0.87 (m, 3H). LCMS (m/z) ES⁺ = 448.2 (M+1), ES⁻ = 446.4 (M-1).

20

Example 42: ((2R,3S,5R)-5-(6-decanamido-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl heptanoate

25





Step 1: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methyl heptanoate.

To a suspension of ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methanol (390 mg, 0.861 mmol) in DCM (25 mL) was added heptanoic acid (0.271 mL, 1.913 mmol) followed by DMAP (117 mg, 0.958 mmol), EDC (550 mg, 2.87 mmol) and DIEA (0.835 mL, 4.78 mmol) and the mixture was stirred at ambient temperature for 1.5 h. The mixture was diluted with dichloromethane and washed with water. The organic phases were dried (Na₂SO₄), concentrated and purified on silica gel (Biotage Isolera 1, 24 g, Gold column, EtOAc/hexanes 0-25% then 50-100%, bis-silyl impurity eluted at 25%, product eluted at 50-100%) to provide ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methyl heptanoate (360 mg, 0.686 mmol, 80 % yield) as an off-white solid. ¹HNMR (400 MHz, CHLOROFORM-*d*) δ ppm 7.87 (s, 1 H), 6.27 (dd, *J*=7.75, 3.70 Hz, 1 H), 5.82 (br s, 2 H), 4.96 (t, *J*=7.39 Hz, 1 H), 4.48 (d, *J*=11.92 Hz, 1 H), 4.26 (d, *J*=11.92 Hz, 1 H), 2.84 – 2.98 (m, 1 H), 2.58 – 2.72 (m, 2 H), 2.28 (td, *J*=7.57, 3.46 Hz, 2 H), 1.50 – 1.61 (m, 2 H), 1.19 – 1.42 (m, 6 H), 0.93 – 1.03 (m, 9 H), 0.81 - 0.92 (m, 3 H), 0.17 (d, *J*=4.29 Hz, 6 H). LCMS (*M*+1) = 520.7.


Step 2: ((2R,3S,5R)-3-((tert-butyldimethylsilyl)oxy)-5-(6-decanamido-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-2-yl)methyl heptanoate.


To a solution of ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methyl heptanoate (280 mg, 0.539 mmol) in DCM (7 mL) was added DIEA (0.565 mL, 3.23 mmol) and DMAP (65.8 mg, 0.539 mmol). The mixture was cooled to 0 °C and decanoyl chloride (0.335 mL, 1.616 mmol) was added dropwise. Stirring at 0 °C continued

for 30 min [LCMS showed only s.m.] and then at ambient temperature for 1.5 h. The mixture was diluted with dichloromethane and washed with saturated NaHCO₃/water and the organic phases were dried (Na₂SO₄), concentrated, and purified on silica gel (Biotage Isolera 1, 24 g column, EtOAc/hexanes 0-10-30-100%, 50-1-1 eluted at 30%, 50-2 at 30-35%, recovered s.m. eluted at 70%) to provide ((2R,3S,5R)-3-((tert-butyldimethylsilyl)oxy)-5-(6-decanamido-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-2-yl)methyl heptanoate (143.5 mg, 0.213 mmol, 39.5 % yield) as a yellowish oil and recovered starting material. LCMS (M+1) = 675.

Step 3: ((2R,3S,5R)-5-(6-decanamido-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl heptanoate. To a solution of ((2R,3S,5R)-3-((tert-butyldimethylsilyl)oxy)-5-(6-decanamido-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-2-yl)methyl heptanoate (138 mg, 0.205 mmol) in THF (2.5 mL) was added a solution of TBAF (0.410 mL, 0.410 mmol) (1 M/THF) containing acetic acid (0.023 mL, 0.410 mmol) and the mixture was stirred at ambient temperature for 5 h. The mixture was diluted with dichloromethane and washed with water. The organic phases were dried (Na₂SO₄), concentrated and purified on silica gel (Biotage Isolera 1, 4 g column, EtOAc/hexanes 0-50-100%, product eluted at 50-100%, two peaks) to provide a clear glass. An off-white solid was obtained by slow evaporation of a MeOH/water solution. ¹HNMR (400 MHz, CHLOROFORM-*d*) δ ppm 8.43 - 8.58 (m, 1 H), 8.05 (s, 1 H), 6.38 (dd, *J*=7.39, 4.77 Hz, 1 H), 4.78 (q, *J*=6.76 Hz, 1 H), 4.47 (d, *J*=1.91 Hz, 2 H), 2.90 - 3.09 (m, 3 H), 2.82 (s, 1 H), 2.71 (dt, *J*=13.71, 7.33 Hz, 1 H), 2.45 (d, *J*=6.44 Hz, 1 H), 2.36 (td, *J*=7.57, 2.50 Hz, 2 H), 1.72 - 1.88 (m, 2 H), 1.54-1.69 (m, 2 H), 1.21 - 1.51 (m, 18 H), 0.81 - 0.99 (m, 6 H). LCMS (M-1) = 558.4.

Example 43: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-(((hexyloxy)carbonyl)oxy)tetrahydrofuran-2-yl)methyl heptanoate





Step 1: ((2R,3S)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl heptanoate.

To a solution of (2R,3S)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-ol (500 mg, 1.705 mmol) in acetonitrile (70 mL) {used sonicator to dissolve} was added heptanoic acid (0.254 mL, 1.790 mmol) and 2-chloro-1-methylpyridin-1-ium iodide (566 mg, 2.216 mmol) and the mixture was stirred at ambient temperature for 15 min. The mixture was cooled to -15 °C (ice/EtOH) and triethylamine (0.713 mL, 5.11 mmol) was added followed by N,N-dimethylpyridin-4-amine (20.83 mg, 0.170 mmol). After 2 h 45 min (final temperature -5 °C), 0.5 M HCl/water (100 mL) was added and the mixture was extracted with dichloromethane. The organic phases were washed with NaHCO₃/water, dried (Na₂SO₄), concentrated and purified on silica gel (Biotage Isolera 1, 80 g Gold column, MeOH/dichloromethane 3% isocratic) to provide ((2R,3S)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl heptanoate (330 mg, 0.814 mmol, 47.7 % yield) (N70935-59-1, fractions 52-73) as an off-white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.26 (s, 1 H), 7.81 (br s, 2 H), 6.25 (dd, *J*=8.11, 4.05 Hz, 1 H), 5.76 (d, *J*=5.25 Hz, 1 H), 4.63 - 4.79 (m, 1 H), 4.42 (d, *J*=11.68 Hz, 1 H), 4.10 (d, *J*=11.68 Hz, 1 H), 3.61 (s, 1 H), 2.80 (ddd, *J*=13.35, 7.27, 3.93 Hz, 1 H), 2.5-2.4 (m, 1 H), 2.05 - 2.31 (m, 2 H), 1.34 - 1.55 (m, 2 H), 1.08 - 1.29 (m, 6 H), 0.83 (t, *J*=7.03 Hz, 3 H). LCMS (*M*+1) = 406.2.

Step 2: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-(((hexyloxy)carbonyl)oxy)tetrahydrofuran-2-yl)methyl heptanoate.


To a solution of ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl heptanoate (320 mg, 0.789 mmol) in DCM (40 mL) was added Et₃N (0.440 mL, 3.16 mmol) and the mixture was cooled to 0 °C then hexyl carbonochloridate (0.258 mL, 1.579 mmol) was added dropwise. After 1 h at 0 °C the mixture was stirred at ambient temperature for 1 h. DMAP

(9.64 mg, 0.079 mmol) was added and after 3.5 h at ambient temperature the mixture was diluted with dichloromethane and washed with saturated NaHCO₃/water. The organic phase was dried (Na₂SO₄), concentrated and purified on silica gel (Biotage Isolera 1, 24 g column, EtOAc/hexanes 0-50-100%) to provide ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-(((hexyloxy)carbonyl)oxy)tetrahydro-furan-2-yl)methyl heptanoate (132 mg, 0.247 mmol, 31.3 % yield) as a white solid (after concentration from MeCN). ¹HNMR (400 MHz, CHLOROFORM-*d*) δ ppm 7.78 - 8.02 (m, 1 H), 6.39 (t, *J*=6.44 Hz, 1 H), 5.76 (br s, 2 H), 5.61 (dd, *J*=7.27, 5.60 Hz, 1 H), 4.56 (d, *J*=12.16 Hz, 1 H), 4.42 (d, *J*=12.16 Hz, 1 H), 4.22 (td, *J*=6.74, 2.98 Hz, 2 H), 3.09 - 3.23 (m, 1 H), 2.76 - 2.88 (m, 1 H), 2.71 (s, 1 H), 2.37 (td, *J*=7.57, 4.41 Hz, 2 H), 1.68 - 1.80 (m, 2 H), 1.60 - 1.68 (m, 2 H), 1.21 - 1.48 (m, 12 H), 0.91 (dt, *J*=12.28, 6.97 Hz, 6 H). LCMS (M+1) = 534.6.

15

Example 44: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-(((hexyloxy)carbonyl)oxy)tetrahydrofuran-2-yl)methyl decanoate

20




Step 1: (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-(((tert-butyl)diphenylsilyl)oxy)methyl)-2-ethynyltetrahydrofuran-3-yl hexyl carbonate. To a stirred solution of (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-(((tert-butyl)diphenylsilyl)oxy)methyl)-2-ethynyltetrahydrofuran-3-ol (500 mg, 0.940 mmol), DMAP (115 mg, 0.940 mmol) and triethylamine (0.393 mL, 2.82 mmol) at 0 °C was slowly added a solution of hexyl carbonochloridate (0.169 mL, 1.034 mmol) in DCM (1.33 mL) and the mixture was stirred at 0 °C for ~ 2 hours. Sat'd NaHCO₃ was added and the mixture was extracted with EtOAc. The extracts were washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was purified on silica gel (40 g gold column, 0-70% hexanes/EtOAc) to afford title compound as white residue (293 mg, 47%). LCMS (M+1) = 660.4.

Step 2: (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl hexyl carbonate. To a solution of (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-(((tert-butyl)diphenylsilyl)oxy)methyl)-2-ethynyltetrahydrofuran-3-yl hexyl carbonate (347 mg, 0.526 mmol) in THF (5.0 mL) at ambient temperature was added TBAF (0.789 mL, 0.789 mmol) and the mixture was stirred for 30 minutes. The mixture was concentrated and then purified on silica gel (0-10% DCM/MeOH) to afford title compound as white solid (179 mg, 81%). LCMS (M+1) = 422.2.

Step 3: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-(((hexyloxy)carbonyl)oxy)tetrahydrofuran-2-yl)methyl decanoate. To a mixture of (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl hexyl carbonate (179 mg, 0.425 mmol), decanoic acid (80 mg, 0.467 mmol), DMAP (51.9 mg, 0.425 mmol) and DIEA (0.371 mL, 2.124 mmol) was added EDC (163 mg, 0.849 mmol) at ambient temperature and the mixture was allowed to stir overnight. The mixture was concentrated and then purified on silica gel (0-10% DCM/MeOH) to afford title compound as white solid (173 mg, 71%). ¹HNMR (400 MHz, DMSO-d₆) δ = 8.31 (s, 1H), 7.85 (br s, 2H), 6.38 - 6.32 (m, 1H), 5.59 (dd, J = 5.4, 7.0 Hz, 1H), 4.43 (d, J = 11.7 Hz, 1H), 4.25 (d, J = 11.7 Hz, 1H), 4.19 - 4.11 (m, 2H), 3.79 (s, 1H), 3.25 - 3.13 (m, 1H), 2.77 - 2.61 (m, 1H), 2.38 - 2.12 (m, 2H), 1.71 - 1.57 (m, 2H), 1.51 - 1.41 (m, 2H), 1.39 - 1.13 (m, 18H), 0.92 - 0.81 (m, 6H); LCMS (M+1) = 576.4.

Example 45: ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl benzoate




- Step 1: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methyl benzoate. A suspension of ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methanol (920 mg, 2.258 mmol) in DCM (22 mL) was treated with benzoic acid (331 mg, 2.71 mmol), DMAP (276 mg, 2.258 mmol), EDC (779 mg, 4.06 mmol), DIEA (1.971 mL, 11.29 mmol), and stirred at rt for 18 hours. The reaction was diluted with water, extracted with DCM, washed with sat. NaHCO₃, brine, dried over Na₂SO₄, filtered, and concentrated.
- Purification with column chromatography (0-100% EtOAc/DCM) afforded ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methyl benzoate (984.4 mg, 1.924 mmol, 85 % yield) as white solid. ¹HNMR (400MHz, CHLOROFORM-d) δ ppm 7.97 - 7.90 (m, 2H), 7.81 (s, 1H), 7.58 - 7.51 (m, 1H), 7.45 - 7.34 (m, 2H), 6.25 (dd, J = 3.5, 8.0 Hz, 1H), 5.66 (br s, 2H), 5.19 (dd, J = 7.0, 8.2 Hz, 1H), 4.74 (d, J = 12.2 Hz, 1H), 4.44 (d, J = 12.2 Hz, 1H), 3.03 (ddd, J = 3.3, 7.1, 13.2 Hz, 1H), 2.74 - 2.62 (m, 2H), 0.96 (s, 9H), 0.18 (s, 6H); LCMS (m/z) ES⁺ = 512.2 (M+1), ES⁻ = 510.4 (M-1).

Step 2: ((2R,3S,5R)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)tetrahydrofuran-2-yl)methyl benzoate. A solution of ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methyl benzoate (475 mg, 0.928 mmol) in DCM (9.2 mL) was treated with Et₃N (0.388 mL, 2.79 mmol), pyridine (0.225 mL, 2.79 mmol), tetradecanoyl chloride (0.379 mL, 1.393 mmol), DMAP (11.34 mg, 0.093 mmol), and then stirred at rt for 18 hours. The reaction was diluted with water, extracted with DCM, washed with aq. sat. NaHCO₃, brine, dried over Na₂SO₄, filtered, and concentrated. Purification with column chromatography (0-100% EtOAc/Hexane) afforded ((2R,3S,5R)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)tetrahydrofuran-2-yl)methyl benzoate (209.8 mg, 0.291 mmol, 31.3 % yield) as yellow film. ¹HNMR (400MHz, CHLOROFORM-d) δ ppm 8.33 (s, 1H), 7.96 (s, 1H), 7.92 - 7.86 (m, 2H), 7.58 - 7.49 (m, 1H), 7.44 - 7.35 (m, 2H), 6.28 (dd, *J* = 3.5, 8.0 Hz, 1H), 5.15 (dd, *J* = 6.9, 8.1 Hz, 1H), 4.77 (d, *J* = 12.2 Hz, 1H), 4.43 (d, *J* = 12.2 Hz, 1H), 3.03 (ddd, *J* = 3.3, 7.0, 13.3 Hz, 1H), 2.93 (t, *J* = 7.5 Hz, 2H), 2.78 - 2.64 (m, 2H), 1.77 (quin, *J* = 7.5 Hz, 2H), 1.50 - 1.39 (m, 2H), 1.39 - 1.19 (m, 18H), 0.97 (s, 9H), 0.92 - 0.84 (m, 3H), 0.29 - 0.10 (m, 6H); LCMS (*m/z*) ES⁺ = 722.5 (M+1), ES⁻ = 720.6 (M-1).

Step 3: ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl benzoate. An ice cold solution of ((2R,3S,5R)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)tetrahydrofuran-2-yl)methyl benzoate (285 mg, 0.395 mmol) in THF (8 mL) was treated with TBAF (1M in THF) (0.592 mL, 0.592 mmol), and stirred at 0 °C for 2 hours. The mixture was treated with additional 1M TBAF (150 μL) and stirred at 0 °C for 40 min. The reaction was quenched with AcOH (~0.5 mL), diluted with water, and extracted with EtOAc. The combined organics was washed with brine, dried over Na₂SO₄, filtered, and concentrated. Purification with column chromatography [0-65% (3:1 EtOAc:EtOH) / Hexane] gave ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl benzoate (194.4 mg, 0.310 mmol, 79 % yield) as off-white solid. ¹HNMR (400MHz, CHLOROFORM-d) δ ppm 8.39 (s, 1H), 8.02 - 7.93 (m, 3H), 7.62 - 7.54 (m, 1H), 7.48 - 7.39 (m, 2H), 6.37 (dd, *J* = 4.5, 7.6 Hz, 1H), 4.95 (q, *J* = 7.0 Hz, 1H), 4.79 - 4.61 (m, 2H), 3.08 (ddd, *J* = 4.5, 6.8, 13.7 Hz, 1H), 2.94 (t, *J* = 7.4 Hz, 2H), 2.85 (s, 1H), 2.73 (td, *J* = 7.5, 13.6 Hz, 1H), 2.48 (d, *J* = 6.7 Hz, 1H), 1.76 (quin, *J* = 7.5 Hz, 2H), 1.49 - 1.39 (m, 2H), 1.38 - 1.20 (m, 18H), 0.96 - 0.83 (m, 3H); LCMS (*m/z*) ES⁺ = 608.4 (M+1), ES⁻ = 606.4 (M-1).

Example 46: ((2R,3S,5R)-5-(6-decanamido-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl benzoate




- 5 Step 1: ((2R,3S,5R)-3-((tert-butyldimethylsilyl)oxy)-5-(6-decanamido-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-2-yl)methyl benzoate. A solution of ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methyl benzoate (470 mg, 0.919 mmol) in DCM (9.2 mL) was treated with Et₃N (0.384 mL, 2.76 mmol), pyridine (0.223 mL, 2.76 mmol), decanoyl chloride (0.286 mL, 1.378 mmol), and
- 10 DMAP (11.22 mg, 0.092 mmol). The reaction was stirred at rt for 18 hours. The reaction was diluted with water, extracted with DCM, washed with aq. sat. NaHCO₃, brine, dried over Na₂SO₄, filtered, and concentrated. Purification with column chromatography (0-100% EtOAc/Hexane) gave ((2R,3S,5R)-3-((tert-butyldimethylsilyl)oxy)-5-(6-decanamido-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-2-yl)methyl benzoate (217.7 mg, 0.327
- 15 mmol, 35.6 % yield) as yellow film. NMR contained aliphatic impurity. ¹HNMR (400MHz, CHLOROFORM-d) δ ppm 8.32 (s, 1H), 7.96 (s, 1H), 7.93 - 7.86 (m, 2H), 7.57 - 7.49 (m, 1H), 7.44 - 7.36 (m, 2H), 6.28 (dd, J = 3.6, 7.9 Hz, 1H), 5.15 (dd, J = 7.0, 8.2 Hz, 1H), 4.77 (d, J = 12.2 Hz, 1H), 4.43 (d, J = 12.2 Hz, 1H), 3.03 (ddd, J = 3.5, 7.0, 13.2 Hz, 1H), 2.97 - 2.88 (m, 2H), 2.78 - 2.63 (m, 2H), 1.77 (quin, J = 7.5 Hz, 2H), 1.48 - 1.20 (m, 12H), 0.97
- 20 (s, 9H), 0.92 - 0.84 (m, 3H), 0.21 - 0.16 (m, 6H); LCMS (m/z) ES⁺ = 666.5 (M+1), ES⁻ = 664.6 (M-1).

- Step 2: ((2R,3S,5R)-5-(6-decanamido-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl benzoate. An ice cold solution of ((2R,3S,5R)-3-((tert-
- 25 butyldimethylsilyl)oxy)-5-(6-decanamido-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-

2-yl)methyl benzoate (272 mg, 0.408 mmol) in THF (8 mL) was treated with TBAF (1M in THF) (0.613 mL, 0.613 mmol), and stirred at 0 °C for 2 hours. The mixture was treated with additional 1M TBAF (100 uL) and stirred at 0 °C for 40 min. The reaction was quenched with AcOH (~0.5 mL), diluted with water, and extracted with EtOAc. The combined organics was washed with brine, dried over Na₂SO₄, filtered, and concentrated. Purification with column chromatography [0-65% (3:1 EtOAc:EtOH) / Hexane] gave ((2R,3S,5R)-5-(6-decanamido-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl benzoate (164.1 mg, 0.292 mmol, 71.4 % yield) as light yellow solid. ¹HNMR (400MHz, CHLOROFORM-d) δ ppm 8.35 (s, 1H), 8.04 - 7.93 (m, 3H), 7.62 - 7.54 (m, 1H), 7.47 - 7.37 (m, 2H), 6.37 (dd, *J* = 4.5, 7.6 Hz, 1H), 4.95 (q, *J* = 7.1 Hz, 1H), 4.78 - 4.62 (m, 2H), 3.08 (ddd, *J* = 4.5, 6.9, 13.6 Hz, 1H), 2.94 (t, *J* = 7.4 Hz, 2H), 2.85 (s, 1H), 2.73 (td, *J* = 7.4, 13.6 Hz, 1H), 2.45 (d, *J* = 6.9 Hz, 1H), 1.77 (quin, *J* = 7.5 Hz, 2H), 1.47 - 1.38 (m, 2H), 1.38 - 1.20 (m, 10H), 0.94 - 0.85 (m, 3H); LCMS (*m/z*) ES⁻ = 550.4 (M-1).

Example 47: ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl heptanoate



Step 1: ((2R,3S,5R)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)tetrahydrofuran-2-yl)methyl heptanoate. To a solution of ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methyl heptanoate (280 mg, 0.539 mmol) and DIEA (0.565

mL, 3.23 mmol) in DCM (7 mL) was added DMAP (32.9 mg, 0.269 mmol) followed by dropwise addition of a solution of tetradecanoyl chloride (266 mg, 1.078 mmol) in dichloromethane (0.5 mL). After 2.5 h more tetradecanoyl chloride (0.09 mL) was added. After 2 h saturated NaHCO₃/water was added and the organic phases were dried

5 (Na₂SO₄), concentrated, and purified on silica gel (Biotage Isolera 1, 12 g column, 0-100% EtOAc/hexanes 0-100%) to provide ((2R,3S,5R)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)tetrahydrofuran-2-yl)methyl heptanoate (153 mg, 0.207 mmol, 38.5 % yield) as a yellowish oil which was in the next

10


Step 2: ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl heptanoate. To a solution of ((2R,3S,5R)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)tetrahydrofuran-2-yl)methyl heptanoate (150 mg, 0.205 mmol) in THF (2 mL) at 0 °C was

15 added TBAF (0.226 mL, 0.226 mmol) (1 M/THF) and the mixture was stirred at 0 °C for 3 h (10 °C final bath temperature). acetic acid (0.013 mL, 0.226 mmol) was added and the mixture was concentrated. The residue was purified on silica gel (Biotage Isolera 1, 4 g column, EtOAc/hexanes 0-100%, product eluted at 90-100%) to provide ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl


20 heptanoate (109.7 mg, 0.176 mmol, 86 % yield) as an off-white solid (by dissolving in a small amount of MeOH, adding 2 drops of water and slow evaporation in open container, dried in vacuo). ¹HNMR (400 MHz, CHLOROFORM-*d*) δ ppm 8.51 - 8.64 (m, 1 H), 8.06 (s, 1 H), 6.38 (br dd, *J*=6.91, 4.77 Hz, 1 H), 4.78 (br d, *J*=6.68 Hz, 1 H), 4.47 (s, 2 H), 2.91 - 3.11 (m, 4 H), 2.82 (s, 1 H), 2.62 - 2.78 (m, 1 H), 2.49 (br d, *J*=6.44 Hz, 1 H), 2.26 - 2.43

25 (m, 2 H), 1.71 - 1.92 (m, 3 H), 1.14 - 1.54 (m, 26 H), 0.82 - 1.02 (m, 6 H). LCMS (M+1) = 617.5.

Example 48: ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl decanoate



30



Step 1: ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-(((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methyl

decanoate. To a mixture of ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)

- 5 diphenylmethyl) amino)-9H-purin-9-yl)-3-(((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methanol (3 g, 3.58 mmol), Et₃N (2.495 mL, 17.90 mmol) and DMAP (0.656 g, 5.37 mmol) in DCM (40 mL) was added Et₃N (2.495 mL, 17.90 mmol). The reaction mixture was stirred at r.t. for 2 h. LCMS indicated completion of reaction. The reaction mixture was quenched with water (50 mL), extracted with DCM (30 mL*3), the
- 10 organic phases were combined, washed with brine (30 mL), dried over Na₂SO₄, concentrated under vacuum. The residue was purified by flash chromatography (silica gel, 120 g, pet. ether: EtOAc = 4:1) to give ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-(((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methyl decanoate (2.7 g, 1.788 mmol, 49.9 % yield)) as a
- 15 yellow solid. LCMS (ESI) m/z calcd for C₆₂H₆₂FN₅O₆:991 Found: 992 (M+H)⁺. ¹HNMR (400 MHz, CDCl₃) δ 8.21 (s, 1H), 7.57 – 7.50 (m, 4H), 7.40 – 7.18 (m, 20H), 7.04 (s, 1H), 6.81 – 6.75 (m, 4H), 6.08 (dd, J = 3.2, 8.0 Hz, 1H), 4.31 (d, J = 12.0 Hz, 1H), 4.05 (d, J = 12.0 Hz, 1H), 3.78 – 3.72 (m, 6H), 3.00 – 2.91 (m, 1H), 2.45 – 2.01 (m, 4H), 1.67 - 1.59 (m, 2H), 1.33 - 1.18 (m, 12H), 0.87 (t, J = 7.2 Hz, 3H).

Step 2: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl decanoate. To a solution ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-(((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methyl decanoate (2.7g, 2.72 mmol) in DCM (30mL) stirred

- 25 at 15 °C was added TFA (5mL, 64.9 mmol) dropwise. The reaction mixture was stirred at

15 °C for 1 h. LCMS indicated completion of reaction. The reaction mixture was quenched with NaHCO₃ (30 ml), and extracted with DCM (30 ml X 2), the organic phases were combined, washed with brine (15 ml), dried over Na₂SO₄, concentrated under vacuum. The residue was purified by flash chromatography (silica gel, 120 g, DCM : MeOH=10: 1) to give ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl decanoate (1 g, 2.201 mmol, 81 % yield) as a white solid. LCMS (ESI) m/z calcd for C₂₂H₃₀FN₅O₄: 447 Found: 448(M+H)⁺. ¹HNMR (400 MHz, CDCl₃) δ 7.88 (s, 1H), 6.31 (dd, J = 4.4, 7.6 Hz, 1H), 6.10 (br, s, 2H), 4.79 (t, J = 7.2 Hz, 1H), 4.50 – 4.40 (m, 2H), 2.99 - 2.92 (m, 1H), 2.81 - 2.60 (m, 2H), 2.38 - 2.30 (m, 2H), 1.65 -1.51 (m, 2H), 1.34 - 1.14 (m, 12H), 0.91 - 0.75 (m, 3H).


Step 3: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methyl decanoate. To a solution of ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl decanoate (1g, 2.235 mmol) in DCM (60 mL) was added imidazole (1.521 g, 22.35 mmol) and tert-butylchlorodimethylsilane (1.347 g, 8.94 mmol), and the resulting mixture was stirred at 30 °C for overnight. LCMS indicated completion of reaction. The reaction mixture was quenched with water (50 mL), extracted with DCM (20 mL*3), the organic phases were combined, washed with brine (50 mL), dried over Na₂SO₄, concentrated under vacuum. The residue was purified by gel silica column (120 g, EtOAc:pet. Ether = 1: 1) to give ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methyl decanoate (1.2 g, 98.09%, yield :94 %) as a white solid. LCMS (ESI) m/z calcd for C₂₈H₄₄FN₅O₄Si:561. Found: 562 (M+H)⁺. ¹HNMR (400 MHz, CDCl₃) δ 7.86 (s, 1H), 6.25 (dd, J = 4.0, 8.0 Hz, 1H), 5.94 (br, s, 2H), 4.93 (t, J = 7.6 Hz, 1H), 4.45 (d, J =12.0 Hz, 1H), 4.23 (d, J =12.0 Hz, 1H), 2.89 - 2.82 (m, 1H), 2.68 - 2.58 (m, 2H), 2.30 - 2.19 (m, 2H), 1.61 - 1.50 (m, 2H), 1.33 - 1.17 (m, 12H), 0.93 (s, 9H), 0.87 (t, J = 7.2 Hz, 3H), 0.13 (d, J =4.8 Hz, 6H).


Step 4: ((2R,3S,5R)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)tetrahydrofuran-2-yl)methyl decanoate. To a solution of ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methyl decanoate (1.2g, 2.136 mmol) in DCM (10 mL) was added DMAP (0.391 g, 3.20 mmol), Et₃N (1.191 mL, 8.54 mmol) and tetradecanoyl chloride (1.318 g, 5.34 mmol). The reaction mixture was stirred at r.t. for 4 h. LCMS indicated completion of reaction. The reaction mixture was quenched with water (10 mL) and extracted with DCM (10mLx3), the organic phases were combined, washed with brine

(10 mL), dried over Na₂SO₄, concentrated under vacuum. The residue was purified by gel silica column (80 g, EtOAc:pet. ether = 4: 1) to give ((2R,3S,5R)-3-((tert-butyltrimethylsilyl)oxy)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)tetrahydrofuran-2-yl)methyl decanoate (700 mg, 85%, 19.52 % yield) as a white semisolid. LCMS (ESI) m/z calcd for C₄₂H₇₀FN₅O₅Si:771. Found: 772 (M+H)⁺. ¹HNMR (400 MHz, CDCl₃) δ 8.88 (s, 1H), 8.08 (d, J = 1.2 Hz, 1H), 6.30 (dd, J = 3.6, 7.6 Hz, 1H), 4.89 (t, J = 7.2 Hz, 1H), 4.44 (d, J = 12.0 Hz, 1H), 4.24 (d, J = 12.0 Hz, 1H), 2.96 - 2.80 (m, 3H), 2.71 - 2.60 (m, 2H), 2.28 - 2.22 (m, 2H), 1.80 - 1.68 (m, 2H), 1.60 - 1.50 (m, 2H), 1.37 - 1.17 (m, 32H), 0.93 (s, 9H), 0.90 - 0.81 (m, 6H), 0.13 (d, J = 5.2 Hz, 6H).

Step 5: ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl decanoate. To a stirred solution of ((2R,3S,5R)-3-((tert-butyltrimethylsilyl)oxy)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)tetrahydrofuran-2-yl)methyl decanoate (700 mg, 0.907 mmol) in THF (5 mL) was added TBAF (1.08 ml, 1 mol/L in THF). The resulting mixture was stirred for 2 hour at room temperature. LCMS indicated completion of reaction. The majority of solvent was removed under vacuum. The residue was purified by gel silica column (80 g, EtOAc: pet. ether = 4: 1) to give the desired product (purity:96%) as a white solid. The solid was triturated with ACN (30 ml) for 16 h. The resulting solid was filtered through a Buchner funnel, rinsed with ACN, dried beside sunlight lamp (T = 50 °C) for 6 h, and was stored in a cool dry place overnight to give ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl decanoate (151 mg, 99.05%, yield: 25.08 %) as a white solid. LCMS (ESI) m/z calcd for C₃₆H₅₆FN₅O₅:657. Found: 658 (M+1)⁺. ¹HNMR (400 MHz, CDCl₃) δ 8.66 (s, 1H), 8.06 (s, 1H), 6.36 (dd, J = 4.4, 7.6 Hz, 1H), 4.77 (t, J = 6.4 Hz, 1H), 4.49 - 4.41 (m, 2H), 2.98 - 2.81 (m, 3H), 2.74 (s, 1H), 2.72 - 2.68 (m, 1H), 2.36 - 2.32 (m, 2H), 1.79 - 1.56 (m, 6H), 1.44 - 1.20 (m, 30H), 0.89 - 0.85 (m, 6H).

Example 49: ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl 2-propylpentanoate





Step 1: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methyl 2-propylpentanoate.

To a stirred solution of ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methanol (200 mg, 0.491 mmol), EDC (141 mg, 0.736 mmol), and DMAP (60.0 mg, 0.491 mmol) in DCM (6 mL) was added 2-propylpentanoic acid (0.079 mL, 0.491 mmol) followed by DIEA (0.214 mL, 1.227 mmol) and the mixture was stirred at r.t. for 1 h. The reaction mixture was concentrated and purified by Isco, 40 gram gold column (DCM/MeOH 0-10%) to give the desired product as a white solid (238 mg, 85%). LCMS (M+1) = 535.3.


Step 2: ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl 2-propylpentanoate.

To a solution of ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methyl 2-propylpentanoate (238 mg, 0.446 mmol), DMAP (5.45 mg, 0.045 mmol) and 2-chloro-1-methylpyridinium iodide (285 mg, 1.115 mmol) in acetonitrile (6.0 mL) and THF (6.0 mL) was added tetradecanoic acid (255 mg, 1.115 mmol) followed by Et₃N (0.373 mL, 2.68 mmol) and the mixture was stirred at 60 °C in a sealed tube overnight. The mixture was diluted with DCM and washed with sat. aq. NaHCO₃, the organic layer dried over sodium sulfate and concentrated. Purification by prep. TLC (Hexanes/EtOAc 1:1) afforded the desired product as a solid. ¹HNMR (400 MHz, CHLOROFORM-*d*) δ ppm 0.16 (s, 3 H) 0.17 (s, 3 H) 0.80 - 0.92 (m, 9 H) 0.96 (s, 9 H) 1.17 - 1.47 (m, 24 H) 1.48 - 1.56 (m, 2 H) 1.62 - 1.71 (m, 2 H) 1.71 - 1.81 (m, 2 H) 2.32 (ddd, *J*=8.70, 5.36, 3.34 Hz, 1 H) 2.35 - 2.46 (m, 1 H) 2.63 (s, 1 H) 2.70 (dt, *J*=13.41, 7.72 Hz, 1 H) 2.85 - 2.95 (m, 2 H) 4.26 (d, *J*=12.16 Hz, 1 H) 4.44 (d, *J*=12.16 Hz, 1 H) 4.89 (t, *J*=7.27 Hz, 1 H) 6.34 (dd, *J*=7.63, 3.81 Hz, 1 H) 8.13 (s, 1 H) 9.38 (br s, 1 H).

To a solution of above solid in THF (5.00 mL) and added TBAF (1M, THF) (0.491 mL, 0.491 mmol) at 0 °C and the mixture was stirred at 0 °C for 1 h and then added acetic acid

(0.028 mL, 0.491 mmol) at 0 °C, allowed to warm to r.t and concentrated. Purification by Isco, 40 gram gold column (DCM/MeOH 0-5%) afforded the desired product as a solid (98 mg, 34%). ¹HNMR (400 MHz, CHLOROFORM-*d*) δ ppm 0.82 - 0.92 (m, 9 H) 1.22 - 1.48 (m, 26 H) 1.51 - 1.66 (m, 2 H) 1.74 - 1.90 (m, 2 H) 2.36 - 2.48 (m, 1 H) 2.73 (dt, *J*=13.71, 6.97 Hz, 1 H) 2.82 (s, 1 H) 2.92 - 3.05 (m, 3 H) 4.41 - 4.49 (m, 2 H) 4.76 (t, *J*=6.68 Hz, 1 H) 6.41 (dd, *J*=7.15, 4.77 Hz, 1 H) 8.12 (s, 1 H) 8.82 (s, 1 H). LCMS (*M*+1) = 630.5. LCMS (*M*-1) = 628.5.

Example 50: ((2*R*,3*S*,5*R*)-5-(6-amino-2-fluoro-9*H*-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl 3-(2-acetoxy-4,6-dimethylphenyl)-3-methylbutanoate



Step 1: 9-((2*R*,4*S*,5*R*)-5-(((*tert*-butyldiphenylsilyl)oxy)methyl)-5-ethynyl-4-((4-methoxyphen-yl)diphenylmethoxy)tetrahydrofuran-2-yl)-2-fluoro-*N*-((4-methoxyphenyl)diphenylmethyl)-9*H*-purin-6-amine. To a stirred suspension of (2*R*,3*S*,5*R*)-5-(6-amino-2-fluoro-9*H*-purin-9-yl)-2-(((*tert*-butyldiphenylsilyl)oxy)methyl)-2-ethynyltetrahydrofuran-3-ol (2.66 g, 5.00 mmol) in DCM (60 mL) was added silver nitrate (2.55 g, 15.01 mmol), 2,4,6-trimethylpyridine (4.00 mL, 30.0 mmol) and 4-methoxytriphenylmethyl chloride (4.63 g, 15.01 mmol). The resulting suspension was stirred at ambient temperature for 2 hours. The mixture was diluted with EtOAc and filtered over Celite. The

filtrate was washed with 10% citric acid (2x), followed by sat'd NaHCO₃ (2x), dried over Na₂SO₄, filtered and concentrated. The residue was purified on silica gel (120 g column, 0-100% hexanes/EtOAc) to afford title compound as white solid (5.138 g, 95%). LCMS (M+1) = 1076.57.

5

Step 2: ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methanol. To

stirred solution of 9-((2R,4S,5R)-5-(((tert-butyl)diphenylsilyl)oxy)methyl)-5-ethynyl-4-((4-methoxyphen-yl)diphenylmethoxy)tetrahydrofuran-2-yl)-2-fluoro-N-((4-methoxyphenyl)diphenylmethyl)-9H-purin-6-amine (5.138 g, 4.77 mmol) in THF (45 mL) was added 1M TBAF/THF (7.16 mL, 7.16 mmol) and the mixture was allowed to stir at ambient temperature for 90 minutes. The mixture was concentrated and the residue was purified on silica gel (120 g column, 0-100% hexanes/EtOAc) to afford title compound as white solid (3.908 g, 98%). LCMS (M+1) = 838.42.

15

Step 3: ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methyl 3-(2-acetoxy-4,6-dimethylphenyl)-3-methylbutanoate. To a mixture of ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenylmethoxy) tetrahydrofuran-2-yl)methanol (315 mg, 0.376 mmol), 3-(2-acetoxy-4,6-dimethylphenyl)-3-methylbutanoic acid (119 mg, 0.451 mmol), DMAP (45.9 mg, 0.376 mmol) and DIEA (0.328 mL, 1.880 mmol) was added EDC (144 mg, 0.752 mmol) at ambient temperature and the mixture was allowed to stir overnight. The mixture was concentrated and then purified on silica gel (24 g column, 0-70% hexanes/EtOAc) to afford title compound as colorless residue (366 mg, 90%). LCMS (M+1) = 1084.61; LCMS (M-1) = 1083.79.

25

Step 4: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl 3-(2-acetoxy-4,6-dimethylphenyl)-3-methylbutanoate. A solution of


((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-((4-methoxy-phenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methyl 3-(2-acetoxy-4,6-dimethylphenyl)-3-methylbutanoate (366 mg, 0.338 mmol) in DCM (1.6 mL) was treated with formic Acid (0.4 mL) and triethylsilane (0.108 mL, 0.675 mmol) and then stirred at ambient temperature for 3 hours. The mixture was concentrated and then purified on silica gel (40 g column, 0-10% DCM/MeOH) to afford title compound as white solid (118 mg, 65%). ¹HNMR (400 MHz, DMSO-d₆) δ = 8.25 (s, 1H), 7.82 (br s, 2H), 6.77 - 6.71 (m, 1H),

35

6.56 - 6.53 (m, 1H), 6.24 (dd, $J = 4.3, 7.9$ Hz, 1H), 5.71 (d, $J = 5.5$ Hz, 1H), 4.66 - 4.59 (m, 1H), 4.27 (d, $J = 11.7$ Hz, 1H), 4.00 (d, $J = 11.9$ Hz, 1H), 3.59 (s, 1H), 2.84 - 2.71 (m, 2H), 2.61 (d, $J = 16.0$ Hz, 1H), 2.53 - 2.43 (m, 1H, overlapping DMSO peak), 2.41 (s, 3H), 2.18 (s, 3H), 2.14 (s, 3H), 1.40 (s, 3H), 1.35 (s, 3H). LCMS ($M+1$) = 540.31.

5

Example 51: (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((heptanoyloxy)methyl)tetrahydrofuran-3-yl tetradecanoate



- 10 Step 1: ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-
9H-purin-9-yl)-3-(((4-methoxyphenyl)diphenylmethoxy)methyl)tetrahydrofuran-2-yl)methyl
heptanoate. To a mixture of ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)
diphenylmethyl)amino)-9H-purin-9-yl)-3-(((4-methoxyphenyl)diphenylmethoxy)methyl)tetrahydro-
furan-2-yl)methanol (420 mg, 0.50 mmol) in DCM (10 mL) was added DMAP (61.2 mg,
 15 0.50 mmol), Et₃N (0.28 mL, 2.00 mmol) and heptanoyl chloride (149 mg, 1.00 mmol). The
 reaction mixture was stirred for 16 hours. LCMS indicated completion of reaction. The
 reaction mixture was diluted with water (10 mL), extracted with DCM (10 mLx3). The
 combined organic phases were washed with water (20 mL), brine (10 mL) and dried over
 Na₂SO₄. After filtration, the filtrate was concentrated to dryness under vacuum. The
 20 residue was purified by silica gel column (120g, pet. ether:EtOAc = 1:1) to afford

((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-(((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methyl heptanoate (300 mg, 63 % yield) as a pale-yellow solid. LCMS (ESI) m/z calcd for C₅₉H₅₆FN₅O₆:949.

Found: 950 (M+H)⁺. ¹HNMR (300 MHz, DMSO-*d*₆) δ 8.06 (s, 1H), 7.96 (s, 1H), 7.53-7.51 (m, 4H), 7.40-7.17 (m, 20H), 6.92-6.78 (m, 4H), 6.13 (dd, *J* = 7.8, 3.9 Hz, 1H), 4.68 (t, *J* = 7.2 Hz, 1H), 4.18 (d, *J* = 12.0 Hz, 1H), 3.97 (s, 1H), 3.79 (d, *J* = 12.0 Hz, 1H), 3.72 (s, 3H), 3.68 (s, 3H), 2.09-2.00 (m, 1H), 1.97-1.79 (m, 3H), 1.37-1.01 (m, 8H), 0.80 (t, *J* = 6.9 Hz, 3H).


- 10 Step 2: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl heptanoate. To the mixture of ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl) amino)-9H-purin-9-yl)-3-(((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methyl heptanoate (300 mg, 0.32 mmol) in DCM (6 mL) was added TFA (1 mL) dropwise at 0 °C. The reaction mixture was stirred for 2 h at 0 °C.
- 15 LCMS indicated completion of reaction. The reaction mixture was concentrated to dryness under vacuum. The residue was re-dissolved in DCM (10 mL) and washed with NaHCO₃(aq, 10 mL), brine(10 mL), dried over Na₂SO₄. After filtration, the filtrate was concentrated to dryness under vacuum to afford ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl heptanoate (120 mg, yield:
- 20 93%) as a white solid. The crude product was used to next step without further purification. LCMS (ESI) m/z calcd for C₁₉H₂₄FN₅O₄:405, Found: 406(M+H)⁺.

Step 3: (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((heptanoyloxy)methyl)tetrahydrofuran-3-yl tetradecanoate. The mixture of tetradecanoic acid (214 mg, 0.94

- 25 mmol), EDCI (241 mg, 1.26 mmol) and DMAP (153 mg, 1.25 mmol) in DMF (4 mL) was stirred for 2 h at 25 °C. To the above mixture was added ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl heptanoate (120 mg, 0.30 mmol). The reaction mixture was stirred at 25 °C for 16 h. LCMS indicated completion of reaction. The reaction mixture was quenched with water (10 mL) and extracted with EtOAc
- 30 (10 mL x 3). The combine organic phases were washed with brine(10 mL) and dried over Na₂SO₄. After filtration, the solvent was removed under vacuum. The residue was purified by Prep-HPLC: Column: XSelect CSH Prep C18 OBD Column, 5μm, 19x150mm; Mobile Phase A: water(0.05% TFA), Mobile Phase B: ACN; Flow rate: 25 mL/min; Gradient: 90 B to 95 B in 8 min; 254 nm; Rt: 6.48 min. The collected fraction (RT: 6.48 min) was lyophilized to
- 35 afford (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((heptanoyloxy)methyl)tetrahydro-furan-3-yl tetradecanoate (93.7 mg, purity :99.66%,

yield : 51 %) as white solid. LCMS (ESI) m/z calcd for $C_{33}H_{50}FN_5O_5$:615. Found: 616 (M+H)⁺. ¹HNMR (300 MHz, DMSO- d_6) δ 8.33 (s, 1H), 7.90 (br s, 2H), 6.34 (t, J = 6.6 Hz, 1H), 5.70 (t, J = 5.4 Hz, 1H), 4.40 (d, J = 11.4 Hz, 1H), 4.22 (d, J = 11.4 Hz, 1H), 3.79 (s, 1H), 3.17-3.13 (m, 1H), 2.66-2.57 (m, 1H), 2.42-2.37 (m, 2H), 2.32-2.21 (m, 2H), 1.60-1.40 (m, 4H), 1.39-1.22 (m, 26 H), 0.89-0.84 (m, 6H).

Example 52: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-(((tridecyloxy)carbonyl)oxy)tetrahydrofuran-2-yl)methyl heptanoate



Step 1: ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-(((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methyl

heptanoate. To a mixture of ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-(((4-methoxyphenyl)diphenylmethoxy)tetrahydro-

furan-2-yl)methanol (1.0 g, 1.19 mmol) in DCM (10 mL) was added DMAP (0.15 g, 1.19 mmol), Et₃N (0.67 mL, 4.77 mmol) and heptanoyl chloride (0.355 g, 2.387 mmol). The reaction mixture was stirred for 16 hours. LCMS indicated completion of reaction. The reaction mixture was diluted with water (10 mL), extracted with DCM (10 mLx3). The combined organic phases were washed with water (20 mL), brine (10 mL) and dried over

Na₂SO₄. After filtration, the filtrate was concentrated to dryness under vacuum. The residue was purified by silica gel column (120g, pet. ether:EtOAc = 1:1) to afford

((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-


9-yl)-3-((4-methoxyphenyl)diphenyl-methoxy)tetrahydrofuran-2-yl)methyl heptanoate (800 mg, yield: 70.6%) as a white solid. LCMS (ESI) m/z calcd for $C_{59}H_{56}FN_5O_6$: 949. Found: 950 (M+H)⁺. ¹HNMR (300 MHz, DMSO- d_6) δ 8.06 (s, 1H), 7.94 (s, 1H), 7.52-7.49 (m, 4H), 7.43-7.12 (m, 20H), 6.96-6.76 (m, 4H), 6.13 (dd, J = 8.0, 4.0 Hz, 1H), 4.68 (t, J = 7.6 Hz, 1H), 4.19 (d, J = 12.0 Hz, 1H), 3.96 (s, 1H), 3.80 (d, J = 12.0 Hz, 1H), 3.72 (s, 3H), 3.69 (s, 3H), 2.09-2.00(m, 1H), 1.96-1.80(m, 3H), 1.41-0.95 (m, 8H), 0.81-0.78 (m, 3H).

Step 2: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl heptanoate. To the mixture of ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenyl-methoxy) tetrahydrofuran-2-yl)methyl heptanoate (800 mg, 0.84 mmol) in DCM (20 mL) was added TFA (2.0 mL) dropwise at 0 °C. The reaction mixture was stirred for 2 h at 0 °C. LCMS indicated completion of reaction. The reaction mixture was concentrated to dryness under vacuum. The residue was dissolved in DCM (20 mL) and washed with NaHCO₃ (aq, 10 mL), brine (10 mL), dried over Na₂SO₄. After filtration, the filtrate was concentrated to dryness under vacuum. The crude product was purified by reverse phase Column: C18 (80 g); Mobile Phase A: water(1% FA), Mobile Phase B: ACN; Flow rate: 60 mL/min; Gradient: 0% B to 100% B in 30 min; 254/220 nm. The collected fractions were concentrated to afford ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl heptanoate (247 mg, yield: 72.4%) as white solid. LCMS (ESI) m/z calcd for $C_{19}H_{24}FN_5O_4$: 405 Found: 406(M+H)⁺.

Step 3: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-((tridecyloxy)carbonyl)oxy) tetrahydrofuran-2-yl)methyl heptanoate. To a stirred mixture of ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl heptanoate (218 mg, 0.54 mmol) and K₂CO₃ (220 mg, 1.59 mmol) in THF (5 mL) was added di(1H-imidazol-1-yl)methanone (150 mg, 0.93 mmol) at 25 °C. The reaction mixture was stirred at 25 °C for 2 h. To the above mixture was added Cs₂CO₃ (380 mg, 1.17 mmol) and tridecan-1-ol (550 mg, 2.74 mmol). The reaction mixture was stirred at 25 °C for 1 h. LCMS indicated completion of reaction. The reaction mixture was quenched with water (10 mL) and extracted with EtOAc(10 mL x3). The organic phases were washed with brine (20mL), dried over Na₂SO₄, concentrated under reduced pressure. The crude product was purified by PreP-HPLC: Column: XBridge Prep OBD C18 Column, 30×150mm 5 μ m; Mobile Phase A: water(0.05% TFA), Mobile Phase B: ACN; Flow rate: 254 mL/min; Gradient: 55 B to 72 B in 7 min; 254 nm; Rt: 6.52 min. The collected fraction (RT: 6.52 min) was lyophilized to afford ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-

(((tridecyloxy)carbonyl)oxy)tetrahydrofuran-2-yl)methyl heptanoate (150 mg, purity:98.7%, yield :44%) as white solid. LCMS (ESI) m/z calcd for $C_{33}H_{50}FN_5O_6$: 631. Found: 632(M+H)⁺. ¹HNMR (400 MHz, DMSO- d_6) δ 8.33 (s, 1H), 8.07-7.72 (m, 2H), 6.35 (t, J = 6.8 Hz, 1H), 5.59 (dd, J = 6.8, 5.2 Hz, 1H), 4.42 (d, J = 11.6 Hz, 1H), 4.23 (d, J = 11.6 Hz, 1H), 4.19-4.07 (m, 2H), 3.81 (s, 1H), 3.25-3.11 (m, 1H), 2.73-2.61 (m, 1H), 2.35-2.16 (m, 2H), 1.68-1.56 (m, 2H), 1.50-1.38 (m, 2H), 1.30-1.15 (m, 26H), 0.90-0.79 (m, 6H).

Example 53: (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((propionyloxy)methyl)tetrahydrofuran-3-yl stearate



Step 1: ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methyl propionate.

To a stirred solution of ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methanol (700 mg, 0.84 mmol), Et₃N (0.70 mL, 5.01 mmol) and DMAP (51 mg, 0.42 mmol) in DCM (7 mL) was added propionyl chloride (232 mg, 2.506 mmol) dropwise at 0 °C. The reaction mixture was stirred at 0 °C for 30 min. LCMS indicated completion of reaction. The reaction was quenched by the addition of water (3 mL), the organic layers were separated and the water phase was extracted with DCM (2 mL*3). The combined organic layers were dried over Na₂SO₄ and evaporated to dryness under vacuum to give the crude title compound (800 mg, 94.5%, yield: 89%) as yellow oil.

LCMS (ESI) m/z calcd for $C_{55}H_{48}FN_5O_6$: 893. Found: 894 (M+1)⁺. ¹HNMR (400 MHz, DMSO-*d*₆) δ 8.07 (s, 1H), 7.99 (s, 1H), 7.60 – 7.45 (m, 4H), 7.40 – 7.14 (m, 20H), 6.91 – 6.77 (m, 4H), 6.15-6.12 (m, 1H), 4.72 (t, *J* = 7.6 Hz, 1H), 4.18 (d, *J* = 12.0 Hz, 1H), 3.96 (s, 1H), 3.75 (d, *J* = 12.0 Hz, 1H), 3.69 (s, 3H), 3.67 (s, 3H), 2.13 – 2.02 (m, 1H), 1.94-1.90 (m, 3H), 0.75 (t, *J* = 7.6 Hz, 3H).

Step 2: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl propionate.


A solution of ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)di-phenylmethyl)amino)-9H-purin-9-yl)-3-(((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methyl propionate (630 mg, 0.71 mmol) in DCM (7 mL) was added trifluoroacetic acid (TFA) (0.050 mL). The reaction solution was stirred at 25 °C for 30 min. LCMS indicated completion of reaction. The reaction was diluted with methanol until the yellow solution turn to colorless and concentrated under vacuum. The residue was subjected to HPLC purification (C18, 0-80% ACN/water with 0.1% FA) to give the desired product (200 mg, 98.7%, yield: 80%) as white solid. LCMS (ESI) m/z calcd for $C_{15}H_{16}FN_5O_4$: 349. Found: 350 (M+1)⁺. ¹HNMR (400 MHz, DMSO-*d*₆) δ 8.28 (s, 1H), 7.86 (br s, 2H), 6.25 (dd, *J* = 8.0, 4.0 Hz, 1H), 5.79 (d, *J* = 5.6 Hz, 1H), 4.74-4.68 (m, 1H), 4.42 (d, *J* = 11.6 Hz, 1H), 4.11 (d, *J* = 11.6 Hz, 1H), 3.64 (s, 1H), 2.90-2.76 (m, 1H), 2.49-2.44 (m, 1H), 2.35 – 2.15 (m, 2H), 0.95 (t, *J* = 7.6 Hz, 3H).

Step 3: (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((propionyloxy)methyl)tetrahydrofuran-3-yl stearate.

A solution of stearic acid (489 mg, 1.72 mmol) in DMF (8 mL) was added EDC (439 mg, 2.29 mmol) and DMAP (280 mg, 2.29 mmol). The reaction mixture was stirred at 25 °C for 30 min. Then ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl propionate (200 mg, 0.57 mmol) was added. The resulting mixture was stirred at 25 °C for 20 hours. LCMS indicated completion of reaction. The reaction was diluted with water (30 mL), and the resulting mixture was extracted with EtOAc (20 mL *3). The combined organic layers were washed with brine (20 mL), dried over anhydrous sodium sulfate and evaporated to dryness under vacuum. The residue was purified by Prep-HPLC (Column: XSelect CSH Prep C18 OBD Column, 5μm, 19*150mm; Mobile Phase A: Water (0.05% TFA), Mobile Phase B: ACN; Flow rate: 25 mL/min; Gradient: 95 B to 95 B in 7 min; 254 nm, RT: 6.05 min) to give the desired product (156.8 g, 99.12%, yield: 44%) as white solid. LCMS (ESI) m/z calcd for $C_{33}H_{50}FN_5O_5$: 615. Found: 616 (M+1)⁺. ¹HNMR (400 MHz, DMSO-*d*₆) δ 8.34 (s, 1H), 7.95 (br s, 2H), 6.34 (t, *J* = 6.8 Hz, 1H), 5.70 (t, *J* = 5.6 Hz, 1H), 4.42 (d, *J* = 11.6 Hz, 1H), 4.21 (d, *J* = 11.6 Hz, 1H),

3.79 (s, 1 H), 3.15-3.12 (m, 1H), 2.62-2.58 (m, 1H), 2.41-2.25 (m, 4 H), 1.60-1.56 (m, 2H), 1.25-1.23 (m, 28 H), 0.98 (t, $J = 7.6$ Hz, 3 H), 0.85 (t, $J = 6.4$ Hz, 3H).

5 **Example 54: ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-heptanamido-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl 2-propylpentanoate**



Step 1: ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-

- 10 9H-purin-9-yl)-3-(((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methyl 2-
propylpentanoate. To a stirred solution of ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-
methoxy-phenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-(((4-methoxyphenyl)diphenyl-
methoxy)tetrahydro-furan-2-yl)methanol (2.00 g, 2.387 mmol), Et₃N (1.0 mL, 7.16 mmol)
 15 and DMAP (146 mg, 1.193 mmol) in DCM (20.00 mL) was added a solution of 2-
 propylpentanoyl chloride (427 mg, 2.63 mmol) in DCM (2 mL) dropwise over 5 min at 0 °C.
 The reaction mixture was stirred at 20 °C for 2 hr. LCMS indicated completion of reaction.
 The reaction mixture was quenched with water, extracted with EtOAc (3x 20 mL). The
 organic phases were combined, washed with brine, dried over Na₂SO₄ and concentrated
 under vacuum. The residue was subjected to Prep-TLC (EtOAc:pet. ether = 1:1) to give
 20 the desired product (1.7 g, 99%, yield: 73%) as off white solid. LCMS (ESI) m/z calcd for
 C₆₀H₅₈FN₅O₆: 963. Found: 964 (M+1)⁺. ¹HNMR (400 MHz, Chloroform-*d*) δ 7.61 (s, 1H),
 7.59 – 7.54 (m, 4H), 7.44-7.21(m, 20H), 7.10 (br s, 1H), 6.89 – 6.78 (m, 4H), 6.14-6.10 (m,
 1H), 4.61 (t, $J = 7.6$ Hz, 1H), 4.35 (d, $J = 12.0$ Hz, 1H), 4.19 (d, $J = 12.0$ Hz, 1H), 3.80(s,

3H), 3.78 (s, 3H), 2.85 (s, 1H), 2.24 – 2.03 (m, 2H), 1.73 – 1.60 (m, 2H), 1.46 – 1.32 (m, 3H), 1.17-1.04 (m, 4H), 0.82-0.78 (m, 6H).

Step 2: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-

- 5 hydroxytetrahydrofuran-2-yl)methyl 2-propylpentanoate. To the stirred solution of ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenylmethoxy) tetrahydrofuran-2-yl)methyl 2-propylpentanoate (1700 mg, 1.763 mmol) in DCM (20 mL) was added trifluoroacetic acid (TFA) (2 mL). The resulting mixture was stirred for 1 hour at room temperature. LCMS
- 10 indicated completion of reaction. The reaction was quenched by pouring into sodium carbonate (aq.) and the mixture was extracted with EtOAc(3x 20 mL). The organic phases were combined, washed with saturated brine, dried over Na₂SO₄ and concentrated under vacuum. The residue was purified by flash chromatography (silica gel, 120 g, EtOAc : pet. ether = 1:1) to give the desired product as white solid (650 mg, 98 %, yield: 86%). LCMS
- 15 (ESI) m/z calcd for C₂₀H₂₆FN₅O₄: 419. Found: 420(M+1)⁺. ¹HNMR (400 MHz, Chloroform-*d*) δ 7.91 (s, 1H), 6.39-6.34 (m, 1H), 6.12 (br s, 2H), 4.77 (t, *J* = 6.8 Hz, 1H), 4.46 (d, *J* = 1.2 Hz, 2H), 3.04-2.98 (m, 1H), 2.80 (s, 1H), 2.73-2.66 (m, 2H), 2.46-2.39 (m, 1H), 1.66 – 1.52 (m, 2H), 1.50 – 1.37 (m, 2H), 1.35-1.18 (m, 4H), 0.89-0.85 (m, 6H).


20 Step 3: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methyl 2-propylpentanoate. To a solution of ((2R,3S,5R)-5-(6-

- amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl 2-propylpenta-noate (640 mg, 1.526 mmol) and imidazole (312 mg, 4.58 mmol) in DMF (10.00 mL) was added a solution of TBS-Cl (690 mg, 4.58 mmol) in DMF (1 mL). The
- 25 reaction mixture was stirred at 40 °C for 16 hr. LCMS indicated completion of reaction. The reaction was quenched by pouring into brine and the mixture was extracted with EtOAc(3x 20 mL). The organic phases were combined, washed with saturated brine, dried over Na₂SO₄ and concentrated under vacuum. The residue was purified by flash chromatography (silica gel, 40 g, EtOAc:pet. ether = 1:1) to give the desired product (500
- 30 mg, 58%, yield: 95%) as off white solid. LCMS (ESI) m/z calcd for C₂₆H₄₀FN₅O₄Si: 533. Found: 534 (M+1)⁺. ¹HNMR (400 MHz, Chloroform-*d*) δ 7.91 (s, 1H), 6.29 (dd, *J* = 7.6, 3.6 Hz, 1H), 5.93 (br s, 2H), 4.94 (t, *J* = 7.2 Hz, 1H), 4.46 (d, *J* = 12.0 Hz, 1H), 4.24 (d, *J* = 12.0 Hz, 1H), 2.96-2.91 (m, 1H), 2.70-2.63 (m, 1H), 2.61 (s, 1H), 2.36-2.29 (m, 1H), 1.61 – 1.44 (m, 2H), 1.44 – 1.31 (m, 2H), 1.31 – 1.18 (m, 4H), 0.96 (s, 9H), 0.87-0.82 (m, 6H),
- 35 0.17 (s, 6H).

Step 4: ((2R,3S,5R)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyl-5-(2-fluoro-6-heptanamido-9H-purin-9-yl)tetrahydrofuran-2-yl)methyl 2-propylpentanoate. ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methyl 2-propylpentanoate (750 mg, 1.405 mmol) was dissolved in DCM (20 mL). Et₃N (0.979 mL, 7.03 mmol) and DMAP (86 mg, 0.703 mmol) were added, and then heptanoyl chloride (418 mg, 2.81 mmol) was added at 0 °C. The reaction mixture was stirred at 0 °C for overnight. LCMS indicated completion of reaction. The solvent was removed under vacuum. The residue was subjected to Prep-TLC (pet. ether:EtOAc = 1: 1) to give the desired product (400 mg, 92%, yield:42%) as off white oil. LCMS (ESI) m/z calcd for C₃₃H₅₂FN₅O₅Si: 645. Found: 646 (M+1)⁺. ¹HNMR (400 MHz, Chloroform-*d*) δ 8.70 (s, 1H), 8.09 (s, 1H), 6.34 (dd, *J* = 7.6, 4.0 Hz, 1H), 4.91 (t, *J* = 7.2 Hz, 1H), 4.45 (d, *J* = 12.0 Hz, 1H), 4.26 (d, *J* = 12.0 Hz, 1H), 3.00-2.87 (m, 3H), 2.73-2.65 (m, 1H), 2.63 (s, 1H), 2.37-2.29 (m, 1H), 1.82-1.74 (m, 2H), 1.61 – 1.10 (m, 14H), 0.96 (s, 9H), 0.88-0.79 (m, 9H), 0.17 (s, 6H).

Step 5: ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-heptanamido-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl 2-propylpentanoate. To the stirred solution of ((2R,3S,5R)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyl-5-(2-fluoro-6-heptanamido-9H-purin-9-yl)tetrahydrofuran-2-yl)methyl 2-propylpentanoate (400 mg, 0.619 mmol) in tetrahydrofuran (THF) (10 mL) was added TBAF (1.2 mL, 1M in THF, 1.2 mmol). The resulting mixture was stirred for 1 hour at room temperature. LCMS indicated completion of reaction. The reaction mixture was concentrated under vacuum. Water was added, the mixture was extracted with EtOAc (3x 20 mL). The combined organic phases were washed with brine, dried over Na₂SO₄ and concentrated under vacuum. The residue was purified by Prep-TLC (MeOH: DCM=1: 10) to give crude product. The crude product was re-purified by Prep-HPLC (Column: XSelect CSH Prep C18 OBD Column, 5μm, 19*150mm; Mobile Phase A: Water(0.05%TFA), Mobile Phase B: ACN; Flow rate: 25 mL/min; Gradient: 65 B to 86 B in 6 min; 254 nm; RT: 4.07) The collected fraction was lyophilized to give the desired product (150mg, 97%, yield: 44%), LCMS (ESI) m/z calcd for C₂₇H₃₈FN₅O₅: 531. Found: 532 (M+1)⁺. ¹HNMR (400 MHz, Chloroform-*d*) δ 8.69 (s, 1H), 8.08 (s, 1H), 6.41 (dd, *J* = 7.6, 5.2 Hz, 1H), 4.75 (t, *J* = 6.8 Hz, 1H), 4.44-4.43 (m, 2H), 3.00 – 2.92 (m, 3H), 2.80 (s, 1H), 2.74-2.69 (m, 1H), 2.42-2.38 (m, 1H), 2.15 (br s, 1H), 1.78-1.72 (m, 2H), 1.60-1.52 (m, 2H), 1.46-1.22 (m, 12H), 0.91-0.83 (m, 9H).

Example 55: ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl propionate



Step 1: ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-(((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methyl

- 5 propionate. To a stirred mixture of ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl) amino)-9H-purin-9-yl)-3-(((4-methoxyphenyl)diphenylmethoxy) tetrahydrofuran-2-yl)methanol (2.5 g, 2.98 mmol), Et₃N (1.25 mL, 8.94 mmol) and DMAP (226 mg, 1.85 mmol) in DCM (30 mL) was added propionyl chloride (550 mg, 5.94 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 30 min. LCMS indicated completion of
- 10 reaction. The reaction mixture was quenched with water (50 mL) and extracted with DCM (30x3 mL). The combined organic layers were washed with brine (30 mL) and dried over Na₂SO₄. After filtration, the filtrate was concentrated to dryness under vacuum. The crude product was purified by silica gel column (120g, EtOAc:pet. ether = 1:1) to afford
- 15 ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl) amino)-9H-purin-9-yl)-3-(((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methyl propionate (2.18 g, yield :73.6 %) as a white solid. LCMS (ESI) m/z calcd for C₅₅H₄₈FN₅O₆: 893. Found:894 (M+H)⁺. ¹HNMR (300 MHz, DMSO-*d*₆) δ 8.07 (s, 1H), 7.99 (s, 1H), 7.58-7.43 (m, 4H), 7.40-7.14 (m, 20H), 6.86-6.81 (m, 4H), 6.16-6.12 (m, 1H), 4.74-4.69 (m, 1H), 4.18 (d, J = 12.0 Hz, 1H), 3.96 (s, 1H), 3.74 (d, J = 12.0 Hz, 1H), 3.72 (s, 3H), 3.69 (s, 3H), 2.13-2.07
- 20 (m, 1H), 1.97-1.82 (m, 3H), 0.75 (t, J = 7.5 Hz, 3H).

Step 2: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl propionate. To a stirred mixture of ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenylmethoxy) tetrahydrofuran-2-yl)methyl propionate (2.18 g, 2.44 mmol) in DCM (50 mL) was added TFA (5.4 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 2 h. LCMS indicated completion of reaction. The reaction mixture was quenched with water (20 mL) and was basified to pH = 8 with sat. NaHCO₃ (aq). The precipitated solids were collected by filtration and washed with water to afford ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl propionate (660 mg, yield :62%) as white solid. The crude product was used in the next step directly without further purification. LCMS (ESI) m/z calcd for C₁₅H₁₆FN₅O₄: 349 Found: 350(M+H)⁺.

Step 3: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methyl propionate. To a stirred mixture of ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl propionate (640 mg, 1.83 mmol) and imidazole (1.3 g, 19.1 mmol) in DMF (10 mL) was added TBS-Cl (1.1 g, 7.30 mmol) at 25 °C. The reaction mixture was stirred at 30 °C for 12 h. LCMS indicated completion of reaction. The reaction mixture was quenched with water (20 mL), extracted with EtOAc (3x 20mL). The combined organic layers were washed with brine (20 mL), dried over with Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by silica gel (80 g, pet. ether/EtOAc = 1:1) to afford ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methyl propionate (730 mg, yield :84%) as a white solid. LCMS (ESI) m/z calcd for C₂₁H₃₀FN₅O₄Si: 463. Found: 464(M+H)⁺. ¹HNMR (400 MHz, DMSO-*d*₆) δ 8.29 (s, 1H), 7.89 (br s, 2H), 6.30-6.27 (m, 1H), 4.97 (t, *J* = 6.8 Hz, 1H), 4.34 (d, *J* = 12.0 Hz, 1H), 4.12 (d, *J* = 12.0 Hz, 1H), 3.67 (s, 1H), 3.09-2.85 (m, 1H), 2.50-2.37 (m, 1H), 2.31-2.01 (m, 2H), 0.98-0.90 (m, 12H), 0.15 (s, 6H).

Step 4: ((2R,3S,5R)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)tetrahydrofuran-2-yl)methyl propionate. To a stirred mixture of ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((tert-butyldimethylsilyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methyl propionate (580 mg, 1.25 mmol), Et₃N (1.38 mL, 9.88 mmol) and DMAP (153 mg, 1.25 mmol) in DCM (10 mL) was added tetradecanoyl chloride (1.23 g, 4.98 mmol) at 0 °C. The reaction mixture was stirred at 25 °C for 12 h. LCMS indicated completion of reaction. The reaction mixture was quenched with water (20 mL),

extracted with EtOAc (3x 20 mL). The combined organic layers were dried over with Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by silica gel column (80 g, pet. ether/EtOAc = 1:1) to afford ((2R,3S,5R)-3-((tert-butyl)dimethylsilyloxy)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-


5 yl)tetrahydrofuran-2-yl)methyl propionate (490 mg, yield : 52.3%) as a yellow oil. LCMS (ESI) m/z calcd for C₃₅H₅₆FN₅O₅Si: 673. Found: 674(M+H)⁺. ¹HNMR (300 MHz, DMSO-*d*₆) δ 11.02 (s, 1H), 8.60 (s, 1H), 6.41-6.37 (m, 1H), 4.97 (t, *J* = 9.0 Hz, 1H), 4.35 (d, *J* = 12.0 Hz, 1H), 4.15 (d, *J* = 12.0 Hz, 1H), 3.69 (s, 1H), 3.09-2.88 (m, 1H), 2.58 (d, *J* = 7.2 Hz, 2H), 2.26-2.13 (m, 2H), 1.66 -1.50 (m, 2H), 1.34-1.17 (m, 24H), 0.96-0.83 (m, 12H), 0.15
10 (s, 6H).

Step 5: ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)-3-

hydroxytetrahydrofuran-2-yl)methyl propionate. To a stirred mixture of ((2R,3S,5R)-3-

15 yl)tetrahydrofuran-2-yl)methyl propionate (470 mg, 0.70 mmol) in THF (20 mL) was added TBAF (1.15 mL, 1.15 mmol, 1N in THF) at 0 °C. The reaction mixture was stirred at 0 °C for 30 min. LCMS indicated completion of reaction. The reaction mixture was quenched with water (20mL), extracted with EtOAc(3x 20 mL). The combined organic layers were washed with sat.NH₄Cl (aq., 3x 20 mL), dried over with Na₂SO₄, filtered and concentrated
20 under reduced pressure. The crude product was purified by Prep-HPLC: Column: XSelect CSH Prep C18 OBD Column, 5μm, 19x150mm; Mobile Phase A: water(0.1%FA), Mobile Phase B: ACN; Flow rate: 25 mL/min; Gradient: 67 B to 95 B in 8 min; 254 nm; Rt: 7.23 min. The collected fraction (RT: 7.23 min) was lyophilized to afford ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl propionate
25 (252 mg, purity: 99.04%, yield : 64%) as a white solid. LCMS (ESI) m/z calcd for C₂₉H₄₂FN₅O₅: 559. Found: 560(M+H)⁺. ¹HNMR (400 MHz, DMSO-*d*₆) δ 11.0 (s, 1H), 8.59 (s, 1H), 6.36-6.33 (m, 1H), 5.84 (d, *J* = 5.2 Hz, 1H), 4.73-4.71 (m, 1H), 4.42 (d, *J* = 11.6 Hz, 1H), 4.13 (d, *J* = 11.6 Hz, 1H), 3.66 (s, 1H), 2.90- 2.78 (m, 1H), 2.57-2.51 (m, 3H), 2.25-2.19(m, 2H), 1.60-1.57 (m, 2H), 1.28-1.23 (m, 20H), 0.93 (t, *J* = 7.6 Hz, 3H), 0.85(t, *J* =
30 6.4Hz, 3H).

Example 56: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((ethoxycarbonyloxy)-2-ethynyltetrahydrofuran-2-yl)methyl tetradecanoate



Step 1: ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methyl

- 5 **tetradecanoate**. To a stirred solution of ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl) amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methanol (550 mg, 0.656 mmol), Et₃N (0.27 mL, 1.97 mmol) and DMAP (40 mg, 0.328 mmol) in DCM (5 mL) was added tetradecanoyl chloride (486 mg, 1.969 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 30 min. LCMS
- 10 indicated completion of reaction. The reaction was quenched with water (3 mL). The organic layers were separated out. The water phase was extracted with DCM (2 mL*3). The combined organic layers were dried over anhydrous sodium sulfate and evaporated to dryness concentrated under vacuum. The residue was purified by Prep-TLC (pet. ether: EtOAc = 1: 1) to give the desired product (638 mg, 92%, yield: 85%) as a yellow solid.
- 15 LCMS (ESI) m/z calcd for C₆₆H₇₀FN₅O₆:1048. Found: 1049 (M+1)⁺. ¹HNMR (300 MHz, DMSO-*d*₆) δ 8.06 (s, 1H), 7.92 (s, 1H), 7.56 – 7.46 (m, 4H), 7.42 – 7.13 (m, 20H), 6.86-6.83 (m, 4H), 6.15-6.11 (m, 1H), 4.71-4.65 (m, 1H), 4.18 (d, *J* = 12.0 Hz, 1H), 3.96 (s, 1H), 3.79(d, *J* = 12.0 Hz, 1H), 3.72 (s, 3H), 3.68(s, 3H), 1.93-1.85 (m, 2H), 1.64 (br s, 2H), 1.24-1.15 (m, 22H), 0.86-0.82 (m, 3H).

Step 2: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl tetradecanoate. A stirred solution of ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenylmethoxy) tetrahydrofuran-2-yl)methyl tetradecanoate (638 mg, 0.61 mmol) in DCM

- 25 (6 mL) was added trifluoroacetic acid (TFA) (0.6 mL). The reaction mixture was stirred at

25 °C for 30 minutes in air. LCMS indicated completion of reaction. The reaction mixture was quenched by the addition of methanol until the red solution turn to colorless and concentrated under vacuum. The residue was purified by Prep-HPLC purification (C18, 0-100% ACN/water with 0.1% FA) to give the desired product (270 mg, 100%, yield: 88%).

5 LCMS (ESI) m/z calcd for $C_{26}H_{38}FN_5O_4$: 503. Found: 504 (M+1)⁺. ¹HNMR (300 MHz, DMSO-*d*₆) δ 8.27 (s, 1H), 7.85 (br s, 2H), 6.26-6.22 (m, 1H), 5.79 (d, *J* = 5.4 Hz, 1H), 4.74-4.67 (m, 1H), 4.42 (d, *J* = 12.0 Hz, 1H), 4.10 (d, *J* = 12.0 Hz, 1H), 3.63 (s, 1H), 2.86-2.70 (m, 1H), 2.47-2.46 (m, 1H), 2.30 – 2.10 (m, 2H), 1.41 (br s, 2H), 1.41-1.17 (m, 20H), 0.90-0.80 (m, 3H).

10


Step 3: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((ethoxycarbonyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methyl tetradecanoate. To a stirred solution of ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl tetradecanoate (270 mg, 0.536 mmol) and K₂CO₃ (222 mg, 1.608 mmol) in THF (2 mL)
15 was added solid CDI (261 mg, 1.608 mmol) at 25 °C. The reaction mixture was stirred at 25 °C for 30 min. LCMS indicated completion of reaction. The reaction was quenched with ice cooled-water (8 mL). The resulting mixture was extracted with EtOAc (10 ml *3). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate and evaporated to dryness in vacuum to give the desired product (250 mg, 95%,
20 yield: 74.1%) as white solid. LCMS (ESI) m/z calcd for $C_{30}H_{40}FN_7O_5$: 597. Found: 598 (M+1)⁺.

Step 4: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((ethoxycarbonyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methyl tetradecanoate. To a stirred solution of (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((tetradecanoyloxy)methyl)tetrahydrofuran-3-yl 1H-imidazole-1-carboxylate (250 mg, 0.418 mmol) and Cs₂CO₃ (291 mg, 0.894 mmol) in tetrahydrofuran (THF) (4 mL) was added ethanol (193 mg, 4.18 mmol) at 25 °C. The reaction mixture was stirred at 25 °C for 2 hours. LCMS indicated completion of reaction. The reaction was quenched with ice cooled-water (8 mL). The resulting mixture was
30 extracted with EtOAc (10 ml *3). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate and evaporated to dryness under vacuum. The residue was purified by Prep-HPLC (Column: XBridge Prep C18 OBD Column, 19*150mm 5um; Mobile Phase A: Water (0.1%FA), Mobile Phase B: ACN; Flow rate: 25 mL/min; Gradient: 75 B to 95 B in 7 min; 220 nm, 254 nm. RT: 6.06 min) to give the desired
35 product (158 mg, 98.84%, yield: 64.4%) as a white solid. LCMS (ESI) m/z calcd for $C_{29}H_{42}FN_5O_6$: 615. Found: 616 (M+1)⁺. ¹HNMR (400 MHz, DMSO-*d*₆) δ 8.32 (s, 1H), 7.89

(br s, 2H), 6.34 (t, $J = 6.8$ Hz, 1H), 5.58 (t, $J = 5.2$ Hz, 1H), 4.42 (d, $J = 11.2$ Hz, 1H), 4.25-4.17 (m, 3H), 3.82 (s, 1H), 3.23-3.16 (m, 1H), 2.70-2.64 (m, 1H), 2.33-2.18 (m, 2H), 1.43-1.42 (m, 2H), 1.27-1.19 (m, 23H), 0.85 (t, $J = 6.8$ Hz, 3H).

5

Example 57: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl (1,3-bis(isobutyryloxy)propan-2-yl) succinate



10

Step 1: 2-oxopropane-1,3-diyl bis(2-methylpropanoate). To a solution of 1,3-dihydroxypropan-2-one (30 g, 333 mmol) in DCM (200 mL) stirred under nitrogen at 0 °C was added DMAP (1.22 g, 9.99 mmol), pyridine (81 mL, 999 mmol) and isobutyryl chloride (78 g, 733 mmol) in DCM (100 mL) dropwise during 30 min. The reaction mixture was stirred at 0 °C for overnight. TLC showed the reaction was completed (pet. ether:EtOAc = 1:1, colored by KMnO_4). The reaction mixture was quenched with saturated NaHCO_3 aq. (100 ml) and the organic layers were washed with brine (100 mL *6). The combined organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by flash chromatography (silica gel, 330 g, pet. ether: EtOAc = 5: 1) to give the desired product (34 g, 90%, yield: 44.3%) as a yellow oil. ^1H NMR (400 MHz, Chloroform-d) δ 4.77 (s, 4H), 2.60 - 2.81 (m, 2H), 1.18 - 1.25 (m, 12H).

15

20

Step 2: 2-hydroxypropane-1,3-diyl bis(2-methylpropanoate). To a solution of 2-oxopropane-1,3-diyl bis(2-methylpropanoate) (10 g, 43.4 mmol) in THF (100 mL) / water (10 mL) stirred at 0 °C was added NaBH₄ (1.97 g, 52.1 mmol) portionwise. The reaction mixture was stirred at 0 °C for 30 min. TLC traces showed the reaction was completed (pet. ether:EtOAc = 1:3, colored by KMnO₄). The reaction mixture was quenched with HCl (1 mmol/L, 100 mL), extracted with EtOAc (80 mL *3). The combined organic layers were dried over Na₂SO₄ and concentrated under vacuum to give the desired product (9 g, 90%, yield: 80%) as a yellow oil. ¹HNMR (400 MHz, Chloroform-d) δ 3.81 - 4.73 (m, 4H), 2.56 - 2.71 (m, 2H), 1.18 - 1.25 (m, 12H).

Step 3: 4-((1,3-bis(isobutyryloxy)propan-2-yl)oxy)-4-oxobutanoic acid. 2-Hydroxypropane-1,3-diyl bis(2-methylpropanoate) (10 g, 43.1 mmol) was dissolved in dichloromethane (DCM) (30 mL)/THF (30 mL)/Pyridine (30 mL), dihydrofuran-2,5-dione (8.62 g, 86 mmol) and DMAP (0.53 g, 4.31 mmol) were added, the resulting mixture was stirred for 6.5 hours at 60 °C. LCMS indicated completion of reaction. The reaction mixture was quenched with HCl (1 M, 80 mL), extracted with EtOAc (80 mL *3). The combined organic layers were dried over Na₂SO₄ and concentrated under vacuum. The residue was purified by flash chromatography (silica gel, 330 g, pet. ether:EtOAc = 3: 2) to give the title compound (13 g, 95 %, yield: 86%) as a colorless oil. LCMS (ESI) m/z calcd for C₁₅H₂₄O₈: 332 Found: 355 (M+Na)⁺. ¹HNMR (400 MHz, Chloroform-d) δ 5.27-5.36 (m, 1H), 3.96-4.49 (m, 4H), 2.44-2.80 (m, 6H), 1.17-1.21 (m, 12H).


Step 4: 1,3-bis(isobutyryloxy)propan-2-yl (((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl) diphenylmethyl)amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenyl-methoxy)tetrahydrofuran-2-yl)methyl) succinate. 4-((1,3-bis(isobutyryloxy)propan-2-yl)oxy)-4-oxobutanoic acid (397 mg, 1.19 mmol) was dissolved in DMF (20 mL), DMAP (365 mg, 2.99 mmol) and 3-(((ethylimino)methyl-ene)amino)-N,N-dimethylpropan-1-amine hydrochloride (572 mg, 2.99 mmol) were added, the resulting mixture was stirred for 2 hours at 20 °C. Then, ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenyl-methyl)amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenyl-methoxy)tetrahydrofuran-2-yl)methanol (500 mg, 0.60 mmol) was added and the resulting mixture was stirred for overnight at 20 °C. LCMS indicated completion of reaction. The reaction was quenched with water (80 mL) and the mixture was extracted with EtOAc (50 mL *3). The combined organic layers were dried over Na₂SO₄ and concentrated under vacuum. The residue was purified by flash chromatography (silica gel, 120 g, pet. ether: EtOAc = 1: 1) to give the desired product (600 mg, 95%, yield: 83%) as a white solid. LCMS (ESI) m/z calcd for


C₆₇H₆₆FN₅O₁₂: 1151. Found: 1152 (M+H)⁺. ¹HNMR (400 MHz, Chloroform-d) δ 7.62 (s, 1H), 7.54 - 7.57 (m, 4H), 7.38 - 7.46 (m, 2H), 7.23 - 7.36 (m, 18H), 7.07 (s, 1H), 6.76 - 6.88 (m, 4H), 6.11 (dd, J = 8.0, 3.6 Hz, 1H), 5.22- 5.35 (m, 1H), 4.64 (t, J = 8.0 Hz, 1H), 4.26 - 4.41 (m, 3H), 4.15 - 4.20 (m, 2H), 3.96 - 4.06 (m, 1H), 3.79 (d, J = 16.4 Hz, 6H), 2.86 (s, 1H), 2.15 - 2.69 (m, 8H), 1.17 - 1.25 (m, 12H).

Step 5: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl (1,3-bis(isobutyryloxy)propan-2-yl) succinate. To a solution of 1,3-bis(isobutyryloxy) propan-2-yl (((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-(((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methyl) succinate (600 mg, 0.52 mmol) in DCM (10 mL) stirred at 15 °C was added TFA (1 ml) dropwise. The reaction mixture was stirred at 15 °C for 1 hour. LCMS indicated completion of reaction. The reaction mixture was quenched with saturated NaHCO₃ aq (30 ml), and extracted with DCM (15 ml *2). The combined organic phases were washed with brine (15 ml) and concentrated under vacuum. The residue was purified by Prep-HPLC purification (Column: XBridge Prep OBDC18 Column, 19*250mm, 5um; Mobile Phase A: Water (10MMOL/L NH₄HCO₃+0.1%NH₃.H₂O), Mobile Phase B: ACN; Flow rate: 25 mL/min; Gradient: 35 B to 57 B in 11 min; 254 nm; RT:9.13 min). The collected fraction (RT: 9.13 min) was lyophilized to give the desired product (103 mg, 98.2%, yield: 32%) as a white solid. LCMS (ESI) m/z calcd for C₂₇H₃₄FN₅O₁₀: 607. Found: 608 (M+H)⁺. ¹HNMR (400 MHz, DMSO-d₆) δ 8.27 (s, 1H), 7.85 (br, s, 2H), 6.25 (dd, J = 8.0, 4.4 Hz, 1H), 5.80 (d, J = 5.2, 1H), 5.17 (dd, J = 6.4, 4.0 Hz, 1H), 4.68 (dd, J = 13.2, 7.6 Hz, 1H), 4.39 (d, J = 11.6, 1H), 4.26-4.09 (m, 5H), 3.62 (s, 1H), 2.80-2.73 (m, 1H), 2.54-2.47 (m, 7H), 1.05 (d, J = 6.4 Hz, 12H).

25


Example 58: (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-((dodecanoyloxy)methyl)-2-ethynyltetrahydrofuran-3-yl dodecanoate






To a stirred mixture of (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-ol (500 mg, 1.705 mmol), Et₃N (0.951 mL, 6.82 mmol) and DMAP (41.7 mg, 0.341 mmol) in DCM (30 mL) was added dodecanoyl chloride (783 mg, 3.58 mmol) dropwise. The reaction mixture was stirred at room temperature for 2 h. LCMS indicated completion of reaction. The reaction was quenched with water (50 mL), and extracted with DCM (3x 50 mL). The combined organic phases were dried over sodium sulphate and concentrated under reduced pressure to afford crude product as a yellow solid. The sample was further purified on a silica column (120 g) using 0%-80% EtOAc/pet. ether solvent gradient over 80 mins, Flow rate: 70 mL/min. The appropriate fractions containing desired product were identified by UV absorbance (254 nm), combined and evaporated in vacuo to give white solid. The solid was triturated with ACN (15 mL), stirred at room temperature overnight. The resulting solid was filtered through a Buchner funnel, rinsed with ACN, dried under sun lamp for 1 h, and was put in a cool dry place overnight. Then the solid was collected to give (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-((dodecanoyloxy)methyl)-2-ethynyltetrahydrofuran-3-yl dodecanoate (520 mg, 0.783 mmol, 45.9 % yield) as a white solid. LCMS (ESI) m/z calcd for C₃₆H₅₆FN₅O₅:657. Found: 658 (M+H)⁺. ¹HNMR (400 MHz, Chloroform-d) δ 7.95 (s, 1H), 6.40 (t, J = 6.4 Hz, 1H), 6.09 (br s, 2H), 5.65 (dd, J = 7.2, 5.6 Hz, 1H), 4.49 (d, J = 12.0 Hz, 1H), 4.39 (d, J = 12.0 Hz, 1H), 2.95 - 3.02 (m, 1H), 2.66 - 2.75 (m, 2H), 2.30 - 2.43 (m, 4H), 1.57 - 1.69 (m, 4H), 1.17 - 1.40 (m, 32H), 0.85 - 0.90 (m, 6H).


Example 59: (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((palmitoyloxy)methyl)tetrahydrofuran-3-yl palmitate






To the stirred mixture of (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-ol (600mg, 2.046 mmol) in DCM (60 mL) was added Et₃N (1.426 mL, 10.23 mmol), DMAP (50.0 mg, 0.409 mmol) and palmitoyl chloride (1406 mg, 5.11 mmol) at 0 °C. The reaction mixture was stirred for 3 h at room temperature. LCMS showed presence 75% of desired product. The reaction mixture was quenched with water (20 mL) and extracted with DCM (20 mL*3). The combined organic layers were washed with water (20 mL), brine (20 mL), dried over Na₂SO₄. After filtration, the mixture was concentrated to dryness under vacuum. The residue was purified by silica gel column (120 g, pet. ether:EtOAc = 1:1) to afford (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((palmitoyloxy)methyl)tetrahydrofuran-3-yl palmitate (520 mg) as white solid. The solid was crystallized in pentane : EtOAc = 10:1 (10 mL) to give a crystal form, which was dried under sun lamp (45 °C) for 2 h to afford (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((palmitoyloxy)methyl)tetrahydrofuran-3-yl palmitate (428 mg, 0.546 mmol, 26.7 % yield) as white crystal solid. LCMS (ESI) m/z calcd for C₄₄H₇₂FN₅O₅: 770. Found: 793 (M+23)⁺, 771 (M+1)⁺. ¹HNMR(300 MHz, CDCl₃) δ 7.97(s,1H), 6.42(t, J=6.3HZ,1H), 5.95(brs,2H), 5.69-5.65(m,1H), 4.53-4.39(m,2H), 3.04-2.99(m,1H), 2.75-2.68(m,2H), 2.46-2.34(m,4H), 1.72-1.61(m,4H), 1.42-1.18(m,48H), 0.99-0.83(m,6H).

Example 60: (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((icosanoyloxy)methyl)tetrahydrofuran-3-yl icosanoate







To the mixture of icosanoic acid (2.66 g, 8.52 mmol) in DCM (100 mL) was added EDC (2.61 g, 13.64 mmol). The reaction mixture was stirred for 30 min at 25 °C. Then (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-ol (1.0 g, 3.41 mmol), DMAP (0.833 g, 6.82 mmol) and DIEA (5.96 mL, 34.1 mmol) were added. The reaction mixture was stirred for overnight at 25 °C. LCMS showed no desired mass but a new spot was found by TLC (pet. ether:EtOAc = 1:1, r_f = 0.8). The reaction mixture was quenched with water (100 mL), extracted with DCM (50 mL*3). The combined organic layers were washed with water (100 mL), brine (100 mL), dried over Na₂SO₄. After filtration, the filtrate was concentrated to dryness under vacuum. The residue was purified by silica gel (330g, pet. ether:EtOAc = 1:1) to afford (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((icosanoyloxy)methyl)tetrahydrofuran-3-yl icosanoate (570 mg) as white solid. The solid (500 mg) was dissolved in DCM (250 mL) and MeOH (75 mL), allowed to stand for 3 days at rt and solids collected by filtration to title compound (260 mg) as irregular crystals. The solid was dried under sun lamp (45°C) for 2 h. LCMS: (ESI) m/z calcd for C₅₂H₈₈FN₅O₅: 631. Found: 883 (M+1)⁺, 905 (M+23)⁺. ¹HNMR (300 MHz, CDCl₃) δ 7.95(s, 1H), 6.42(t, J=6.3Hz, 1H), 6.05(br s, 2H), 5.68(t, J=5.4Hz, 1H), 4.52(d, J=12Hz, 1H), 4.41(d, J=12Hz, 1H), 3.07-2.98(m, 1H), 2.78-2.67(m, 2H), 2.46-2.34(m, 4H), 1.69-1.60(m, 4H), 1.36-1.23(m, 64H), 0.90(t, J=6.3Hz, 3H).

20


Example 61: (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((undecanoyloxy)methyl)tetrahydrofuran-3-yl undecanoate






To the mixture of (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-ol (600 mg, 2.046 mmol), Et₃N (1.141 mL, 8.18 mmol) and DMAP (50.0 mg, 0.409 mmol) in DCM (15 mL) was added undecanoyl chloride (1.3g, 6.35 mmol) dropwise. The reaction mixture was stirred at r.t. for 2 hours. LCMS indicated completion of reaction. The reaction mixture was diluted with water (10 mL), extracted with DCM (10 mLx3). The organic phases were combined, washed with brine (10 mL), dried over Na₂SO₄, and concentrated under vacuum. The residue was purified by gel silica column (80 g, EtOAc: pet. ether = 1: 1) to give the desired product (purity:97%) as a white solid. The solid was triturated with EtOAc (20 ml x 3). The resulting solid was filtered through a Buchner funnel, rinsed with EtOAc, dried sun lamp (T=50 °C) for 6 h, and was put in a cool dry place overnight to give (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((undecanoyloxy)methyl)tetrahydro-furan-3-yl undecanoate (560mg, 99.59%, 42.7 % yield) as a white solid. LCMS (ESI) m/z calcd for C₃₄H₅₂FN₅O₅:629. Found: 630 (M+H)⁺. ¹HNMR (400 MHz, Chloroform-d) δ 7.95 (s, 1H), 6.40 (t, J = 6.0 Hz, 1H), 6.05 (br, s, 2H), 5.65 (dd, J = 5.2, 6.8 Hz, 1H), 4.48 (d, J = 12.0 Hz, 2H), 4.39 (d, J = 12.0 Hz, 1H), 3.03 – 2.96 (m, 1H), 2.74 - 2.66 (m, 1H), 2.43 - 2.30 (m, 4H), 1.70 - 1.57 (m, 4H), 1.39 - 1.18 (m, 28H), 0.90 - 0.85 (m, 6H).


Example 62: (2R,3aS,26aR)-2-(6-amino-2-fluoro-9H-purin-9-yl)-26a-ethynyldocosahydro-2H-furo[3,2-b][1,5]dioxacyclopentacosine-5,24-dione






To a solution of 20-(((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methoxy)-20-oxoicosanoic acid (1.0 g, 1.456 mmol) in ACN (10 mL) and DCM (10 mL) was added TCFH (1.134 g, 4.05 mmol) and NMI (356 mg, 4.86 mmol). The mixture was stirred at r.t. overnight. The LCMS trace showed the reaction was completed. The mixture was concentrated under vacuum and purified by silica gel (80 g, EtOAc/pet. ether = 2/1) to give the crude product (500 mg). The crude product was purified by reversed phase (C18, 120 g, A: water (0.05% TFA), B: ACN: 20% to 100% in 60 min, 254/220 nm), then re-crystallized from (DCM/EtOAc = 2/1) to give (2R,3aS,26aR)-2-(6-amino-2-fluoro-9H-purin-9-yl)-26a-ethynyl-docosahydro-2H-furo[3,2-b][1,5]dioxacyclopentacosine-5,24-dione (272.4 mg, 99.5%, yield 27.1 %) as a white solid. LCMS (ESI) m/z calcd for $C_{32}H_{46}FN_5O_6$: 599 Found: 600 (M+H)⁺. ¹HNMR: (400 MHz, DMSO- d_6) δ 8.341 (s, 1H), 7.915-7.894 (brs, 2H), 6.376-6.344 (t, J=6.4 Hz, 1H), 5.737-5.709 (t, J=5.6 Hz, 1H), 4.392 (d, J=11.2 Hz, 1H), 4.267 (d, J=11.2 Hz, 1H), 3.713 (s, 1H), 3.172-3.106 (m, 1H), 2.633-2.584 (m, 1H), 2.443-2.225 (m, 4H), 1.587-1.533 (m, 4H), 1.266-1.243 (m, 28H).

Example 63: (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((hexanoyloxy)methyl)tetrahydrofuran-3-yl hexanoate



To the mixture of (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-ol (800 mg, 2.73 mmol), Et₃N (1.901 mL, 13.64 mmol) and DMAP (167 mg, 1.364 mmol) in DCM (20 mL) stirred at room temperature was added hexanoyl chloride (1102 mg, 8.18 mmol) dropwise and stirred at for 1 hour. LCMS indicated completion of reaction. The reaction mixture was diluted with water (10 mL), extracted with DCM (10 mL x3). the organic phases were combined, washed with brine (10 mL), dried over Na₂SO₄, and concentrated under vacuum. The residue was purified by gel silica column (80 g, EtOAc: pet. ether = 1:1) to give the desired product as a yellow solid. The solid was triturated with EtOAc (10 mL) and stirred for 16 h, the resulting solid was filtered through a Buchner funnel, rinsed with EtOAc, dried beside sun lamp (T = 50 °C) for 6 h, and was put in a cool dry place overnight to give (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((hexanoyloxy)methyl)tetrahydrofuran-3-yl hexanoate (215 mg, 98.05% purity, 15.79 % yield) as a white solid. LCMS (ESI) m/z calcd for C₂₄H₃₂FN₅O₅: 489. Found: 490 (M+H)⁺. ¹HNMR (400 MHz, Chloroform-d) δ 8.70 (s, 1H), 6.46 (d, J = 5.6 Hz, 1H), 5.51 (d, J = 5.2 Hz, 1H), 4.55 (d, J = 12.0 Hz, 1H), 4.42 (d, J = 12.0 Hz, 1H), 2.92 (s, 2H), 2.74 (s, 1H), 2.46 - 2.33 (m, 4H), 1.75 - 1.55 (m, 6H), 1.40 - 1.25 (m, 8H), 0.97 - 0.85 (m, 6H).

Example 64: (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((nonanoyloxy)methyl)tetrahydrofuran-3-yl nonanoate



To a stirred mixture of (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxy-methyl)tetrahydrofuran-3-ol (500 mg, 1.705 mmol) in DCM (4 mL) was added DMAP (83 mg, 0.682 mmol), triethylamine (863 mg, 8.52 mmol) and nonanoyl chloride (753 mg, 4.26 mmol) at 0 °C. The reaction mixture was stirred for 6 h at room temperature. LCMS showed 49% of desired product. The reaction mixture was quenched


with water (10 mL), extracted with DCM(3*10 mL). The combined organic layers were washed with brine and dried over Na₂SO₄. After filtration, the filtrate was concentrated to dryness in vacuum. The residue was purified by silica gel column (40 g, pet. ether:EtOAc = 1:1) to afford (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-

- 5 ((nonanoyloxy)methyl)tetrahydrofuran-3-yl nonanoate as a yellow oil. Then, the product was re-crystallized from EtOAc/Hexane in the ratio of 1:1. The solid was collected by filtration, dried under sun lamp (45 °C) to afford (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((nonanoyloxy)methyl)tetrahydrofuran-3-yl nonanoate (262 mg, 0.435 mmol, 25.5 % yield) as a white solid. LCMS (ESI) m/z calcd for C₃₀H₄₄FN₅O₅:573. Found:
- 10 574 (M+1)⁺. ¹HNMR(300 MHz, CDCl₃) δ 8.00 (s, 1H), 6.47-6.38 (m, 1H), 6.14-5.80 (m, 2H), 5.64 (t, J=6 Hz, 1H), 4.51-4.38 (m, 2H), 3.04-2.97 (m, 1H), 2.77-2.67 (m, 2H), 2.44-2.32 (m, 4H), 1.69-1.50 (m, 4H), 1.48-1.28 (m, 20H), 0.95-0.85 (m, 6H).

15

Example 65: (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((octanoyloxy)methyl)tetrahydrofuran-3-yl octanoate

20




- To a solution of (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl) tetrahydrofuran-3-ol (800 mg, 2.73 mmol), Et₃N (1.141 mL, 8.18 mmol) and DMAP (66.7 mg, 0.546 mmol) in DCM (8 mL) stirred under nitrogen at 0 °C was added
- 25 octanoyl chloride (1331 mg, 8.18 mmol) dropwise. The reaction mixture was stirred at 0 °C for 2 h. LCMS indicated completion of reaction. The reaction mixture was quenched with water and extracted with DCM (20 mL). The organic phases were washed with water 50

mL, dried over sodium sulphate and evaporated in vacuo to give the crude products as a yellow oil. The crude product was added to a gel silica column (120 g, wet method) and was eluted with Hex/EtOAc(0-30%). Collected fractions:evaporated in vacuo to give (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((octanoyloxy)methyl)tetrahydrofuran-3-yl octanoate (233.1 mg, purity :99.1%, yield :15.52 %) as a white solid. The solid in ACN:water = 1:1 (5 mL) was stirred at room temperature for 1 hour to obtain crystalline material. LCMS (ESI) m/z calcd for C₂₈H₄₀FN₅O₅:545. Found: 546 (M+1)⁺. ¹HNMR(300MHz, DMSO-d₆) δ 8.32(s,1H), 7.89(s, 2H), 6.34(t, J=6.6 Hz,1H), 5.69(t, J=5.7 Hz,1H), 4.41(d, J=11.4Hz,1H), 4.23(d, J=11.7Hz,1H), 3.78(s, 1H), 3.32-3.10(m, 1H), 2.65-2.56(m, 1H), 2.41-2.31(m, 2H), 1.59-1.45(m, 4H), 1.28-1.20(m,16H), 0.92-0.79 (m, 6H).

15

Example 66: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl 3-(2,4-dimethyl-6-(pivaloyloxy)phenyl)-3-methylbutanoate



20

Step 1: 4,4,5,7-tetramethylchroman-2-one. A mixture of 3,5-dimethylphenol (5.0 g, 40.9 mmol) and methyl 3-methylbut-2-enoate (4.67 g, 40.9 mmol) in MeSO₃H (25 mL) was stirred at 70 °C for 6 h. Then, the reaction was cooled, diluted with water (30 mL), extracted with ethyl acetate (2* 20 mL) and the combined organic extracts were washed

with saturated aqueous sodium hydrogencarbonate (2* 10 mL) and brine (50 mL). The mixture was concentrated to dryness under vacuum. The residue was purified by silica gel column (80 g, pet. ether:EtOAc = 4:1) to afford 4,4,5,7-tetramethylchroman-2-one (8.0 g, 39.2 mmol, 96 % yield) as white solid. LCMS (ESI) m/z calcd for C₁₃H₁₆O₂: 204. Found: 246 (M+1+ACN)⁺. ¹HNMR (300 MHz, CDCl₃) δ: 6.76 (s, 2H), 2.61 (s, 2H), 2.48 (s, 3H), 2.29 (s, 3H), 1.46 (s, 6H).

Step 2: 2-(4-hydroxy-2-methylbutan-2-yl)-3,5-dimethylphenol. To a solution of 4,4,5,7-tetramethylchroman-2-one (10 g, 49.0 mmol) in THF (70 mL) was added LiAlH₄ (7.43 g, 196 mmol) in portions at 0 °C. The reaction mixture was stirred for 12 h at room temperature. LCMS showed the reaction completed. The reaction was quenched with NH₄Cl (sat., aq) at 0 °C, extracted with EtOAc (200 mL*3). The combine organic layers were washed with brine, dried over Na₂SO₄. After filtration, the filtrate was concentrated to dryness in vacuum and the resulting crude product was used in the next step without purification. LCMS (ESI) m/z calcd for C₁₃H₂₀O₂: 208. Found: 209 (M+1)⁺.

Step 3: 2-(4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)-3,5-dimethylphenol. To a solution of 2-(4-hydroxy-2-methylbutan-2-yl)-3,5-dimethylphenol (10 g, 48.0 mmol) in DMF (100 mL) was added imidazole (8.17 g, 120 mmol) and TBS-Cl (8.68 g, 57.6 mmol) at 25 °C. The reaction mixture was stirred for 16 h at room temperature. Then, the reaction mixture was quenched with water (200 mL), extracted with EtOAc (3x 100 mL). The combined organic layers were washed with water, brine and dried over Na₂SO₄. After filtration, the filtrate was concentrated in vacuum. The crude product was purified by silica gel (120 g, pet. ether: EtOAc = 20:1) to afford 2-(4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)-3,5-dimethylphenol (9 g, 26.5 mmol, 55.2 % yield) as white solid. LCMS (ESI) m/z calcd for C₁₉H₃₄O₂Si:322. Found: 323 (M+1)⁺.

Step 4: 2-(4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)-3,5-dimethylphenyl pivalate.

To a stirred mixture of 2-(4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)-3,5-dimethylphenol (3.0 g, 9.30 mmol) in DCM (30 mL) was added Et₃N (1.556 mL, 11.16 mmol), DMAP (0.170 g, 1.395 mmol) and pivaloyl chloride (1.346 g, 11.16 mmol) at 0 °C. The reaction mixture was stirred for 6 h at room temperature. Then, the reaction mixture was quenched with water (30 mL), organic layer separated and aqueous layer extracted with DCM (20 mL*3). The combined organic layers were washed with water (20 mL), brine (20 mL) and dried over Na₂SO₄. After filtration, the filtrate was concentrated to dryness under vacuum. The residue was purified by silica gel column (80 g, pet. ether:EtOAc =

4:1) to afford 2-(4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)-3,5-dimethylphenyl pivalate (3.4 g, 8.36 mmol, 90 % yield) as yellow oil. LCMS (ESI) m/z calcd for $C_{24}H_{42}O_3Si$: 406. Found: 407 (M+1)⁺.

- 5 Step 5: 2-(4-hydroxy-2-methylbutan-2-yl)-3,5-dimethylphenyl pivalate. To a stirred mixture of 2-(4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)-3,5-dimethylphenyl pivalate (3.4 g, 8.36 mmol) in THF (35 mL) was added water (35.0 mL) and AcOH (100 mL, 1747 mmol) at room temperature. The reaction mixture was stirred for 6 h at room temperature. Then, the reaction mixture was quenched with water (50 mL) and extracted with DCM (50 mL*3).
- 10 The combined organic layers were washed with water (20 mL), brine (20 mL) and dried over Na_2SO_4 . After filtration, the filtrate was concentrated to dryness under vacuum. The residue was purified by silica gel column (80 g, pet. ether:EtOAc = 3:1) to afford 2-(4-hydroxy-2-methylbutan-2-yl)-3,5-dimethylphenyl pivalate (2.13 g, 7.28 mmol, 87 % yield) as yellow oil. LCMS (ESI) m/z calcd for $C_{18}H_{28}O_3$: 292. Found: 293 (M+1)⁺. ¹HNMR (300
- 15 MHz, $CDCl_3$). δ 6.82 (s, 1H), 6.43 (s, 1H), 3.57 (t, J=6 Hz, 2H), 2.55 (s, 3H), 2.24 (s, 3H), 2.07-2.02 (m, 2H), 1.56 (s, 1H), 1.51 (s, 6H), 1.39 (s, 9H).

- Step 6: 3,5-dimethyl-2-(2-methyl-4-oxobutan-2-yl)phenyl pivalate. To a stirred mixture of 2-(4-hydroxy-2-methylbutan-2-yl)-3,5-dimethylphenyl pivalate (2.0 g, 6.84 mmol) in DCM (30
- 20 mL) was added DMP (5.80 g, 13.68 mmol) at 0 °C. The reaction mixture was stirred for 3 h at room temperature. The reaction mixture was quenched with $Na_2S_2O_3$ (30 mL), $NaHCO_3$ (30 mL) and extracted with DCM (30 mL*3). The combined organic layers were washed with $Na_2S_2O_3$ (50 mL), $NaHCO_3$ (50 mL), brine (50 mL) and dried over Na_2SO_4 . After filtration, the filtrate was concentrated to dryness to afford as yellow oil, which was
- 25 purified by silica gel column (80 g, pet. ether:EtOAc = 5:1) to afford 3,5-dimethyl-2-(2-methyl-4-oxobutan-2-yl)phenyl pivalate (1.6 g, 5.51 mmol, 81 % yield) as yellow oil. LCMS (ESI) m/z calcd for $C_{18}H_{26}O_3$: 290. Found: 308 (M+1+ NH_3)⁺.


- Step 7: 3-(2,4-dimethyl-6-(pivaloyloxy)phenyl)-3-methylbutanoic acid. To a stirred mixture of 3,5-dimethyl-2-(2-methyl-4-oxobutan-2-yl)phenyl pivalate (1.6 g, 5.51 mmol) in
- 30 methanol (20 mL) was added water (4.00 mL) and oxone (6.77 g, 11.02 mmol) at 0 °C. The reaction mixture was stirred for 6 h at room temperature. The pH was adjusted to 5~6 with saturated aqueous $NaHCO_3$. Then reaction mixture was concentrated under vacuum. The water was extracted with DCM (30 mL*3). The combined organic layers were washed
- 35 with water (20 mL), brine (20 mL) and dried over Na_2SO_4 . After filtration, the filtrate was concentrated to dryness under vacuum. The residue was purified by silica gel column (80

g, pet. ether:EtOAc = 4:1) to afford 3-(2,4-dimethyl-6-(pivaloyloxy)phenyl)-3-methylbutanoic acid (900 mg, 2.94 mmol, 53.3 % yield) as white solid. LCMS (ESI) m/z calcd for $C_{18}H_{26}O_4$:306. Found: 324 (M+1+NH₃)⁺.

- 5 Step 8: ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methyl 3-(2,4-dimethyl-6-(pivaloyloxy)phenyl)-3-methylbutanoate. To a solution of 3-(2,4-dimethyl-6-(pivaloyloxy)phenyl)-3-methylbutanoic acid (400 mg, 1.305 mmol), 3-(((ethylimino)methylene)amino)-N,N-dimethyl-propan-1-amine hydrochloride (501 mg, 2.61 mmol) in
- 10 DCM (5 mL) stirred at room temperature was added N,N-dimethylpyridin-4-amine (31.9 mg, 0.261 mmol) and Et₃N (0.546 mL, 3.92 mmol) at room temperature. The reaction mixture was stirred at room temperature for 1 hr. To the above mixture was added
- 15 ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenyl-methyl)amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methanol (985 mg, 1.175 mmol). The reaction mixture was stirred at room temperature for 16 hr. The reaction mixture was quenched with water (20 mL) and extracted with DCM (3*20 mL). The combined organic layers were washed with brine and dried over Na₂SO₄. After filtration, the filtrate was concentrated to dryness in vacuum. The residue was purified by silica gel column (80 g, DCM:MeOH = 1:1) to afford ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-
- 20 methoxyphenyl)di-phenylmethyl)amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methyl 3-(2,4-dimethyl-6-(pivaloyloxy)phenyl)-3-methylbutanoate (1.0 g, 0.888 mmol, 68.0 % yield) as yellow oil. LCMS (ESI) m/z calcd for $C_{70}H_{68}FN_5O_8$:1126. Found: 1127 (M+1)⁺.
- 25 Step 9: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl 3-(2,4-dimethyl-6-(pivaloyloxy)phenyl)-3-methylbutanoate. To a stirred mixture of ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methyl 3-(2,4-dimethyl-6-(pivaloyloxy)phenyl)-3-methylbutanoate (1.0 g, 0.888 mmol) in DCM (10 mL)
- 30 was added TFA (2 mL) at room temperature. The reaction mixture was stirred for 6 h at room temperature. LCMS showed 88% of desired product. The pH of the reaction mixture was adjusted to 6-7 with saturated aqueous NaHCO₃ and extracted with DCM(3*10 mL). The combined organic layers were washed with brine, dried over Na₂SO₄. After filtration, the filtrate was concentrated to dryness in vacuum. The residue was purified by silica gel
- 35 column (80 g, pet. ether:EtOAc = 1:9) to afford ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl 3-(2,4-dimethyl-6-

(pivaloyloxy)phenyl)-3-methylbutanoate as yellow oil. Then, the product was crystallized from 1:1 EtOAc/Hexane. The solid was collected by filtration and dried under sun lamp (45 °C) to afford ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl 3-(2,4-dimethyl-6-(pivaloyloxy)phenyl)-3-methylbutanoate (224 mg, 0.382 mmol, 43.1 % yield) as white irregular crystal solid. LCMS (ESI) m/z calcd for C₃₀H₃₆FN₅O₆:581. Found: 582 (M+1)⁺. ¹HNMR (300 MHz, CDCl₃) δ 7.88 (s, 1H), 6.75 (s, 1H), 6.42 (s, 1H), 6.29-6.25 (m, 1H), 6.02 (br s, 2H), 4.27-4.18 (m, 2H), 3.97-3.93 (m, 1H), 3.02 (s, 1H), 2.97 (s, 1H), 2.71-2.56 (m, 7H), 2.19 (s, 3H), 1.58 (d, J=6 Hz, 6H), 1.35 (s, 9H).

Example 67: 2-(4-(((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methoxy)-2-methyl-4-oxobutan-2-yl)-3,5-dimethylphenyl decanoate



Step 1: 2-(4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)-3,5-dimethylphenyl decanoate.

To a mixture of 2-(4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)-3,5-dimethylphenol (4.5 g, 13.95 mmol), DMAP (0.170 g, 1.395 mmol) and Et₃N (2.333 mL, 16.74 mmol) in DCM (45 mL) was added decanoyl chloride (3.19 g, 16.74 mmol) at 0 °C.

The reaction mixture was stirred for 5 hours at room temperature. LCMS indicated completion of reaction. The reaction mixture was quenched with water (50 mL) and extracted with DCM (3 * 50 mL). The combined organic layers were washed with brine and dried over Na₂SO₄. After filtration, the filtrate was concentrated to dryness in vacuum. The residue was purified by silica gel (120 g, pet. ether:EtOAc = 8:1) to afford 2-(4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)-3,5-dimethylphenyl decanoate (5.5 g, 11.53

mmol, 83 % yield) as colorless oil. LCMS (ESI) m/z calcd for $C_{29}H_{52}O_3Si$: 476. Found: 477 (M+H)⁺.

Step 2: 2-(4-hydroxy-2-methylbutan-2-yl)-3,5-dimethylphenyl decanoate. To a mixture of
5 2-(4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)-3,5-dimethylphenyl decanoate (3 g,
6.29 mmol) in THF (5 mL) and water (5.00 mL) was added acetic Acid (15.00 mL) at
25 °C. The reaction mixture was stirred for 5 hours at 25 °C. LCMS indicated completion
of reaction. The reaction mixture was quenched with water (30 mL) and extracted with
EtOAc (3 * 30 mL). The combined organic layers were washed with NaHCO₃ (aq, 30 mL *
10 2), brine (30 mL) and dried over Na₂SO₄. After filtration, the filtrate was concentrated to
dryness in vacuum. The residue was purified by gel silica column (80 g, pet. ether: EtOAc
= 6: 1) to give 2-(4-hydroxy-2-methylbutan-2-yl)-3,5-dimethylphenyl decanoate (1.5 g, 3.72
mmol, 59.2 % yield) as colorless oil. LCMS (ESI) m/z calcd for $C_{23}H_{38}O_3$: 362. Found:
426(M+23+ACN)⁺. ¹HNMR (400 MHz, Chloroform-*d*) δ 6.82 (d, J = 2.0 Hz, 1H), 6.52 (d, J
15 = 2.0 Hz, 1H), 3.54 (t, J = 7.2 Hz, 2H), 2.57 - 2.50 (m, 5H), 2.23 (s, 3H), 2.05 (t, J = 7.2 Hz,
2H), 1.81 - 1.69 (m, 2H), 1.48 (s, 6H), 1.45 - 1.23 (m, 12H), 0.92 - 0.84 (m, 3H).

Step 3: 3,5-dimethyl-2-(2-methyl-4-oxobutan-2-yl)phenyl decanoate. To a mixture of 2-(4-
hydroxy-2-methylbutan-2-yl)-3,5-dimethylphenyl decanoate (1.5 g, 4.14 mmol) in DCM (30
20 mL) was added Dess-Martin periodinane (3.51 g, 8.27 mmol) at 25 °C. The reaction
mixture was stirred for 4 hours at 25 °C. LCMS indicated completion of reaction. The
reaction mixture was quenched with Na₂S₂O₃ (aq, 30 mL), NaHCO₃ (aq, 30 mL) and
extracted with DCM (3 * 50 mL). The combined organic layers were concentrated to
dryness in vacuum. The residue was purified by silica gel (pet. ether:EtOAc = 10:1) to
25 afford 3,5-dimethyl-2-(2-methyl-4-oxobutan-2-yl)phenyl decanoate (910 mg, 2.272 mmol,
54.9 % yield) as yellow oil. LCMS (ESI) m/z calcd for $C_{23}H_{36}O_3$: 360. Found: 378(M+1+
NH₃)⁺.

Step 4: 3-(2-(decanoyloxy)-4,6-dimethylphenyl)-3-methylbutanoic acid. To a mixture of
30 3,5-dimethyl-2-(2-methyl-4-oxobutan-2-yl)phenyl decanoate (910 mg, 2.52 mmol) in
methanol (60 mL) and water (12.00 mL) was added oxone (3103 mg, 5.05 mmol) at 0 °C.
The reaction mixture was stirred for 12 hours at 25 °C. LCMS indicated completion of
reaction. The reaction mixture was extracted with ethyl acetate (3 * 80 mL). The combined
organic phases were washed with water and saturated brine, dried over sodium sulphate
35 and evaporated in vacuum to give the crude product as yellow oil. The residue was
purified by gel silica column (80 g, pet. ether: EtOAc = 1: 1) to give 3-(2-(decanoyloxy)-4,6-

dimethylphenyl)-3-methylbutanoic acid (450 mg, 1.076 mmol, 42.6 % yield) as yellow oil. LCMS (ESI) m/z calcd for C₂₃H₃₆O₄: 376. Found: 394(M+1+ NH₃)⁺. ¹HNMR (400 MHz, Chloroform-*d*) δ 6.80 (d, *J* = 2.0 Hz, 1H), 6.56 (d, *J* = 2.0 Hz, 1H), 2.83 (s, 2H), 2.59 - 2.51 (m, 5H), 2.22 (s, 3H), 1.80 - 1.70 (m, 2H), 1.56 (s, 6H), 1.44 - 1.22 (m, 12H), 0.95 - 0.85 (m, 3H).

Step 5: 2-(4-(((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methoxy)-2-methyl-4-oxobutan-2-yl)-3,5-dimethylphenyl decanoate.


To a solution of 3-(2-(decanoyloxy)-4,6-dimethylphenyl)-3-methylbutanoic acid (400 mg, 1.062 mmol), 3-(((ethylimino)methylene)amino)-N,N-dimethylpropan-1-amine hydrochloride (407 mg, 2.125 mmol) in DCM (5 mL) stirred at room temp was added N,N-dimethylpyridin-4-amine (260 mg, 2.125 mmol). The reaction mixture was stirred at room temperature for 1 hour. To the above mixture was added ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methanol (801 mg, 0.956 mmol). The reaction mixture was stirred at room temperature for 24 hours. LCMS indicated completion of reaction. The reaction mixture was quenched with water and extracted with dichloromethane 20 mL. The combined organic phases were washed with saturated brine 10 mL, dried over sodium sulphate and evaporated in vacuum to give the crude product as colorless oil. The residue was purified by gel silica column (40 g, pet. ether: EtOAc = 1: 1) to give 2-(4-(((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl) amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methoxy)-2-methyl-4-oxobutan-2-yl)-3,5-dimethylphenyl decanoate (800 mg, 0.595 mmol, 56.0 % yield) as colorless oil. LCMS (ESI) m/z calcd for C₇₅H₇₈FN₅O₈: 1196. Found: 1197(M+H)⁺. ¹HNMR (400 MHz, Chloroform-*d*) δ 7.56 (s, 1H), 7.52 (d, *J* = 7.6 Hz, 4H), 7.42 - 7.34 (m, 2H), 7.34 - 7.15 (m, 17H), 7.00 (s, 1H), 6.84 - 6.75 (m, 4H), 6.72 (d, *J* = 2.0 Hz, 1H), 6.51 (d, *J* = 2.0 Hz, 1H), 6.08 (dd, *J* = 7.6, 4.0 Hz, 1H), 4.51 (d, *J* = 7.6 Hz, 1H), 4.21 (d, *J* = 12.4 Hz, 1H), 3.96 (d, *J* = 12.0 Hz, 1H), 3.77 (d, *J* = 18.4 Hz, 6H), 2.78 (s, 1H), 2.71 - 2.57 (m, 2H), 2.51 (s, 1H), 2.46 (td, *J* = 7.6, 3.6 Hz, 2H), 2.39 (s, 3H), 2.28 (s, 1H), 2.19 (s, 3H), 1.73 - 1.63 (m, 2H), 1.43 (s, 3H), 1.36 (s, 3H), 1.28 (s, 6H), 1.24 (s, 6H), 0.91 - 0.83 (m, 3H).

Step 6: 2-(4-(((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methoxy)-2-methyl-4-oxobutan-2-yl)-3,5-dimethylphenyl

decanoate. To a solution of 2-(4-(((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl) amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)

diphenylmethoxy)tetrahydrofuran-2-yl)methoxy)-2-methyl-4-oxobutan-2-yl)-3,5-dimethylphenyl decanoate (700 mg, 0.585 mmol) in DCM (10 mL) was added TFA (2 mL, 26.0 mmol). The reaction mixture was stirred at room temperature for 1 hr. LCMS indicated completion of reaction. The reaction mixture was quenched with water, extracted with dichloromethane 20 mL. The combined organic phases were washed with saturated brine 10 mL, dried over sodium sulphate and evaporated in vacuum to give the crude product as yellow oil. The residue was purified by reverse phase (C18) column (120 g, FA with water/MeCN = 1:10) to 2-(4-(((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methoxy)-2-methyl-4-oxobutan-2-yl)-3,5-dimethylphenyl decanoate (104.3 mg, 0.157 mmol, 26.9 % yield) as yellow solid. LCMS (ESI) m/z calcd for $C_{35}H_{46}FN_5O_6$: 651. Found: 652(M+H)⁺. ¹HNMR (400 MHz, Chloroform-*d*) δ 8.03 (s, 1H), 6.73 (d, J = 2.0 Hz, 1H), 6.54 (d, J = 2.0 Hz, 1H), 6.27 (dd, J = 7.2, 4.4 Hz, 1H), 4.21 (q, J = 12.2 Hz, 2H), 3.80 (t, J = 7.6 Hz, 1H), 3.11 - 3.00 (m, 2H), 2.71 - 2.51 (m, 9H), 2.18 (s, 3H), 1.74 (q, J = 7.4 Hz, 2H), 1.59 (d, J = 18.8 Hz, 6H), 1.43 - 1.21 (m, 12H), 0.92 - 0.84 (m, 3H).

Example 68: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl (1,3-bis(heptanoyloxy)propan-2-yl) succinate



Step 1: 2-oxopropane-1,3-diyl diheptanoate. To a solution of 1,3-dihydroxypropan-2-one (14 g, 155 mmol) in DCM (100 mL) stirred under nitrogen at 0°C was added pyridine (37.7 mL, 466 mmol), DMAP (0.570 g, 4.66 mmol), and heptanoyl chloride (50.8 g, 342 mmol) in

DCM (50 mL) dropwise over 15 min. The reaction mixture was stirred at 0 °C overnight. LCMS indicated completion of reaction. The reaction mixture was quenched with Na₂HCO₃ (100 mL) and the organic layers were washed with NaCl (100 mL*6), the combined organic layers were dried over Na₂SO₄ and evaporated to dryness in vacuo.

5 The residue was purified by flash chromatography (silica gel, 120 g, EtOAc: pet. ether = 1:1) to give the desired product (18 g, yield: 36.8%) as a yellow solid. LCMS (ESI) m/z calcd for C₁₇H₃₀O₅: 314. Found: 315 (M+1)⁺. ¹HNMR (400 MHz, Chloroform-*d*): δ 4.77 (s, 4H), 2.46-2.36 (m, 4H), 1.72-1.59 (m, 4H), 1.41-1.27 (m, 12H), 0.93-0.89 (m, 6H).

10 Step 2: 2-hydroxypropane-1,3-diyl diheptanoate. To 2-oxopropane-1,3-diyl diheptanoate (18.0 g, 57.2 mmol) in THF (20 mL) and water (2.000 mL) stirred at 0 °C was added sodium borohydride (3.25 g, 86 mmol) portionwise and stirred at 0 °C for 30 min. LCMS indicated completion of reaction. The reaction mixture was added with water (40 mL), extracted with EtOAc (20 mL*3), the organic phases were combined, washed with brine
15 (40 mL), dried over Na₂SO₄, and concentrated under vacuum to give crude product (14.8 g, yield: 82%) as white solid which was used in the next step without purification. LCMS (ESI) m/z calcd for C₁₇H₃₂O₅: 316. Found: 317 (M+1)⁺. ¹HNMR (400 MHz, Chloroform-*d*) δ 4.31-4.06 (m, 4H), 3.73-3.62 (m, 1H), 2.64-2.43 (m, 1H), 2.39-2.30 (m, 4H), 1.66-1.53 (m, 4H), 1.35-1.23 (m, 12H), 0.92-0.86 (m, 6H).

20 Step 3: 4-((1,3-bis(heptanoyloxy)propan-2-yl)oxy)-4-oxobutanoic acid. To a solution of 2-hydroxypropane-1,3-diyl diheptanoate (6 g, 18.96 mmol) was dissolved in DCM (30 mL)/THF (30.0 mL) was added pyridine (30.0 mL), DMAP (0.232 g, 1.896 mmol) and dihydrofuran-2,5-dione (3.79 g, 37.9 mmol). The resulting mixture was stirred for 6.5 h at
25 60 °C. LCMS indicated completion of reaction. The reaction mixture was diluted with HCl aqueous solution (100 mL), extracted with EtOAc (50 mL*3), the organic phases were combined, dried over Na₂SO₄, and concentrated under vacuum. The residue was purified by C18 reversed phase column (50-100% ACN/water with 0.1% FA) to give the desired product (7 g, 83.30%, yield: 73.8%) as yellow oil. LCMS (ESI) m/z calcd for C₂₁H₃₆O₈: 416.
30 Found: 417 (M+1)⁺. ¹HNMR (300 MHz, DMSO-*d*₆): δ 12.21 (s, 1H), 5.21-5.14 (m, 1H), 4.27-4.09 (m, 4H), 2.46-2.41 (m, 4H), 2.32-2.26 (m, 4H), 1.54-1.45 (m, 4H), 1.29-1.19 (m, 12H), 0.89-0.82 (m, 6H).

35 Step 4: 1,3-bis(heptanoyloxy)propan-2-yl (((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl) diphenylmethyl)amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methyl) succinate. To a solution of

- 4-((1,3-bis(heptanoyloxy)propan-2-yl)oxy)-4-oxobutanoic acid (596 mg, 1.432 mmol) in DMF (6 mL) was added DMAP (525 mg, 4.30 mmol) and 3-(((ethylimino)methylene)amino)-N,N-dimethylpropan-1-amine hydrochloride (824 mg, 4.30 mmol). The resulting mixture was stirred for 30 min at room temperature. Then,
- 5 ((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methanol (600 mg, 0.716 mmol) was added and the resulting mixture was stirred for overnight at room temperature. LCMS indicated completion of reaction. The reaction mixture was quenched with water (10 mL), extracted with EtOAc (5 mL*3), the organic phases were combined, washed with
- 10 brine (10 mL), dried over Na₂SO₄, and concentrated under vacuum. The residue was purified by flash chromatography (silica gel, 80 g, EtOAc: pet. ether = 1: 1) to give the desired product (470 mg, 97.45%, yield: 51.7%) as a white solid. LCMS (ESI) m/z calcd for C₇₃H₇₈FN₅O₁₂: 1236. Found: 1237 (M+1)⁺. ¹HNMR (400 MHz, Chloroform-*d*) δ 7.67 (s, 1H), 7.54-7.49 (m, 4H), 7.41-7.36 (m, 2H), 7.33-7.27 (m, 8H), 7.25-7.16 (m, 10H), 6.81-6.77 (m, 4H), 6.10-6.07 (m, 1H), 5.26-5.20 (m, 1H), 4.61-4.54 (m, 1H), 4.34 (d, *J* = 8Hz, 1H), 4.29-4.24 (m, 2H), 4.16-4.11 (m, 2H), 4.00 (d, *J* = 8Hz, 1H), 3.76 (d, *J* = 16Hz, 6H), 2.83 (s, 1H), 2.52-2.43 (m, 1H), 2.47-2.34 (m, 2H), 2.32-2.26 (m, 4H), 1.63-1.58 (m, 8H), 1.31-1.25 (m, 12H), 0.88-0.83 (m, 6H).
- 20 Step 5: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl (1,3-bis(heptanoyloxy)propan-2-yl) succinate. To a solution of 1,3-bis(heptanoyloxy)propan-2-yl (((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-3-((4-methoxyphenyl)diphenylmethoxy)tetrahydrofuran-2-yl)methyl succinate (450 mg, 0.364
- 25 mmol) in DCM (5 mL) was added TFA (0.561 mL, 7.28 mmol) and the resulting mixture was stirred for 1h at room temperature. LCMS indicated completion of reaction. The reaction mixture was added with MeOH (5 mL), then DCM was removed under vacuum. The mixture was subjected to prep-HPLC (Column: XBridge Prep OBD C18 Column, 19*250mm, 5μm; Mobile Phase A: Water(10MMOL/L NH₄HCO₃+0.1%NH₃.H₂O), Mobile
- 30 Phase B: ACN; Flow rate: 25 mL/min; Gradient: 65 B to 85 B in 8 min; 254 nm; RT1: 6.95;) to give the desired product (29.6 mg, 98.89%, yield: 11.63%) as a white solid. LCMS (ESI) m/z calcd for C₃₃H₄₆FN₅O₁₀: 691. Found: 692 (M+1)⁺. ¹HNMR (400 MHz, DMSO) δ 8.27 (s, 1H), 7.84 (br, 2H), 6.26-6.23 (m, 1H), 5.78 (d, *J*=4Hz, 1H), 5.15-5.13 (m, 1H), 5.70-5.64 (m, 1H), 4.39 (d, *J*=12Hz, 1H), 4.21-4.09 (m, 5H), 3.62 (s, 1H), 2.79-2.73 (m, 1H), 2.56-2.53 (m, 4H), 2.48-2.42 (m, 1H), 2.29-2.25 (m, 4H), 1.51-1.35 (m, 4H), 1.37-1.18 (m, 12H), 0.84-0.81 (m, 6H).
- 35

ANTI-HIV ACTIVITY**PSV Assay**

5 A pseudotyped virus assay (PSV) was used to assess the potency of the HIV inhibitor. Replication defective virus was produced by co-transfection of a plasmid containing an NL4-3 provirus [containing a mutation in the envelope open reading frame (ORF) and a luciferase reporter gene replacing the nef ORF] and a CMV-promoter expression plasmid containing an ORF for various HIV gp160 envelope clones. The
10 harvested virus was stored at -80C in small aliquots and the titer of the virus measured to produce a robust signal for antiviral assays.

The PSV assay was performed by using U373 cells stably transformed to express human CD4, the primary receptor for HIV entry and either human CXCR4 or human CCR5 which are the co-receptors required for HIV entry as target cells for infection. Molecules of
15 interest (including, but not limited to small molecule inhibitors of HIV, neutralizing antibodies of HIV, antibody-drug conjugate inhibitors of HIV, peptide inhibitors of HIV, and various controls) are capable of being diluted into tissue culture media and diluted via serial dilution to create a dose range of concentrations, and this was carried out for Example 1. This dose-range was applied to U373 cells and the pre-made pseudotyped
20 virus added. The amount of luciferase signal produced after 3 days of culture was used to reflect the level of pseudotyped virus infection. An IC₅₀, or the concentration of inhibitor required to reduce PSV infection by 50% from the infection containing no inhibitor was calculated. Assays to measure cytotoxicity were performed in parallel to ensure the antiviral activity observed for an inhibitor was distinguishable from reduced target cell viability. IC₅₀
25 values were determined from a 10 point dose response curve using 3-4-fold serial dilution for each compound, which spans a concentration range > 1000 fold.

These values are plotted against the molar compound concentrations using the standard four parameter logistic equation:

$$30 \quad y = ((V_{\max} * x^n) / (K^n + x^n)) + Y_2$$

where:

Y₂ = minimum y

n = slope factor

V_{max} = maximum y

x = compound concentration [M]

K = EC₅₀

35

The resulting data is shown in Table 3.

Table 3

Example	WT IC ₅₀ (μM)	M184V IC ₅₀ (μM)
1	0.002	0.008
2	0.003	0.013
3	0.002	0.01
4	0.003	0.017
5	0.001	0.007
6	0.004	0.025
7	0.004	0.024
8	0.002	0.011
9	0.035	0.167
10	0.009	0.044
11	0.008	0.037
12	0.034	0.151
13	0.508	3.61
14	0.033	0.148
15	0.077	0.328
16	0.008	0.031
17	1.74	10.3
18	0.01	0.073
19	0.018	0.087
20	0.005	0.025
21	0.007	0.044
22	0.007	0.035
23	0.011	0.068
24	0.066	0.351
25	0.021	0.186
26	0.007	0.028
27	0.008	0.046
28	0.006	0.026

29	0.238	1.35
30	0.334	1.5
33	0.017	0.086
34	0.004	0.025
35	0.001	0.009
36	0.004	0.021

Antiviral Persistence Assay

5 The PSV assay was adapted to determine the antiviral persistence of each compound. This assay evaluates the ability of each compound to remain active in cells for two days i.e prevent PSV infection of cells in a dose dependent manner, 48 h after the removal of compound. Duplicate plates of U373 cells were treated with a serial dilution of small molecule inhibitors for 6 h at 37 °C. Compounds were removed from cells by

10 washing twice cells with 1XPBS. For baseline group (i.e immediately after washing or 0 h), cells were infected with prepared PSVs and cultured for three days. For experimental group (48 h), the culture medium is added to the washed cells and the plate incubated at 37 °C for 48 h. After two days of culture, the prepared PSVs were added to the cells and the mixture cultured for three days. The amount of luciferase signal produced after culture

15 was used to reflect the level of pseudotyped virus infection in the baseline group (0 h) and experimental group (48 h) for each compound. An IC₅₀, or the concentration of inhibitor required to reduce PSV infection by 50% from the infection containing no inhibitor was calculated. The persistence index, which is the ratio of the IC₅₀ determined at 48 and 0 h is presented in Table 2 as well as the fold change of the persistence index relative to EFdA

20 [(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-ol].

Statistical analysis and graphing of the data were performed in JMP 13.2.1 (SAS Institute, Cary, NC). A four-parameter logistic Hill Model was fit to %Inhibition and log₁₀ concentration values, separately for each compound, time point and run. A pilot

25 experiment included 2 independent experimental runs and a later follow-up experiment included 4 runs. Quality control criteria based on R² and 95% confidence interval ranges of all four parameter estimates were used to exclude curves with poor fits. Using inverse prediction, log₁₀ concentrations were obtained that correspond to 50% Inhibition (log₁₀IC50*) and the log₁₀ persistence index was calculated for each compound and run

30 using the following formula: log₁₀ persistence Index = log₁₀IC50*_{48hrs} - log₁₀IC50*_{0hrs}. Next,

a linear mixed effects model was fit on $\log_{10}$ persistence index values with a fixed effect for compound and a random effect for experimental run, followed by post hoc contrasts to compare the $\log_{10}$ persistence index of the positive control EFdA to the $\log_{10}$ persistence index of other test compounds. The estimated LSMeans and differences were then back-transformed via 10^{Estimate} to the original scale and reported as persistence index and fold change respectively. Raw p-values were reported. Antiviral persistence data for examples 15, 16, 18 and EFdA are shown in Table 4. IC_{50} curve shifts from $t = 0$ to $t = 48$ h for EFdA and Example 18 are illustrated in Figures 1A and 1B. The curves in Figure 1 were obtained from a single curve fit across replicate runs instead of separate fits for each run as described above.

Table 4

Example	WT IC_{50} (μ M) at $t = 0$ h	WT IC_{50} (μ M) at $t = 48$ h	Persistence Index	Fold Change vs EFdA	p-Value
EFdA	0.0074	0.3156	42.87	1.00	-
15	0.0343	0.1203	3.51	12.23	0.0002
16	0.0055	0.0359	6.49	6.61	0.0042
18	0.0161	0.0442	2.75	15.59	< 0.0001

Pharmacokinetics

15

Protocol for EFdA rat PK studies

A total of seven naïve male Wistar Han rats, 200-250g, were received from the supplier equipped with a surgically-implanted jugular vein catheter (JVC) for blood sample collection. Following an acclimation period, the animals were assigned to the study based on acceptable health as determined by a staff veterinarian and catheter patency. Animals were placed into two groups of 3 rats per group. Fasting of the animals before or after dosing was not required.

The final study design is presented in the Table 5 below.

Table 5

Group	No. of Males	Test Compound	Dose Level (mg/kg)	Dose Conc. (mg/mL)	Dose Volume (mL/kg)	Dose Vehicle	Dose Route
1	3	EFdA	20	60.46	0.33	0.5% P407/ 0.5% PEG3350/ 3.5% Mannitol in water	Subcutaneous
2	3		20	60.46	0.33		Intramuscular

PEG3350 = Polyethylene glycol 3350.

On Day 1 each animal in Group 1 received a single subcutaneous injection of prepared test article at a target dose level of 20 mg/kg and at a dose volume of 0.33 mL/kg. Each animal in Group 2 received a single intramuscular injection of prepared test article into a thigh muscle at a target dose level of 20 mg/kg and at a dose volume of 0.33 mL/kg. The injection sites were shaved prior to dosing and identified with an indelible marker for daily monitoring during the study. The animals were manually restrained for dosing and were not sedated. The dose suspension was mixed well by inversion before each dose to ensure homogeneity. All dosing was performed as detailed in the study protocol and was completed without incident. Following dosing and at each sample collection time point the animals and injection sites were observed for any clinically relevant abnormalities. In addition, all animals are monitored twice daily by the veterinary staff for clinical abnormalities. No abnormal clinical observations and no injection site reactions were noted during the study period.

Blood samples were collected from the study animals as detailed in the sample collection Table 6 below.


Table 6

Dose Group/ Collection Information	Whole Blood for PK
1 and 2	0.5, 1, 4, 7, 24, 48, 72 hours post-dose and Day 6, 8, 11, 15, 22, 25, 29
Anticoagulant	NaF/Na ₂ EDTA
Volume/Time point	250 µL

Each blood sample for PK (250 µL) was collected from the jugular vein catheter or by venipuncture of a jugular vein. The blood was transferred to a tube containing NaF/Na₂EDTA anticoagulant and inverted several times to mix. The blood samples were maintained on crushed ice before centrifugation at 2200 × g for 10 minutes at 5°C to isolate plasma. The resulting plasma samples were transferred to individual polypropylene tubes in a 96-well plate format and immediately placed on dry ice until storage at nominally -80°C prior to analysis.

The PK plasma samples were analyzed by the Testing Facility to determine the concentration of EFdA using an LC-MS/MS Research Grade Assay (RGA-1) with sensitivity to 0.1 ng/mL. Following review of sample analysis data through Day 29, further

sample analysis was discontinued and the study was terminated. The sample concentration data are presented in Tables 7 and 8 and mean concentration-time profiles are shown in Figures 2 and 3.



(2*R*,3*S*,5*R*)-5-(6-amino-2-fluoro-9*H*-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-ol

5

(EFdA)

Table 7: Plasma concentration of EFdA from rat SC PK study

Assayed Concentrations (ng/mL)				
Time	Rat#1	Rat#2	Rat#3	Mean
0.5 hr	1000	640	2210	1283.33
1 hr	1160	1040	3030	1430.0
4 hr	534	676	708	639.33
7 hr	320	372	216	302.67
24 hr	6.70	14.7	2.53	7.98
48 hr	0.771	0.713	0.543	0.68
72 hr	0.251	0.270	0.201	0.241
Day 6	BQL	BQL	0.117	0.04
Day 8	BQL	BQL	BQL	BQL
Day 11	BQL	BQL	BQL	BQL
Day 15	BQL	BQL	BQL	BQL
Day 22	BQL	BQL	BQL	BQL
Day 25	0.221	BQL	BQL	0.221
Day 29	BQL	BQL	BQL	BQL
BQL - Below Quantitation Limit, < 0.100 ng/mL				

10

Table 8: Plasma concentration of EFdA from rat IM PK study

Assayed Concentrations (ng/mL)				
Time	Rat#1	Rat#2	Rat#3	Mean
0.5 hr	929	1150	684	921.0
1 hr	957	1640	1400	1332.33
4 hr	662	436	733	610.33
7 hr	241	191	426	286.0
24 hr	24.7	1.96	32.6	19.75
48 hr	5.25	0.369	0.915	2.18
72 hr	0.301	0.316	0.241	0.29
Day 6	0.102	BQL	0.103	0.10
Day 8	BQL	BQL	BQL	BQL
Day 11	BQL	BQL	BQL	BQL
Day 15	BQL	BQL	BQL	BQL
Day 22	BQL	BQL	BQL	BQL
Day 25	BQL	BQL	BQL	BQL
Day 29	BQL	BQL	BQL	BQL
BQL - Below Quantitation Limit, < 0.100 ng/mL				

5

General protocol for prodrugs rat PK studies

A total of three naïve male Wistar Han rats, 250-300g, were received and following an acclimation period, the animals were assigned to the study based on acceptable health as determined by a staff veterinarian and catheter patency. Fasting of the animals before or after dosing was not required.

10 The final study design is presented in the Table 9 below.

Table 9

No. of Males	Dose Level (mg/kg)	Dose Conc. (mg/mL)	Dose Vehicle	Dose Route
3	20 (equivalent of EFdA)	2	2%Kolliphor P407+2%PEG3350+3.5%Mannitol+92.5%water	Intramuscular

PEG3350 = Polyethylene glycol 3350.

On Day 1, each animal received a single intramuscular injection of prepared test article at a target dose level of 20 mg/kg equivalent of EFdA and at a dose volume of 2 mL/kg. The injection sites were at gastrocnemius and identified with an indelible marker for daily monitoring during the study. The animals were manually restrained for dosing and were not sedated. The dose suspension was mixed well by inversion before each dose to ensure homogeneity. All dosing was performed as detailed in the study protocol and was completed without incident. Following dosing and at each sample collection time point the animals and injection sites were observed for any clinically relevant abnormalities. In addition, all animals are monitored twice daily by the veterinary staff for clinical abnormalities. No abnormal clinical observations and no injection site reactions were noted during the study period.

Blood samples were collected from the study animals as detailed in the sample collection Table 10 below

Table 10

Collection Information	Whole Blood for PK
Collection time	0.5, 1, 3, 5 and 7 hr, 1, 2, 3, 4, 5 and 7 days post dose then 2x/week (Day10 and Day14, etc)
Anticoagulant	NaF/Na ₂ EDTA
Volume/Time point	200 µL blood

Each blood sample for PK (200 µL) was collected from tail vein. The blood was transferred to a tube containing NaF/Na₂EDTA anticoagulant and inverted several times to mix. Draw 150 µL whole blood from the tube, add 150 µL 100 mM ammonium acetate, pH 4 buffer and mix well. The resulting blood samples were transferred to individual polypropylene tubes and immediately placed on dry ice until storage at nominally -80°C prior to LC-MS/MS analysis. The mean sample concentration data are presented in Tables 11 to 31 and mean concentration-time profiles are shown in Figures 4 to 24.

Reference to Example 11

Table 11: Plasma concentration of Example 11 and EFdA from Example 11 rat IM PK study

Dose (mg/kg)/ Dose route	Sampling time (day)	Mean concentration of Example 11 (ng/mL)	Mean concentration of EFdA (ng/mL)
20/IM	0.0208	6.71	94.0
	0.0417	3.37	121

	0.125	0.872	55.1
	0.208	BQL	38.1
	0.292	BQL	26.6
	1	BQL	5.77
	2	BQL	3.90
	3	BQL	2.93
	4	BQL	3.00
	5	BQL	2.85
	7	BQL	5.29
	10	BQL	1.26
	14	BQL	1.22
	17		BQL
	21		BQL
	24		BQL
	28		BQL
	31		BQL
	35		BQL
	38		BQL
	42		BQL

5

Reference to Example 17**Table 12:** Plasma concentration of Example 17 and EFdA from Example 17 rat IM PK study

Dose (mg/kg)/ Dose route	Sampling time (day)	Mean concentration of Example 17 (ng/mL)	Mean concentration of EFdA (ng/mL)
20 (equivalent to EFdA)/IM	0.0208	15.7	BQL
	0.0417	28.4	0.900
	0.125	29.1	1.43
	0.208	23.0	0.981
	0.292	26.7	BQL
	1	14.3	BQL
	2	2.90	BQL

	3	1.47	1.23
	4	1.15	BQL
	5	0.99	BQL
	7	1.25	BQL
	10	1.40	0.878
	14	0.757	1.12

Reference to Example 18

Table 13: Plasma concentration of Example 18 and EFdA from Example 18 rat IM PK study

Dose (mg/kg)/ Dose route	Sampling time (day)	Mean concentration of Example 18 (ng/mL)	Mean concentration of EFdA (ng/mL)
20 (equivalent to EFdA)/IM	0.0208	43.1	BQL
	0.0417	87.0	2.97
	0.125	58.0	4.62
	0.208	47.1	4.02
	0.292	49.2	4.74
	1	2.44	BQL
	2	BQL	1.91
	3	BQL	2.69
	4	BQL	2.06
	5	BQL	2.39
	7	BQL	1.88
	10	BQL	1.91
	14	BQL	2.53
	17	BQL	1.90
	21	BQL	1.62
	24	BQL	1.73
	28	BQL	1.38
	31	BQL	1.56
	35	BQL	1.59
	38	BQL	1.35
	42	BQL	BQL
	45		0.836
	49		BQL

	52		BQL
	56		BQL
	59		BQL
	63		BQL
	66		BQL

Reference to Example 31

Table 14: Plasma concentration of Example 31 and EFdA from Example 31 rat IM PK study

Dose (mg/kg)/ Dose route	Sampling time (day)	Mean concentration of Example 31 (ng/mL)	Mean concentration of EFdA (ng/mL)
20 (equivalent to EFdA)/IM	0.0208	8.33	98.4
	0.0417	13.6	370
	0.125	1.65	1107
	0.208	BQL	669
	0.292	BQL	284
	1	BQL	46.9
	2	6.51	14.7
	3	17.3	4.88
	4	1.60	2.37
	5	4.05	BQL
	7	BQL	BQL
	10	68.7	BQL
	14	BQL	BQL
	17	BQL	BQL
	21	BQL	BQL
	24	BQL	BQL
	28	BQL	BQL
	31	BQL	BQL

5

Reference to Example 32

Table 15: Plasma concentration of Example 32 and EFdA from Example 32 rat IM PK study

10

Dose (mg/kg)/ Dose route	Sampling time (day)	Mean concentration of Example 32 (ng/mL)	Mean concentration of EFdA (ng/mL)
20 (equivalent to EFdA)/IM	0.0208	23.2	138
	0.0417	20.4	246
	0.125	6.58	185
	0.208	4.58	102
	0.292	2.08	74.2
	1	BQL	45.9
	2	BQL	41.9
	3	BQL	33.8
	4	BQL	26.8
	5	BQL	19.3
	7	BQL	3.96
	10	BQL	4.28
	14	BQL	BQL
	17	BQL	BQL
	21	BQL	BQL
	24	BQL	BQL
	28	BQL	BQL
	31	BQL	BQL

Reference to Example 37

- 5 **Table 16:** Plasma concentration of Example 37 and EFdA from Example 37 rat IM PK study

Dose (mg/kg)/ Dose route	Sampling time (day)	Mean concentration of Example 37 (ng/mL)	Mean concentration of EFdA (ng/mL)
20 (equivalent to EFdA)/IM	0.0208	13.8	31.4
	0.0417	13.7	49.3
	0.125	10.0	32.3
	0.208	4.84	25.4
	0.292	BQL	17.3
	1	BQL	13.7

	2	BQL	18.5
	3	BQL	13.8
	4	BQL	11.7
	5	7.53	12.2
	7	BQL	15.2
	10	7.72	12.9
	14	BQL	7.13
	17	1.82	2.68
	21	1.47	1.76
	24	1.25	BQL
	28	1.58	BQL
	31	6.65	BQL
	35	1.70	BQL
	38	24.1	BQL
	42	BQL	BQL

Reference to Example 38

Table 17: Plasma concentration of Example 38 and EFdA from Example 38 rat IM PK study

Dose (mg/kg)/ Dose route	Sampling time (day)	Mean concentration of Example 38 (ng/mL)	Mean concentration of EFdA (ng/mL)
20 (equivalent to EFdA)/IM	0.0208	11.2	1.96
	0.0417	11.5	3.34
	0.125	14.3	4.30
	0.208	10.5	4.78
	0.292	6.80	3.25
	1	BQL	2.31
	2	BQL	164
	3	BQL	81.7
	4	1.83	80.6
	5	2.00	48.9
	7	BQL	2.84
	10	BQL	3.29
	14	BQL	3.75
	17	BQL	3.09

	21	BQL	3.63
	24	BQL	3.86
	28	BQL	2.55
	31	BQL	1.89
	35	BQL	2.02
	38		1.57
	42		1.38
	45		1.25
	49		0.994
	52		0.885
	56		0.949
	59		1.11
	63		0.822
	66		0.868
	70		BQL
	73		BQL
	77		BQL
	80		BQL
	84		BQL
	87		BQL

5

Reference to Example 39**Table 18:** Plasma concentration of Example 39 and EFdA from Example 39 rat IM PK study

Dose (mg/kg)/ Dose route	Sampling time (day)	Mean concentration of Example 39 (ng/mL)	Mean concentration of EFdA (ng/mL)
20 (equivalent to EFdA)/IM	0.0208	33.9	69.4
	0.0417	36.0	168
	0.125	21.0	165
	0.208	11.6	156
	0.292	7.90	131
	1	BQL	121

	2	5.52	104
	3	BQL	89.2
	4	BQL	105
	5	8.32	109
	7	6.13	83.4
	10	BQL	39.3
	14	BQL	6.92
	17	BQL	3.35
	21	BQL	BQL
	24	BQL	BQL
	28	BQL	2.88
	31	BQL	BQL
	35	BQL	BQL
	38	BQL	BQL
	42	BQL	BQL

Reference to Example 40

Table 19: Plasma concentration of Example 40 and EFdA from Example 40 rat IM PK study

Dose (mg/kg)/ Dose route	Sampling time (day)	Mean concentration of Example 40 (ng/mL)	Mean concentration of EFdA (ng/mL)
20 (equivalent to EFdA)/IM	0.0208	BQL	198
	0.0417	BQL	304
	0.125	BQL	288
	0.208	BQL	210
	0.292	BQL	157
	1	BQL	51.0
	2	BQL	9.36
	3	BQL	4.16
	4	BQL	1.67
	5	BQL	BQL
	7	BQL	BQL
	10	BQL	BQL
	14	BQL	BQL
	17	BQL	BQL
	21	BQL	BQL

Reference to Example 42

- 5 **Table 20:** Plasma concentration of Example 42 and EFdA from Example 42 rat IM PK study

Dose (mg/kg)/ Dose route	Sampling time (day)	Mean concentration of Example 42 (ng/mL)	Mean concentration of EFdA (ng/mL)
20 (equivalent to EFdA)/IM	0.0208	2.26	104
	0.0417	BQL	148
	0.125	BQL	117
	0.208	BQL	94.2
	0.292	BQL	93.2
	1	BQL	35.6
	2	BQL	13.3
	3	BQL	6.00
	4	BQL	BQL
	5	BQL	BQL
	7	BQL	BQL
	10	BQL	BQL
	14	BQL	BQL
	17	BQL	BQL
	21	BQL	BQL
	24	BQL	BQL
	28	BQL	BQL
	31	BQL	BQL

10

Reference to Example 45

- Table 21:** Plasma concentration of Example 45 and EFdA from Example 45 rat IM PK study

Dose (mg/kg)/ Dose route	Sampling time (day)	Mean concentration of Example 45 (ng/mL)	Mean concentration of EFdA (ng/mL)
-----------------------------	------------------------	--	--

20 (equivalent to EFdA)/IM	0.0208	35.6	30.1
	0.0417	49.1	90.3
	0.125	42.8	181
	0.208	15.7	98.5
	0.292	6.15	61.4
	1	0.847	23.1
	2	BQL	16.9
	3	BQL	12.7
	4	BQL	6.53
	5	1.56	6.96
	7	BQL	5.59
	10	BQL	5.64
	14	BQL	BQL
	17	BQL	BQL
	21	BQL	BQL
	24		BQL
	28		BQL
	31		BQL
	35		BQL

5

Reference to Example 48**Table 22:** Plasma concentration of Example 48 and EFdA from Example 48 rat IM PK study

Dose (mg/kg)/ Dose route	Sampling time (day)	Mean concentration of Example 48 (ng/mL)	Mean concentration of EFdA (ng/mL)
20 (equivalent to EFdA)/IM	0.0208	10.4	BQL
	0.0417	15.9	1.43
	0.125	7.04	2.32
	0.208	4.43	2.13
	0.292	2.00	2.51
	1	BQL	4.11

	2	BQL	6.57
	3	BQL	10.3
	4	BQL	14.3
	5	BQL	17.7
	7	BQL	10.8
	10	BQL	1.86
	14	BQL	BQL
	17	BQL	BQL
	21	BQL	BQL

Reference to Example 50

Table 23: Plasma concentration of Example 50 and EFdA from Example 50 rat IM PK study

Dose (mg/kg)/ Dose route	Sampling time (day)	Mean concentration of Example 50 (ng/mL)	Mean concentration of EFdA (ng/mL)
20 (equivalent to EFdA)/IM	0.0208	BQL	3223
	0.0417	BQL	3077
	0.125	BQL	239
	0.208	BQL	38.7
	0.292	BQL	19.3
	1	BQL	1.48
	2	BQL	BQL
	3	BQL	BQL
	4	BQL	BQL
	5	BQL	BQL
	7	BQL	BQL
	10	BQL	BQL
	14	BQL	BQL
	17	BQL	BQL
	21	BQL	BQL

5

Reference to Example 58

Table 24: Plasma concentration of Example 58 and EFdA from Example 58 rat IM PK study

Dose (mg/kg)/ Dose route	Sampling time (day)	Mean concentration of Example 58 (ng/mL)	Mean concentration of EFdA (ng/mL)
20 (equivalent to EFdA)/IM	0.0208	11.4	1.20
	0.0417	14.9	1.10
	0.125	9.18	1.02
	0.208	7.95	BQL
	0.292	7.82	BQL
	1	2.96	BQL
	2	1.05	BQL
	3	0.844	BQL
	4	BQL	BQL
	5	BQL	0.838
	7	BQL	1.34
	10	BQL	1.62
	14		1.94
	17		2.10
	21		BQL
	24		1.22
	28		1.23
	31		0.879
	35		BQL
	38		BQL
	42		BQL
	45		BQL
	49		BQL

5

Reference to Example 59**Table 25:** Plasma concentration of Example 59 and EFdA from Example 59 rat IM PK study

Dose (mg/kg)/ Dose route	Sampling time (day)	Mean concentration of Example 59 (ng/mL)	Mean concentration of EFdA (ng/mL)
-----------------------------	------------------------	--	--

20 (equivalent to EFdA)/IM	0.0208	20.8	BQL
	0.0417	26.7	0.899
	0.125	43.3	2.29
	0.208	42.4	2.08
	0.292	42.4	BQL
	1	8.72	BQL
	2	4.23	BQL
	3	2.52	BQL
	4	2.36	BQL
	5		BQL
	7		BQL
	10		2.66
	14		2.31

Reference to Example 61

Table 26: Plasma concentration of Example 61 and EFdA from Example 61 rat IM PK

5 study

Dose (mg/kg)/ Dose route	Sampling time (day)	Mean concentration of Example 61 (ng/mL)	Mean concentration of EFdA (ng/mL)
20 (equivalent to EFdA)/IM	0.0208	93.3	BQL
	0.0417	189	2.21
	0.125	64.3	2.63
	0.208	88.7	2.02
	0.292	87.4	1.63
	1	13.6	BQL
	2	BQL	BQL
	3	BQL	BQL
	4	BQL	BQL
	5	BQL	BQL
	7	BQL	BQL
	10	BQL	BQL
	14	BQL	BQL
	17	BQL	BQL
	21	BQL	BQL

Reference to Example 62

- 5 **Table 27:** Plasma concentration of Example 62 and EFdA from Example 62 rat IM PK study

Dose (mg/kg)/ Dose route	Sampling time (day)	Mean concentration of Example 62 (ng/mL)	Mean concentration of EFdA (ng/mL)
20 (equivalent to EFdA)/IM	0.0208	26.7	5.50
	0.0417	27.6	17.2
	0.125	8.98	34.8
	0.208	4.98	27.7
	0.292	4.79	24.5
	1	1.47	8.31
	2	0.839	6.42
	3	0.887	5.51
	4	1.57	5.93
	5	2.08	5.43
	7	2.36	5.06
	10	1.82	3.94
	14	1.68	2.23
	17	BQL	BQL
	21	BQL	BQL
	24	BQL	BQL
	28	BQL	BQL

Reference to Example 63

- 10 **Table 28:** Plasma concentration of Example 63 and EFdA from Example 63 rat IM PK study

Dose (mg/kg)/ Dose route	Sampling time (day)	Mean concentration of Example 63 (ng/mL)	Mean concentration of EFdA (ng/mL)
20 (equivalent to EFdA)/IM	0.0208	3.28	183
	0.0417	1.92	386
	0.125	BQL	176
	0.208	BQL	98.0
	0.292	BQL	75.1
	1	BQL	43.6

	2	BQL	23.0
	3	BQL	12.7
	4	BQL	5.64
	5	BQL	3.63
	7	BQL	2.23
	10	BQL	BQL
	14	BQL	BQL
	17		BQL
	21		BQL
	24		BQL
	28		BQL

Reference to Example 64

Table 29: Plasma concentration of Example 64 and EFdA from Example 64 rat IM PK study

Dose (mg/kg)/ Dose route	Sampling time (day)	Mean concentration of Example 64 (ng/mL)	Mean concentration of EFdA (ng/mL)
20 (equivalent to EFdA)/IM	0.0208	1.30	5.48
	0.0417	2.05	19.9
	0.125	0.994	22.1
	0.208	BQL	16.6
	0.292	BQL	9.58
	1	BQL	8.61
	2	BQL	7.63
	3	BQL	8.31
	4	1.07	8.99
	5	BQL	13.2
	7	BQL	13.3
	10	BQL	4.70
	14	BQL	2.98
	17		2.38
	21		1.42
	24		BQL
	28		BQL

5

Reference to Example 65

Table 30: Plasma concentration of Example 65 and EFdA from Example 65 rat IM PK study

Dose (mg/kg)/ Dose route	Sampling time (day)	Mean concentration of Example 65	Mean concentration of
-----------------------------	------------------------	-------------------------------------	--------------------------

		(ng/mL)	EFdA (ng/mL)
20 (equivalent to EFdA)/IM	0.0208	2.75	24.7
	0.0417	4.33	105
	0.125	9.69	130
	0.208	BQL	88.3
	0.292	BQL	61.0
	1	BQL	35.1
	2	BQL	29.5
	3	BQL	17.1
	4	BQL	15.0
	5	BQL	10.5
	7	BQL	2.51
	10		BQL
	14		BQL
	17		BQL
	21		BQL
	24		BQL
	28		BQL

Reference to Example 66

Table 31: Plasma concentration of Example 66 and EFdA from Example 66 rat IM PK study

Dose (mg/kg)/ Dose route	Sampling time (day)	Mean concentration of Example 66 (ng/mL)	Mean concentration of EFdA (ng/mL)
20 (equivalent to EFdA)/IM	0.0208	1.51	322
	0.0417	0.928	480
	0.125	BQL	209
	0.208	BQL	135
	0.292	BQL	117
	1	BQL	44.7
	2	BQL	22.5
	3	BQL	13.3
	4	BQL	4.83
	5	BQL	3.78
	7	BQL	1.25
	10		BQL
	14		BQL
	17		BQL
	21		BQL
	24		BQL
	28		BQL

Protocol for Example 18 rat PK studies

- Example 18 referenced herein was made in accordance with Synthesis B. A total of seven naïve male Wistar Han rats, 250-275g, were received from the supplier equipped with a surgically-implanted jugular vein catheter (JVC) to facilitate blood sample collection during the first several days of the study. Following an acclimation period, the animals were assigned to the study based on acceptable health as determined by a staff veterinarian and catheter patency. Six animals were placed into two groups of 3 rats per group. Fasting of the animals before or after dosing was not required.
- The final study design is presented in the Table 32 below.

Table 32

Group	No. of Males	Test Article	Dose Level (mg/kg)	Dose Conc. (mg/mL)	Dose Volume (mL/kg)	Dose Vehicle	Dose Route
1	3	Example 18 (prodrug)	20	84.53 (prodrug) 41.19 (parent, EFdA)	0.49	1% P407/ 1% PEG 3350 in PBS	Subcutaneous
2	3		20	84.53 (prodrug) 41.19 (parent, EFdA)	0.49		Intramuscular

PEG = polyethylene glycol; PBS = phosphate-buffered saline

- On Day 1 each animal in Group 1 received a single intrascapular subcutaneous injection of prepared test article at a target dose level of 20 mg parent/kg and at a dose volume of 0.49 mL/kg. Each animal in Group 2 received a single intramuscular injection of prepared test article into a thigh muscle at a target dose level of 20 mg parent/kg and at a dose volume of 0.49 mL/kg. The animals were manually restrained for dosing and were not sedated. The dose sites were clipped of hair and wiped with alcohol before dosing. All dosing was performed as detailed in the study protocol and was completed without incident.

- Following dosing and at least twice daily until the end of the study, the animals and dose sites were observed for any clinically relevant abnormalities. All animals appeared normal at the time of each observation and no dose site reactions were observed.
- Blood samples were collected from the study animals as detailed in the sample collection Table 33 below.

Table 33

Group/ Collection Information	Whole Blood for PK
1A and 2A (N=3 per group)	0.5, 1, 3, 5, 7, 24, 48, 72 hours post-dose and Day 8, 11, 15, 22, 25, 29, 32, 36, 39, 43, 46, 50, 53, 57, 60, 64, 67, 71, 74, 78, 81, 85, 88, 92
Anticoagulant	NaF tubes containing Na ₂ EDTA
Volume/Time point	250 µL of whole blood

- Interim blood samples for PK (Groups 1A and 2A) were collected from the jugular vein catheter or by venipuncture of a jugular vein if the catheter was not patent. Blood was transferred to a blood collection tube containing NaF/Na₂EDTA anticoagulant, mixed by inversion, and maintained on wet ice until processing. The blood samples were centrifuged at 2200 × g for 10 minutes at 5°C to isolate plasma. The resulting plasma samples were transferred to individual polypropylene tubes in a 96-well plate format and immediately placed on dry ice until storage at nominally -80°C prior to analysis.
- The PK plasma samples were analyzed every 1-2 weeks by the Testing Facility to determine the concentration of prodrug and parent using an LC-MS/MS Research Grade Assay (RGA-1) with sensitivity to 0.1 ng/mL. Following interim review of sample analysis data, analysis for prodrug was discontinued after the Day 29 sample collections. The sample concentration data are presented in Tables 34 and 35, and mean concentration-time profiles are shown in Figures 25 and 26

Table 34: Plasma concentration of Example 18 and EFdA from Example 18 rat SC PK study

SC Dosing 20 mg/kg equivalent of EFdA								
Time, Day	Assayed Example 18 Concentrations				Assayed EFdA Concentrations			
	Rat#1	Rat#2	Rat#23	Mean	Rat#1	Rat#2	Rat#3	Mean
0.021	7.40	BQL	BQL	7.40	0.464	0.194	0.220	0.29
0.042	3.88	0.103	BQL	1.99	0.819	0.337	0.349	0.50
0.125	4.19	0.157	0.143	1.50	1.63	0.644	0.701	0.99
0.208	1.80	0.155	0.200	0.72	1.74	0.870	0.768	1.13
0.292	0.804	0.127	0.150	0.36	1.61	0.770	0.704	1.03

1	0.211	BQL	BQL	0.21	1.38	0.792	0.855	1.01
2	BQL	BQL	BQL	BQL	1.11	0.631	0.515	0.75
3	BQL	BQL	BQL	BQL	1.18	0.570	0.499	0.75
8	0.158	BQL	0.156	0.16	1.12	0.979	0.874	0.99
11	BQL	BQL	BQL	BQL	1.32	1.28	0.949	1.18
15	0.101	BQL	BQL	0.10	1.50	1.84	1.41	1.58
22	BQL	BQL	BQL	BQL	0.787	0.971	1.07	0.94
25	BQL	BQL	BQL	BQL	1.03	1.10	0.913	1.01
29	BQL	BQL	BQL	BQL	0.681	1.27	0.833	0.93
32					0.533	0.905	0.742	0.73
36					0.573	0.668	0.726	0.66
39					0.504	0.811	0.630	0.65
43					0.546	0.728	0.768	0.68
46					0.399	0.603	0.652	0.55
50					0.715	0.850	1.13	0.90
53					0.696	0.614	1.04	0.78
57					0.475	0.631	0.770	0.63
61					0.520	0.589	0.517	0.54
64					0.359	0.567	0.742	0.56
67					0.318	0.476	0.454	0.42
71					0.315	0.524	0.546	0.46
74					0.673	0.476	0.473	0.54
78					0.379	0.373	0.490	0.41
81					0.392	0.491	0.896	0.59
85					0.719	0.423	1.80	0.98
88					0.338	0.407	0.465	0.40
92					0.666	0.484	0.689	0.61

5

Table 35: Plasma concentration of Example 18 and EFdA from Example 18 rat IM PK study

IM Dosing 20 mg/kg equivalent of EFdA								
Time, Day	Assayed Example 18 Concentrations				Assayed EFdA Concentrations			
	Rat#1	Rat#2	Rat#23	Mean	Rat#1	Rat#2	Rat#3	Mean
0.021	0.111	15.9	0.233	5.41	0.279	0.405	0.299	0.33
0.042	0.620	11.5	0.408	4.18	0.734	0.779	1.01	0.84
0.125	0.689	1.45	0.314	0.82	1.37	1.67	1.62	1.55
0.208	0.594	3.26	0.340	1.40	1.55	2.05	2.09	1.90

0.292	0.377	8.80	0.239	3.14	1.41	1.75	1.46	1.54
1	0.325	0.276	BQL	0.30	1.28	1.22	1.41	1.30
2	BQL	BQL	BQL	BQL	1.15	1.21	1.35	1.24
3	BQL	BQL	BQL	BQL	1.33	1.12	1.12	1.19
8	0.133	0.156	BQL	0.14	1.45	1.22	1.30	1.32
11	0.130	0.102	BQL	0.12	1.58	0.864	1.48	1.31
15	0.130	BQL	BQL	0.13	1.35	1.24	1.28	1.29
22	BQL	BQL	BQL	BQL	1.59	0.974	1.11	1.22
25	BQL	BQL	BQL	BQL	1.23	0.934	1.45	1.20
29	BQL	BQL	BQL	BQL	0.976	1.01	1.27	1.09
32					0.789	0.608	0.920	0.77
36					0.688	0.588	0.857	0.71
39					0.869	0.690	0.863	0.81
43					0.869	0.919	0.865	0.88
46					0.875	0.595	0.825	0.77
50					1.10	0.868	1.25	1.07
53					0.690	0.756	0.724	0.72
61					0.571	0.903	0.923	0.80
64					0.524	0.457	0.785	0.59
67					0.648	0.457	1.04	0.72
71					0.468	0.597	1.03	0.70
74					0.435	0.400	0.704	0.51
78					0.486	0.410	0.841	0.58
81					0.563	0.444	0.622	0.54
85					0.434	0.704	0.622	0.59
88					0.419	0.465	0.586	0.49
92					0.734	0.628	1.02	0.79

5

Protocol for Example 18 (Compound) dog PK studies

Example 18 referenced herein was made in accordance with Synthesis B. Six male beagle dogs (+1 spare) were selected from the Testing Facility's colony of non-naïve animals. The animals were assigned to the study based on acceptable health as

10 determined by a Testing Facility veterinarian. Six animals were selected and placed into two groups of three animals each. Fasting of the animals before or after dosing was not required.

On Day 1 each animal in Group 1 received a single intrascapular subcutaneous injection of prepared test article at a target dose level of 5 mg parent/kg in 2% P404/2%

PEG3350/PBS (dose concentration 97.36 mg/mL prodrug) and at a dose volume of 0.1 mL/kg. Each animal in Group 2 received a single intramuscular injection of prepared test article in a hind quarter (quadriceps) at a target dose level of 5 mg parent/kg in 2% P404/2% PEG3350/PBS (dose concentration 97.36 mg/mL prodrug) and at a dose volume of 0.1 mL/kg. The animals were manually restrained for dosing and were not sedated. The dose sites were clipped of hair and wiped with alcohol before dosing. All dosing was performed as detailed in the study protocol and was completed without incident. Following dosing and at least twice daily until the end of the study, the animals and dose sites were observed for any clinically relevant abnormalities. All animals appeared normal at the time of each observation and no dose site reactions were observed. Blood samples were collected from the study animals as detailed in the sample collection Table 26 below.

Table 36

Group/ Collection Information	Whole Blood for PK
1 - 2	0.5, 1, 3, 5, 7, 24, 48, 72 hours post-dose and Day 8, 10, 17, 19, 22, 25, 29, 32, 36, 39, 43, 46, 50, 53, 57, 60, 64, 67, 71, 74, 78, 81, 85, 88, 92
Anticoagulant	NaF tubes containing Na2EDTA
Volume/Time point	500 µL of whole blood

Blood samples were collected by venipuncture of a cephalic vein. For PK, blood was transferred to a blood collection tube containing NaF/Na2EDTA anticoagulant, mixed by inversion, and maintained on wet ice until processing. The blood samples were centrifuged at $2200 \times g$ for 10 minutes at 5°C to isolate plasma. The resulting plasma samples were transferred to individual polypropylene tubes in a 96-well plate format and immediately placed on dry ice until storage at nominally -20°C prior to shipment for analysis.

The PK plasma samples were analyzed approximately every two weeks by the Testing Facility to determine the concentration of Example 18 (prodrug) and parent using an LC-MS/MS Research Grade Assay (RGA-1) with sensitivity to 0.1 ng/mL. Following interim review of sample analysis data, analysis for Example 18 (prodrug) was discontinued after the Day 57 sample collections. The sample concentration data are presented in Tables 37 and 38, and mean concentration-time profiles are shown in figures 27 and 28

Table 37: Plasma concentration of Example 18 and EFdA from Example 18 Dog SC PK study

SC Dosing 20 mg/kg equivalent of EFdA								
Time (days)	Example 18 Assayed Concentrations (ng/mL)				EFdA Assayed Concentrations (ng/mL)			
	Dog1001	Dog1002	Dog1003	Mean	Dog1001	Dog1002	Dog1003	Mean
0.021	BQL	BQL	BQL	BQL	BQL	BQL	BQL	BQL
0.042	BQL	0.176	BQL	0.176	BQL	BQL	BQL	BQL
0125	0.205	2.00	0.461	0.889	0.110	0.638	0.174	0.307
0.208	0.673	1.94	1.33	1.31	0.204	1.11	0.628	0.647
0.292	1.11	2.11	1.74	1.65	0.446	1.44	1.22	1.04
1	4.19	3.62	5.59	4.47	1.80	2.17	2.90	2.29
2	1.14	1.18	1.06	1.13	1.54	1.38	1.86	1.59
3	0.906	0.931	0.747	0.861	1.70	1.56	2.04	1.77
8	0.281	0.215	0.600	0.365	1.93	1.72	2.11	1.92
10	0.111	0.171	0.264	0.182	1.79	1.46	2.04	1.76
17	BQL	0.106	BQL	0.106	0.916	0.942	1.37	1.08
19	BQL	BQL	BQL	BQL	0.824	0.904	0.935	0.888
22	0.116	BQL	BQL	0.116	0.869	0.699	1.40	0.989
25	BQL	BQL	BQL	BQL	0.588	0.434	0.702	0.575
29	BQL	BQL	0.101	0.101	0.555	0.556	0.747	0.619
32	BQL	BQL	0.108	0.108	0.622	0.471	0.791	0.628
36	BQL	BQL	BQL	BQL	0.533	0.440	0.738	0.570
39	BQL	BQL	BQL	BQL	0.550	0.660	0.353	0.521
43	BQL	BQL	BQL	BQL	0.433	0.372	0.582	0.462
46	BQL	BQL	BQL	BQL	0.364	0.319	0.526	0.403
50	BQL	BQL	BQL	BQL	0.251	0.251	0.295	0.266
53	BQL	BQL	BQL	BQL	0.363	0.345	0.457	0.388
57	BQL	BQL	BQL	BQL	0.265	0.244	0.249	0.253
60					0.265	0.246	0.283	0.265
64					0.187	0.222	0.280	0.230
67					0.189	0.229	0.260	0.226
71					0.203	0.185	0.240	0.209
74					0.259	0.277	0.422	0.319
78					0.229	0.235	0.350	0.271
81					0.238	0.164	0.324	0.242

85					0.194	0.214	0.250	0.219
88					0.146	0.123	0.190	0.153
92					0.152	0.170	0.124	0.149
BQL - Below Quantitation Limit, < 0.100 ng/mL								

Table 38: Plasma concentration of Example 18 and EFdA from Example 18 dog IM PK study

IM Dosing 20 mg/kg equivalent of EFdA								
Time (days)	Example 18 plasma concentrations (ng/mL)				EFdA plasma concentrations (ng/mL)			
	Dog2001	Dog2002	Dog2003	Mean	Dog2001	Dog2002	Dog2003	Mean
0.021	2.43	2.67	1.47	2.19	0.158	0.344	BQL	0.251
0.042	3.38	2.85	1.90	2.71	0.682	1.51	0.566	0.919
0.125	10.5	7.99	4.36	7.62	3.47	3.92	2.30	3.23
0.208	9.34	7.61	7.51	8.15	3.79	4.17	3.61	3.86
0.292	8.41	7.29	4.96	6.89	3.07	3.81	3.41	3.43
1	2.45	2.69	2.03	2.39	2.56	3.67	2.57	2.93
2	1.04	1.21	1.19	1.15	1.92	2.98	2.02	2.31
3	1.09	0.877	0.818	0.928	1.92	2.18	2.23	2.11
8	0.204	0.419	0.201	0.275	2.10	2.16	2.20	2.15
10	0.129	0.198	0.150	0.159	1.46	1.88	2.05	1.80
17	0.110	0.172	0.116	0.133	1.25	1.51	1.17	1.31
19	0.109	BQL	BQL	0.109	0.864	1.14	0.961	0.988
22	BQL	0.113	BQL	BQL	0.997	1.25	1.27	1.17
25	BQL	BQL	BQL	BQL	0.492	0.675	0.681	0.616
29	BQL	BQL	BQL	BQL	0.734	0.679	0.927	0.780
32	BQL	BQL	BQL	BQL	0.581	0.739	0.688	0.669
36	BQL	BQL	BQL	BQL	0.643	0.575	0.702	0.640
39	BQL	BQL	BQL	BQL	0.677	0.600	0.590	0.622
43	BQL	BQL	BQL	BQL	0.441	0.465	0.506	0.471
46	BQL	BQL	BQL	BQL	0.519	0.464	0.527	0.503
50	BQL	BQL	BQL	BQL	0.229	0.244	0.284	0.252
53	BQL	BQL	BQL	BQL	0.387	0.444	0.395	0.409
57	BQL	BQL	BQL	BQL	0.218	0.244	0.244	0.235
60					0.290	0.262	0.360	0.304
64					0.272	0.215	0.219	0.235

67					0.308	0.244	0.277	0.276
71					0.171	0.246	0.217	0.211
74					0.372	0.273	0.419	0.355
78					0.364	0.285	0.269	0.306
81					0.239	0.214	0.335	0.263
85					0.239	0.201	0.302	0.247
88					0.182	0.165	0.210	0.186
92					0.111	0.137	0.132	0.127
BQL - Below Quantitation Limit, < 0.100 ng/mL								

Protocol for Example 18 (Compound) Cynomolgus Monkey PK study

Example 18 referenced herein was made in accordance with Synthesis B. Six male cynomolgus monkeys (+1 spare) were selected from the Testing Facility's colony of non-naïve animals. The animals were assigned to the study based on acceptable health as determined by a Testing Facility veterinarian. Six animals were selected and placed into two groups of three animals each. Fasting of the animals before or after dosing was not required.

On Day 1 each animal in Group 1 received a single intrascapular subcutaneous injection of prepared test article at a target dose level of 5 mg parent/kg in 2% P404/2% PEG3350/PBS (dose concentration 97.36 mg/mL prodrug) and at a dose volume of 0.1 mL/kg. Each animal in Group 2 received a single intramuscular injection of prepared test article in a hind quarter (quadriceps) at a target dose level of 5 mg parent/kg in 2% P404/2% PEG3350/PBS (dose concentration 97.36 mg/mL prodrug) and at a dose volume of 0.1 mL/kg. The animals were manually restrained for dosing and were not sedated. The dose sites were clipped of hair and wiped with alcohol before dosing. All dosing was performed as detailed in the study protocol and was completed without incident.

Following dosing and at least twice daily until the end of the study, the animals and dose sites were observed for any clinically relevant abnormalities. All animals appeared normal at the time of each observation and no dose site reactions were observed.

Blood samples were collected from the study animals as detailed in the sample collection Table 39 below.

Table 39:

Group/ Collection Information	Whole Blood for PK
1 - 2	0.5, 1, 3, 5, 7, 24, 48, 72 hours post-dose and Day 8, 10, 17, 19, 22, 25, 29, 32, 36, 39, 43, 46, 50, 53, 57, 60, 64, 67, 71, 74, 78, 81, 85, 88, 92, 106,
Anticoagulant	NaF tubes containing Na2EDTA
Volume/Time point	500 µL of whole blood

- Blood samples were collected by venipuncture of a cephalic vein. For PK, blood was transferred to a blood collection tube containing NaF/Na2EDTA anticoagulant, mixed by inversion, and maintained on wet ice until processing. The blood samples were centrifuged at $2200 \times g$ for 10 minutes at 5°C to isolate plasma. The resulting plasma samples were transferred to individual polypropylene tubes in a 96-well plate format and immediately placed on dry ice until storage at nominally -20°C prior to shipment for analysis.
- The PK plasma samples were analyzed approximately every two weeks by the Testing Facility to determine the concentration of Example 18 (prodrug) and parent using an LC-MS/MS Research Grade Assay (RGA-1) with sensitivity to 0.1 ng/mL. Following interim review of sample analysis data, analysis for Example 18 (prodrug) was discontinued after the Day 57 sample collections. The bioanalytical report and sample concentration data are presented in Tables 40 and 41, and mean concentration-time profiles are shown in figures 29 and 30

Table 40: Plasma concentration of Example 18 and EFdA from Example 18 monkey SC PK study

SC Dosing 20 mg/kg equivalent of EFdA								
	Example 18 plasma concentrations (ng/mL)				EFdA plasma concentrations (ng/mL)			
Time (days)	Monkey 1001	Monkey 1002	Monkey 1002	Mean	Monkey 1001	Monkey 1002	Monkey 1003	Mean
0.021	49.4	0.337	0.133	0.235	BQL	BQL	BQL	BQL
0.042	70.3	1.63	0.179	0.905	0.126	BQL	BQL	0.126
0.125	149	5.59	2.29	3.940	0.492	0.241	0.561	0.431
0.208	92.8	7.99	1.91	4.950	0.767	0.721	0.894	0.794
0.292	146	6.67	2.38	4.525	1.13	0.738	0.970	0.946
1	36.5	1.60	0.641	1.121	2.27	1.06	1.49	1.607
2	0.734	0.230	0.579	0.405	1.56	1.12	1.85	1.510
3	0.694	0.228	0.396	0.312	1.62	1.27	1.56	1.483
8	BQL	0.102	0.131	0.117	1.79	1.37	1.45	1.537

10	0.146	0.111	0.146	129	1.64	1.28	1.57	1.497
17	BQL	BQL	BQL	BQL	1.84	1.35	1.51	1.567
19	BQL	BQL	BQL		2.57	1.40	1.70	1.890
22	BQL	BQL	BQL		2.71	1.59	1.68	1.993
25	BQL	BQL	BQL		2.16	1.47	1.92	1.850
29	BQL	BQL	BQL		1.66	1.20	1.66	1.507
32	BQL	BQL	BQL		1.94	1.23	1.67	1.613
36	BQL	BQL	BQL		1.82	1.05	1.50	1.457
39	BQL	BQL	BQL		1.56	1.00	1.49	1.350
43	BQL	BQL	BQL		1.36	0.929	1.52	1.270
46	BQL	BQL	BQL		1.21	0.935	1.22	1.122
50	BQL	BQL	BQL		1.36	0.802	1.08	1.081
53	BQL	BQL	BQL		0.895	0.741	0.908	0.848
57	BQL	BQL	BQL		1.18	0.639	0.693	0.837
60					1.12	0.703	0.739	0.854
64					1.02	0.721	0.847	0.863
67					0.845	0.670	0.921	0.812
71					1.02	0.569	0.682	0.757
74					1.32	0.876	1.08	1.092
78					1.16	0.899	1.01	1.023
81					1.39	0.795	0.744	0.976
85					1.16	0.490	0.744	0.798
88					0.957	0.527	0.484	0.656
92					0.803	0.608	0.527	0.646
106					0.713	0.692	0.696	0.700
120					0.564	0.430	0.538	0.511
BQL - Below Quantitation Limit, < 0.100 ng/mL								

Table 41: Plasma concentration of Example 18 and EFdA from Example 18 monkey IM PK study

IM Dosing 20 mg/kg equivalent of EFdA								
	Example 18 plasma concentrations (ng/mL)				EFdA plasma concentrations (ng/mL)			
Time (days)	Monkey 2001	Monkey 2002	Monkey 2003	Mean	Monkey 2001	Monkey 2002	Monkey 2003	Mean
0.021	21.8	40.2	1.93	11.865	0.135	BQL	BQL	0.135
0.042	29.2	82.6	0.790	14.995	0.843	0.317	0.258	0.473
0.125	53.7	363	3.31	28.505	1.59	1.15	0.745	1.162
0.208	51.3	692	5.27	28.285	3.57	1.66	1.26	2.163
0.292	30.1	821	6.42	18.260	2.44	2.44	1.79	2.223
1	6.89	110	2.08	4.485	4.24	4.15	5.01	4.467
2	0.652	0.674	0.387	0.520	3.35	2.93	2.42	2.900
3	0.379	0.533	0.630	0.505	2.86	2.77	2.24	2.623
8	0.203	0.248	0.171	0.187	4.03	3.34	2.31	3.227

10	0.156	0.251	0.190	0.173	2.99	3.02	2.50	2.837
17	0.135	0.160	0.154	0.145	4.10	2.28	2.90	3.093
19	0.119	0.149	0.129	0.124	2.72	2.04	2.30	2.353
22	0.146	0.114	0.113	0.130	2.21	1.99	2.53	2.243
25	BQL	0.125	0.151	0.151	2.18	1.85	3.70	2.577
29	0.155	0.135	BQL		4.39	2.90	1.87	3.053
32	BQL	BQL	BQL		3.13	1.61	1.80	2.180
36	BQL	BQL	BQL		1.56	1.55	1.65	1.587
39	BQL	BQL	BQL		1.92	1.51	1.41	1.613
43	BQL	BQL	BQL		1.27	1.29	1.57	1.377
46	BQL	BQL	0.105		1.29	1.19	1.36	1.280
50	BQL	BQL	BQL		1.16	1.16	1.24	1.187
53	BQL	BQL	BQL		1.42	1.77	1.40	1.530
57	BQL	BQL	BQL		1.20	0.791	1.05	1.014
60					1.91	1.95	1.14	1.667
64					1.24	0.974	0.984	1.066
67					1.23	1.36	0.817	1.136
71					1.84	0.712	0.861	1.138
74					1.32	1.15	1.28	1.250
78					1.12	1.09	1.10	1.103
81					1.21	1.18	1.02	1.137
85					0.835	1.01	0.890	0.912
88					1.02	0.750	0.626	0.799
92					0.699	0.582	0.724	0.668
106					0.855	0.828	0.816	0.833
120					0.643	0.595	0.589	0.609
BQL - Below Quantitation Limit, < 0.100 ng/mL								

As shown above pharmacokinetic results, in rat IM and SC administration of 20 mg/kg EFdA showed a detectable duration of exposure of EFdA for less than 8-days, likely reflecting rapid absorption of the compound as a consequence of its high solubility and high permeability. Therefore, an approach involving design of novel lipophilic prodrugs of EFdA as a means to modulate the physicochemical properties of the EFdA as a strategy to improve its suitability for use as a long-acting injectable antiviral agent was pursued. The rat, dog and monkey IM and SC PK data demonstrate that sustained exposure of EFdA for extended period was achieved with several lipophilic prodrugs suggests potential utility of lipophilic prodrugs in HIV therapy as a long-acting IM or SC administrative prodrugs of EFdA.

The specific pharmacological responses observed may vary according to and depending on the particular active compound selected or whether there are present pharmaceutical carriers, as well as the type of formulation and mode of administration

employed, and such expected variations or differences in the results are contemplated in accordance with practice of the present disclosure.

5

10


15

20

25


WHAT IS CLAIMED IS:

1. A compound of formula (I):



wherein:

R_1 is:




wherein :

X is selected from the group consisting of NH₂, F and Cl;

R⁵ is selected from the group consisting of H and (C₁-C₁₄) alkyl;

R⁶ is selected from the group consisting of H and $-(C=O)-(C_1-C_{14})$ alkyl;

R² is selected from the group consisting of (C₁-C₂₄) alkyl; (CH₂)_{n1}-O-(CH₂CH₂O)_{n2}-(C₁-C₁₄ alkyl) where n1 and n2 are integers independently selected from 1-4 -R⁷-NH-(C=O)-R⁸ wherein R⁷ may be (C₁-C₁₄) alkyl and R⁸ may be independently selected from H and (C₁-C₁₄) alkyl; -R⁹-(C₆-C₁₄) aryl, wherein R⁹ is a bond or (C₁-C₆) alkyl; -R¹⁰-(C₃-C₁₄) cycloalkyl, wherein R¹⁰ is a bond or (C₁-C₆) alkyl; -(C₁-C₂₀) alkylene-(C=O)-O-R¹¹ wherein R¹¹ may be selected from H and (C₁-C₂₀) alkyl; and



and;

R³ is selected from the group consisting of H, -(C=O)-(C₁-C₂₄) alkyl; -(C=O)-O-(C₁-C₂₄) alkyl; and C₃-C₁₄ cycloalkyl or

R² and R³ join together to form a C₃ to C₂₈ cyclic structure; and

with the proviso that when R² is (C₁-C₁₄ alkyl) at least one of R³, R⁵ and R⁶ is not H.

5

2. The compound according to Claim 1, wherein X is F, and R⁵ and R⁶ are each H.

10 3. The compound according to any of Claims 1-2, wherein X is F, R⁵ is H and R⁶ is -(C=O)-(C₁-C₁₄) alkyl

4. The compound according to any of Claims 1-3, wherein R³ is H.

15 5. The compound according to any of Claims 1-3, wherein R³ is -(C=O)-(C₁-C₂₀) alkyl

6. The compound according to any of Claims 1-5, wherein R² is C₆ aryl.

20 7. The compound according to any of Claims 1-5, wherein R² is C₆ cycloalkyl.

8. The compound according to Claim 1, wherein R³ is H, X is F, R⁵ is H, R⁶ is H, and R² is (CH₂)_{n1}-O-(CH₂CH₂O)_{n2}-(C₁-C₁₄ alkyl).

25 9. The compound according to Claim 1, wherein R³ is H, X is F, R⁵ is H, R⁶ is H, and R² is -R⁷-NH-(C=O)-R⁸.

10. The compound according to Claim 1, wherein R³ is H, X is F, R⁵ is H, R⁶ is H, and R² is -(C₁-C₂₀) alkylene-(C=O)-O-R¹¹.








30

11. The compound according to Claim 1, wherein R³ is -(C=O)-(C₁-C₂₄) alkyl, X is F, R⁵ is H, R⁶ is H and R² is -(C₁-C₂₄) alkyl.








12. The compound according to Claim 1, wherein R³ is -(C=O)-O-(C₁-C₂₄) alkyl, X is F, R⁵ is H, R⁶ is H and R² is -(C₁-C₂₄) alkyl.









35









13. A compound selected from the group consisting of:

Parent Structure	Chemical Name
	[(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxyoxolan-2-yl]methyl cyclohexanecarboxylate
	[(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxyoxolan-2-yl]methyl benzoate
	[(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxyoxolan-2-yl]methyl 2-phenylacetate
	[(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxyoxolan-2-yl]methyl (1rs,4rs)-4-tert-butylcyclohexane-1-carboxylate
	[(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxyoxolan-2-yl]methyl (1rs,4sr)-4-pentylcyclohexane-1-carboxylate
	[(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxyoxolan-2-yl]methyl 2-(2-methoxyethoxy)acetate
	[(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxyoxolan-2-yl]methyl 2-[2-(2-methoxyethoxy)ethoxy]acetate
	[(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxyoxolan-2-yl]methyl 2-(2-butoxyethoxy)acetate









	10-[(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxyoxolan-2-yl]methoxy-10-oxodecanoic acid
	14-[(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxyoxolan-2-yl]methoxy-14-oxotetradecanoic acid
	20-[(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxyoxolan-2-yl]methoxy-20-oxoicosanoic acid
	1-[(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxyoxolan-2-yl]methyl 5-[1,3-bis(heptanoyloxy)propan-2-yl]pentanedioate
	1-[(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxyoxolan-2-yl]methyl 5-[1,3-bis(tetradecanoyloxy)propan-2-yl]pentanedioate
	1-[(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxyoxolan-2-yl]methyl 5-tetradecyl pentanedioate
	[(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-[(ethoxycarbonyl)oxy]-2-ethynyloxolan-2-yl]methyl decanoate









	[(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-(heptanoyloxy)oxolan-2-yl]methyl heptanoate
	[(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-(tetradecanoyloxy)oxolan-2-yl]methyl tetradecanoate
	[(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-(decanoyloxy)-2-ethynyloxolan-2-yl]methyl decanoate
	(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-[(pentanoyloxy)methyl]oxolan-3-yl tridecanoate
	(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-[(pentanoyloxy)methyl]oxolan-3-yl heptanoate
	(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-[(pentanoyloxy)methyl]oxolan-3-yl undecanoate
	(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-[(pentanoyloxy)methyl]oxolan-3-yl nonanoate







	[(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-(pentanoyloxy)oxolan-2-yl]methyl pentanoate
	[(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-(propanoyloxy)oxolan-2-yl]methyl pentanoate
	[(2R,3S,5R)-5-(6-butanamido-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxyoxolan-2-yl]methyl pentanoate
	[(2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-octanamido-9H-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl pentanoate
	[(2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl pentanoate
	[(2R,3S,5R)-5-(6-dodecanamido-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxyoxolan-2-yl]methyl pentanoate
	(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-[(2-propylpentanoyl)oxy]methyl}oxolan-3-yl dodecanoate
	[(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-(butanoyloxy)-2-ethynyloxolan-2-yl]methyl 2-propylpentanoate

	[(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-(butanoyloxy)-2-ethynyloxolan-2-yl]methyl decanoate
	[(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-(heptanoyloxy)oxolan-2-yl]methyl benzoate
	(2R,3aS,20aR)-2-(6-amino-2-fluoro-9H-purin-9-yl)-20a-ethynyl-octadecahydro-2H-furo[3,2-b]1,5-dioxacyclononadecane-5,18-dione
	[(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxyoxolan-2-yl]methyl 2-heptanamidoacetate
	[(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxyoxolan-2-yl]methyl 2-tetradecanamidoacetate
	[(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxyoxolan-2-yl]methyl (2S)-2-heptanamidopropanoate
	[(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-(butanoyloxy)-2-ethynyloxolan-2-yl]methyl tetradecanoate
	[(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-[(hexyloxy)carbonyloxy]oxolan-2-yl]methyl tetradecanoate

	(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-[(2-propylpentanoyl)oxy]methyl oxolan-3-yl heptanoate
	((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl tetradecanoyl-L-alaninate
	(2R,3S,5R)-2-(acetoxymethyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-3-yl heptanoate
	((2R,3S,5R)-5-(6-decanamido-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl heptanoate
	((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-(((hexyloxy)carbonyl)oxy)tetrahydrofuran-2-yl)methyl heptanoate
	((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-(((hexyloxy)carbonyl)oxy)tetrahydrofuran-2-yl)methyl decanoate
	((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl benzoate
	((2R,3S,5R)-5-(6-decanamido-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl benzoate

	((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl heptanoate
	((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl decanoate
	((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl 2-propylpentanoate
	((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl 3-(2-acetoxy-4,6-dimethylphenyl)-3-methylbutanoate
	(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((heptanoyloxy)methyl)tetrahydrofuran-3-yl tetradecanoate
	((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-(((tridecyloxy)carbonyl)oxy)tetrahydrofuran-2-yl)methyl heptanoate
	(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((propionyloxy)methyl)tetrahydrofuran-3-yl stearate
	((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-heptanamido-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl 2-propylpentanoate


	((2R,3S,5R)-2-ethynyl-5-(2-fluoro-6-tetradecanamido-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl propionate
	((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3-((ethoxycarbonyl)oxy)-2-ethynyltetrahydrofuran-2-yl)methyl tetradecanoate
	((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl (1,3-bis(isobutyryloxy)propan-2-yl) succinate
	(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-((dodecanoyloxy)methyl)-2-ethynyltetrahydrofuran-3-yl dodecanoate
	(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((palmitoyloxy)methyl)tetrahydrofuran-3-yl palmitate
	(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((icosanoyloxy)methyl)tetrahydrofuran-3-yl icosanoate
	(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((undecanoyloxy)methyl)tetrahydrofuran-3-yl undecanoate
	(2R,3aS,26aR)-2-(6-amino-2-fluoro-9H-purin-9-yl)-26a-ethynyldocosahydro-2H-furo[3,2-b][1,5]dioxacyclopentacosine-5,24-dione

	(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((hexanoyloxy)methyl)tetrahydrofuran-3-yl hexanoate
	(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((nonanoyloxy)methyl)tetrahydrofuran-3-yl nonanoate
	(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-((octanoyloxy)methyl)tetrahydrofuran-3-yl octanoate
	((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl 3-(2,4-dimethyl-6-(pivaloyloxy)phenyl)-3-methylbutanoate
	2-(4-(((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methoxy)-2-methyl-4-oxobutan-2-yl)-3,5-dimethylphenyl decanoate
	((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl (1,3-bis(heptanoyloxy)propan-2-yl) succinate


and

pharmaceutically acceptable salts thereof.

10 14. A compound of the formula (Ia):



15 wherein:
R₁ is:




wherein:

X is selected from the group consisting of NH₂, F and Cl;

5 R⁵ is selected from the group consisting of H and (C₁-C₁₄) alkyl;

R⁶ is selected from the group consisting of H and -(C=O)-(C₁-C₁₄) alkyl;

R² is selected from the group consisting of (C₁-C₂₄) alkyl; C₃-C₁₄ cycloalkyl; (CH₂)_{n1}-O-(CH₂CH₂O)_{n2}-(C₁-C₁₄) alkyl where n1 and n2 are integers independently selected from 1-4, -R⁷-NH-(C=O)-R⁸ wherein R⁷ may be (C₁-C₁₄) alkyl and R⁸ may be independently
 10 selected from H and (C₁-C₁₄) alkyl; -R⁹-(C₆-C₁₄) aryl, wherein R⁹ is a bond or (C₁-C₆) alkyl; -R¹⁰-(C₃-C₁₄) cycloalkyl, wherein R¹⁰ is a bond or (C₁-C₆) alkyl; -(C₁-C₂₀) alkylene-(C=O)-O-R¹¹ wherein R¹¹ may be selected from H and (C₁-C₂₀) alkyl; and



15


and;

R³ is selected from the group consisting of H, -(C=O)-(C₁-C₂₄) alkyl; -(C=O)-O-(C₁-C₂₄) alkyl; and C₃-C₁₄ cycloalkyl; or

R² and R³ join together to form a C₃ to C₂₈ cyclic structure; and


20 with the proviso that when R² is (C₁-C₁₈) alkyl at least one of R³, R⁵ and R⁶ is not H.

15 A compound of the formula:



or a pharmaceutically acceptable salt thereof.


16. A compound of the formula:



5

or a pharmaceutically acceptable salt thereof.


17. A compound of the formula:



10


or a pharmaceutically acceptable salt thereof.

18. A compound of the formula:




15

19. A compound of the formula:



20

20. A compound of the formula:



5

21. The compound according to any of Claims 1-20, present in crystalline form.

10 22. The compound according to any of Claims 1-20, present in amorphous form.

23. A pharmaceutical composition comprising a compound according to any of Claims 1-22, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

15

24. The composition of Claim 23, wherein the composition is present in parenteral form.

20 25. The composition of Claim 23, wherein the composition is in a tablet form.

26. The composition of Claim 23, wherein the composition is formulated as a long acting parenteral injection.

25

27. A method of treating an HIV infection in a patient comprising administering to the subject a compound of any of Claims 1-22, or a pharmaceutically acceptable salt thereof.

30 28. A method of preventing an HIV infection in a patient at risk for developing an HIV infection, comprising administering to the subject a compound of any of Claims 1-22, or a pharmaceutically acceptable salt thereof.

29. A compound according to any of Claims 1-22, for use in treating an

HIV infection.

30. A compound according to any of Claims 1-22, for use in preventing an HIV infection.

5

31. Use of a compound according to any of Claims 1-22, in the manufacture of a medicament for treating an HIV infection.

32. Use of a compound according to any of Claims 1-22, in the
10 manufacture of a medicament for preventing an HIV infection.

Figure 1A




Figure 1B




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5

Mean plasma concentration-time profiles of Example 17 and EFdA after single IM injection of Example 17 at 20 mg equivalent of EFdA/kg in male Wistar Han rats (N = 3/time point)




FIGURE 6

Mean plasma concentration-time profiles of Example 18, EFdA and Met1 after single IM injection of Example 18 at 20 mg equivalent of EFdA/kg in male Wistar Han rats (N = 3/time point)




FIGURE 7




FIGURE 8




FIGURE 9

Mean plasma concentration-time profiles of Example 37, EFdAA, Met1 and Met2 after single IM injection of Example 37 at 20 mg equivalent of EFdA/kg in male Wistar Han rats (N = 3/time point)




FIGURE 10

Mean plasma concentration-time profiles of Example 38, EFdA, Met1 and Met2 after single IM injection of Example 38 at 20 mg equivalent of EFdA/kg in male Wistar Han rats (N = 3/time point)




FIGURE 11

Mean plasma concentration-time profiles of Example 39, EFdA, Met1 and Met2 after single IM injection of Example 39 at 20 mg equivalent of EFdA/kg in male Wistar Han rats (N = 3/time point)




FIGURE 12

Mean plasma concentration-time profiles of Example 40 and EFdA after single IM injection of Example 40 at 20 mg equivalent of EFdA/kg in male Wistar Han rats (N = 3/time point)




FIGURE 13

Mean plasma concentration-time profiles of Example 42, EFdA, Met1 and Met2 after single IM injection of Example 42 at 20 mg/kg in male Wistar Han rats (N=3/time point)




FIGURE 14




FIGURE 15




FIGURE 16




FIGURE 17




FIGURE 18




FIGURE 19




FIGURE 20




FIGURE 21




FIGURE 22




FIGURE 23




FIGURE 24




FIGURE 25




FIGURE 26




FIGURE 27




FIGURE 28




FIGURE 29





FIGURE 30



INTERNATIONAL SEARCH REPORT

International application No

PCT/IB2020/051878

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61P31/18 A61K31/7076 C07H19/173
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61P A61K C07H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 1 589 026 A1 (YAMASA CORP [JP]) 26 October 2005 (2005-10-26) the whole document	1-32
Y	----- WO 2017/053216 A2 (MERCK SHARP & DOHME [US]; MERCK SHARP & DOHME [GB] ET AL.) 30 March 2017 (2017-03-30) the whole document	1-32
X,P	----- WO 2019/171285 A1 (GLAXOSMITHKLINE IP NO 2 LTD [GB]; VIIV HEALTHCARE CO [US]) 12 September 2019 (2019-09-12) the whole document -----	1-32



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

27 May 2020

Date of mailing of the international search report

15/06/2020

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Klein, Didier

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/IB2020/051878

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 1589026	A1	26-10-2005	AT 388958 T 15-03-2008
		CA 2502109 A1 24-09-2005	
		DE 602005005240 T2 12-03-2009	
		EP 1589026 A1 26-10-2005	
		ES 2300892 T3 16-06-2008	
		JP 4253342 B2 08-04-2009	
		JP 5213194 B2 19-06-2013	
		JP 2011256173 A 22-12-2011	
		JP WO2005090349 A1 31-01-2008	
		US 2005215512 A1 29-09-2005	
		US 2008153774 A1 26-06-2008	
		US 2009234110 A1 17-09-2009	
		WO 2005090349 A1 29-09-2005	
WO 2017053216	A2	30-03-2017	AU 2016328303 A1 22-03-2018
			CA 2998646 A1 30-03-2017
			CN 108289931 A 17-07-2018
			EP 3352781 A2 01-08-2018
			JP 2018532726 A 08-11-2018
			KR 20180052758 A 18-05-2018
			RU 2018114463 A 23-10-2019
			US 2019022115 A1 24-01-2019
			WO 2017053216 A2 30-03-2017
WO 2019171285	A1	12-09-2019	NONE